Pharmaceutical Sciences Faculty Patents   Pharmaceutical Sciences

5-26-2009

Genes Encoding Several Poly (ADP-Ribose) Glycohydrolase (PARG) Enzymes, the Proteins and Fragments Thereof, and Antibodies Immunoreactive Therewith

Myron Jacobson
University of Kentucky

Elaine L. Jacobson
University of Kentucky

Jean-Christoph Amé

Winston Lin
University of Kentucky, winston.lin@uky.edu

Follow this and additional works at: https://uknowledge.uky.edu/ps_patents

Part of the Pharmacy and Pharmaceutical Sciences Commons

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation

US007538194B2

US007538194B2

(12) **United States Patent** (10) **Patent No.:** **US 7,538,194 B2**
Jacobson et al. (45) **Date of Patent:** **May 26, 2009**

(54) **GENES ENCODING SEVERAL POLY (ADP-RIBOSE) GLYCOHYDROLASE (PARG) ENZYMES, THE PROTEINS AND FRAGMENTS THEREOF, AND ANTIBODIES IMMUNOREACTIVE THEREWITH**

(75) Inventors: **Myron K. Jacobson**, Lexington, KY (US); **Elaine L. Jacobson**, Lexington, KY (US); **Jean-Christophe Amé**, Obernai (FR); **Winston Lin**, Lexington, KY (US)

(73) Assignee: **University of Kentucky Research Foundation**, Lexington, KY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 189 days.

(21) Appl. No.: **11/638,012**

(22) Filed: **Dec. 13, 2006**

(65) **Prior Publication Data**

US 2007/0136833 A1 Jun. 14, 2007

Related U.S. Application Data

(62) Division of application No. 11/058,995, filed on Feb. 15, 2005, now abandoned, which is a division of application No. 09/973,451, filed on Oct. 9, 2001, now Pat. No. 6,906,180, which is a division of application No. 09/302,812, filed on Apr. 30, 1999, now Pat. No. 6,333, 148.

(60) Provisional application No. 60/083,768, filed on May 1, 1998.

(51) **Int. Cl.**
C12Q 1/68 (2006.01)

(52) **U.S. Cl.** **530/387.1**; 435/4; 435/6; 435/18; 435/183

(58) **Field of Classification Search** 530/387.1; 435/4, 6, 18, 183
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

6,333,148 B1 * 12/2001 Jacobson et al. 435/4

OTHER PUBLICATIONS

Tavossoli et al. (Biochimica et Biophysica Acta 1985; 827: 228-234).*

* cited by examiner

Primary Examiner—Brandon J Fetterolf
(74) *Attorney, Agent, or Firm*—Fulbright & Jaworski, LLP

(57) **ABSTRACT**

The isolation and characterization of cDNAs encoding poly (ADP-ribose) glycohydrolase (PARG) enzymes and the amino acid sequences of PARGs from several species are described. PARG is involved in the cellular response to DNA damage and its proper function is associated with the body's response to neoplastic disorder inducing agents and oxidative stress. Expression vectors containing the cDNAs and cells transformed with the vectors are described. Probes and primers that hybridize with the cDNAs are described. Expression of the cDNA in *E. coli* results in an enzymatically active protein of about 111 kDa and an active fragment of about 59 kDa. Methods for inhibiting PARG expression or overexpressing PARG in a subject for therapeutic benefit are described. Exemplary of PARG inhibitors are anti-sense oligonucleotides. The invention has implications for treatment of neoplastic disorder, heart attack, stroke, and neurodegenerative diseases. Methods for detecting a mutant PARG allele are also described. Antibodies immunoreactive with PARGs and fragments thereof are described.

8 Claims, 24 Drawing Sheets

FIGURE 1

FIGURE 2

FIGURE 3

FIGURE 4

FIGURE 5

```
bPARG  (422)  ED.....KRKEQCEMKHQRTE..RKIPKYIPPH         SEQ ID NO: 19
hPARG  (421)  ED.....RRKEQWETKHQRTE..RKIPKYVPPH         SEQ ID NO: 20
mPARG  (413)  ED.....RRKEQCEVRHQRTE..RKIPKYIPPN         SEQ ID NO: 21
CePARG  (29)  HQVPTMKRRKLTEHGNTTESLLKEDPEEPKS           SEQ ID NO: 22

hPARP  (205)  EG.....KRKGD.EVDG.VDEVAKKKSKKEKDK         SEQ ID NO: 23
mPARP  (205)  EG.....KRKGD.EVDG.TDEVAKKKSRKETDK         SEQ ID NO: 24
bPARP  (208)  EG.....KRKGD.EVDG.IDEVTKKKSKKEKDK         SEQ ID NO: 25
aPARP  (205)  EG.....KRKGE.EVDG..NVVAKKKSRKEKEK         SEQ ID NO: 26
XlPARP (204)  EG.....KRKAD.EVDG.HSAATKKKIKKEKEK         SEQ ID NO: 27
DmPARP (202)  EELPDTKRAKM.ELSDTNEEGEKKQR.......         SEQ ID NO: 28
SpPARP (205)  EGVSSAKAKI.EKIDEEDAASIKELTEKIKK          SEQ ID NO: 29
```

FIGURE 6

FIGURE 7

FIGURE 8

FIGURE 9

FIGURE 10

FIGURE 11

FIGURE 12

FIGURE 13

FIGURE 14

Strategy to Obtain Homologous PARG Sequences

FIGURE 15

Domain Organization of PARGs

SEQ ID NO:

```
2   Bparg    1   MSAGPGCEPCTKRPRWDAAATSPPAAASDARSFPGRQRRVLDSKDAPVQFRVPPSSSGCALGRAGQERGSATSL
4   Eparg    1   MNAGPGCEPCTKATRWGAATTS.PAASDARSFPSRQRRVLDPKDAEVQFRVPPSSPACVPGQAGQERGSATSL
6   Mparg    1   MSAGPGWEPCTKA.RWGAAGTSAPIASDARSFPGRQRRVLDPKDAPVQFRVPPSSPACVSGRAGPERGSATHF
8   Dparg    1   ------
10  Ceparg1      ------

2   Bparg   74   VFKQKTITSWMDTKGIKTVESKSLESXEHHHTREESMMSSVQKDHFYQHHMEKLEHVSQLGFDKSPVEKGTQY
4   Eparg   73   VFKQKTITSWMDTKGIKTVESKSLDSXEHHHTREESMMSSVQKDHFYQHHVEKLVHVSQLSLDKSLTEKSTQY
6   Mparg   73   VFKQKTITSWMDTKGIKTVESK...SXEHHHTREESMMSSVQKDHFYPHKVEKLEHVPQLNLDKSPTEKSSQY
8   Dparg    1   ------
10  Ceparg1      ------

2   Bparg  218   LKQHQTAAMCKWQHHGPHSERLLESEPPAVTLVPBQFSHAHVDQSSPKDDHSDTNSEESRDNQQFLTHVKL...
4   Eparg  217   LKQHQTAAMCKWQHHGKHTEQLLESEPQTVTLVPBQFSHAHIDRSSPQNDHSDTDSEEHRDNQQFLTTVKL...
6   Mparg  214   LKQQQTASVCKWQHHGKHABQLLASEPPAGTPLPKQLSHAHIGQSPETDDHSDTDHEEDRDNQQFLTPIKL...
8   Dparg    1   ------
10  Ceparg1      ------MSKKFIELGDPVTQDEKDYEDYVGVFAEQVP

2   Bparg  298   .ANAKQTMEDEQGREARSHQKCGKACHPAEACAGCQQEETDVVSESPLSDTGSEDVGTGLKHAHRLHRQESSL
4   Eparg  297   .ANAKQTTEDEHAREAKSHQKCSKSCHPGEDCASCQQDEIDVVPKSPLSDVGSEDVGTGSKHDHKLIRQESCL
6   Mparg  291   .ANTKPTVGDGQ...ARSHCKCSGSRQSKEDCTGCQQEEVDVLPESPLSDVGAEDIGTGPKHDHKLTGQESSL
8   Dparg    1   ------
10  Ceparg  33   TMKRRKLTEEGNTTESKEDPEEPKSRDVFVSSQSSDESQEDSAENPEIAKEVSENCENLTETLKISNIESLDN

2   Bparg  396   GHSPPFEKESEPESPMDVDNSKHSCQDSEADEETSPGFDE.QEDSSSAQTANKPSRFQPREADTELRKRSSAK
4   Eparg  395   GHSPPFEKESEPESPMDVDNSKHSCQDSEADEETSPGFDE.QEDGSSSQTANKPSRFQARDADIEFRKRYSTK
6   Mparg  387   GDSPPFEKESEPESPMDVDNSKHSCQDSEADEETSPVFDE.QEDRSS.QTANKLSSCQAREADGDLRKRYLTK
8   Dparg    1   MQEFRSHLIFPIFQ.KVIQS.TANRRR.ASASVL......TNRLGK...ALCLNCARMSKSPDGGISEIE...
10  Ceparg106    VTERSEHTLDN....HKSTEPHEE.DVNNKSHIDVAINSDEDDELVLEENHKEMRDGEQVQQLS..QDLFADD
```

FIG. 16A

SEQ ID NO:

```
Bparg 468  GGEIRLHFQFQEGGESRAGMN.DVNAKRPGSTSSLNVECRNSKQEGRKDSKITDEFMRVPKAEDKRKEQCEMKH
Eparg 467  GGEVRLHFQFQEGGESRTGMN.DLNAKLPGNISSLNVECRNSKQEGKKDSKITDELMRLPKAEDRRKEQWETKH
Mparg 354  GGEVRLHFQFR.GEMNAGTS.DLNAKPSGNSSSLNVECRSSKQEGKRDSKITDEFMRISKSEDRRKEQCEVRH
Dparg  59  ..TEEE.PENLANSL..DDSWRGVSMEAIHRNRQPFELENLPPVTAGNLHRVMIQLPIRET..PPR.PIKSPG
Ceparg172  QELIEIPIGIMKDTTTQLDITDSEVETAQKMEMIEETEADSTFVGEDSKATKTVRTSSSSF...LSTVSTCEAP

Bparg 540  QRTERKIPKYYPPHLSPDKKWLGTPIEEM..RRMPRCGIRLPPLRPSANHTVTIRVDLLRIGEVPK.PFPTHF
Eparg 539  QRTERKIPKYVPPELSPDKKWLGTPIEEM..RRMPRCGIRLPLLRPSANHTVTIRVDLLRAGEVPK.PFPTHY
Mparg 425  QRTERKIPKYIPPMLPPEKKWLGTPIEEM..RKMPRCGIHLPSLRPSASHTVTRVDLLRAGEVPK.PFPTHY
Dparg 125  X..WDSEEVRLPCAPESKYPRENPDGS.TTIDFRWEMIERALLQPIKTCEELQAAIISIHTTIRDQWEFRALE
Ceparg242  AKGRARMIQKELEKEVIAFTEGNLT.....LQPDLNKVDPDRNIRI.CTIPNFPASQG...KLRED.NRIG..

Bparg 610  KDLMDNKEVXMPCSEQNLYPVEDENGE.RAAGSRWELIQTALLHRLTRPQNLKDAILKINVAISKKWDFTALI
Eparg 609  KDLMDNKEVXMPCSEQNLYPVEDENGE.RTAGSRWELIQTALLHKFTRPQNLKDAILKINVAISKKWDFTALI
Mparg 495  KDLMDNKEVXMPCSEQNLYPVEDENGE.RTAGSRWELIQTALLHKFTRPQNLKDAILKINVAISKKWDFTALV
Dparg 196  QLLDEELDESETRVFFQSILPDMVKIALCLPNICTQPIPLLKQRMNHSITMSQEQIASLLANAFFCTFPRRNA
Ceparg367  PKIVLPQRWRE.FDSRGRR...RDSYFYFKRKLDGILKCIKTTGYFMFVGLLH......HMWE..FDPDITIK

Bparg 682  DFWDXVLEEAEAQHLYQSILPDMVKIALCLPNICTQPIPLLKQRMNHSITMSQEQIASLLANAFFCTFPRRNA
Eparg 681  DFWDXVLEEAEAQHLYQSILPDMVKIALCLPNICTQPIPLLKQRMNHSITMSQEQIASLLANAFFCTFPRRNA
Mparg 567  DFWDXVLEEAEAQHLYQSILPDMVKIALCLPNICTQPIPLLKQRMNHSVTMSQEQIASLLANAFFCTFPRRNA
Dparg 269  .KMKSEISSYPDIHFNRLFEGRSSRKPEKLKTLFCIFRRV..TERDASNVPTGVVTFVRRSGLPEE.L.IDWS
Ceparg424  ....LPAL.EMYYKEMSELVGREEVLEKFARVARIAKTAEDILPERIYRLVGDVE.SATLSHKQCAALVARMF

Bparg 755  .KMKSEISSYPDIHFNRLFEGRSSRKPEKLKTLFCIFRRV..TEKK....PTGLVTFIRQS.L.ED.F.PEWE
Eparg 754  .KMKSEISSYPDIHFNRLFEGRSSRKPEKLKTLFCIFRRV..TEKK....PTGLVTFIRQS.L.ED.F.PEWE
Mparg 387  .KMKSEISSYPDIHFNRLFEGRSSRKPEKLKTLFCIFRRV..TEKK....PTGLVTFIRQS.L.ED.F.PEWE
Dparg 337  QSAAPLGDVPLEVDAEGTIEDEGIGLLQVDFAHKYLGGGVLGHGCVQEEIRFVICPELLVGKLFTECLRPFEA
Ceparg491  FA......RPDSPFS......FCRILSSDKSICVEKLKFLFTIF......DKMSMDPPDGAVSF.RLTKMD
```

FIG. 16B

```
SEQ ID NO:

2   Bparg   817   RCEKLL..TRLEVIYEGTIEGNGQGMLQVDFAHRFVGGGVTSAGLVQEEIRFLIHPELIVSRLFIEVLDHNEC
4   Eparg   816   RCEKPL..TRLEVIYEGTIEENGQGMLQVDFAHRFVGGGVTSAGLVQEEIRFLIHPELIISRLFIEVLDHNEC
6   Mparg   702   RCEKPL..TRLEVIYEGTIEGNGRGMLQVDFAHRFVGGGVTGAGLVQEEIRFLIHPELIVSRLFIEVLDHNEC
8   Dparg   410   LVMLGAERYSNYTGIAGSFEWS.....GNFEDSTP.RDSSGRRQTAIVAIDALHFA.QSHH....QYREDL
10  Ceparg  543   KDIFNEEM.XDXXLRSLPEVEFFDEMLIEDTAL.CTQVDFAHEHLGGGVLNHGSVQEEIRFLMCPEMMVGMLL

2   Bparg   888   LIITGTEQISEYTGIAETYRWA.....RSHEDRSE.RDDWQRRTEIVAIDALHFR.RYLD....QFVPEKIR
4   Eparg   887   LIITGTEQISEYTGIAETYRWS.....RSHEDRSE.RDDCERRCTEIVAIDALHFR.RYLD....QFVPEKMR
6   Mparg   773   LIITGTEQISEYTGIAETYRWA.....RSHEDRSE.KDDWQRRCTEIVAIDALHFR.RYLD....QFVPEKVR
8   Dparg   472   MERELHKAYIGFVHWMVTPP..PGVATGNWGCGAFGGDSYIKALLQLMVCAQLGRPLAYYTFGNVEFRDDF
10  Ceparg  614   CEKMKQLEAISIVGAYVFSSYTGYGHTLKWAELQPNHSRQNTNEFRDRFGRLRVETIAIDAILFKGSKLDCQT

2   Bparg   951   RELHKAYCGFLRPGVSSEHLSAVATGNWGCGAFGGDARLKALIQYLAAAVAERDVVIFTFGDSELMRDIYSMH
4   Eparg   950   RELHKAYCGFLRPGVSSEHLSAVATGNWGCGAFGGDARLKALIQYLAAAVAERDVVIFTFGDSELMRDIYSMH
6   Mparg   835   RELHKAYCGFLRPGVPSEHLSAVATGNWGCGAFGGDARLKALIQYLAAAAAERDVVIFTFGDSELMRDIYSMH
8   Dparg   543   HEMWLLFRNDGTTVQQ.LWS.ILRSYSRLIKEKSSKEPRENKASKKKLYDFI...KEELKKVRDVPGEGAS
10  Ceparg  687   EQLNKANIIREMKKASIGFMSQGPKFTHIP.IVTGWWGCGAFNGDKPLKFIIQVIAAGVADRPLHFCSFGEPE

2   Bparg   1021  TFLTERKLTVGE.VYKLLLRYYNEECRNCSTPGP......DIKLYPFIYHAVESCTQTTNQPGQRTGA------
4   Eparg   1020  IFLTERKLTVGD.VYKLLLRYYNEECRNCSTPGP......DIKLYPFIYHAVESCAETADHSGQRTGT------
6   Mparg   907   TFLTERKLDVGK.VYKLLLRYYNEECRNCSTPGP......DIKLYPFIYHAVESSAEFTDMPGQKAGT------
8   Dparg   611   AEAGSSRVAGLGEGKSETSAKSSPELNKQPARPQITITQQSTDLLPAQLSQDNSNSSEDQALLMLSDDEEA
10  Ceparg  759   LAAXCKKIIERMKQKDVTLGKSCFSIFS--------------------------------------------

2   Bparg   1087  -----------------------------------------------------------------------
4   Eparg   1086  -----------------------------------------------------------------------
6   Mparg   969   -----------------------------------------------------------------------
8   Dparg   684   NAMMEAASLEAKSSVEISNSSTTSKTSSTATKSMGSGGGRQLSLLEMLDTHYEKGSASKRPRKSPNCSKAEG
10  Ceparg  787   -----------------------------------------------------------------------
```

FIG. 16C

SEQ ID NO:

2	Bparg	1
4	Eparg	1
6	Mparg	1
8	Dparg	410 TDKDEKDDIVD
10	Ceparg	543

2	Bparg	101
4	Eparg	100
6	Mparg	97
8	Dparg	472
10	Ceparg	614

2	Bparg	201
4	Eparg	200
6	Mparg	197
8	Dparg	543
10	Ceparg	687

FIG. 16D

FIGURE 17

FIGURE 18

FIGURE 19

FIGURE 20

Genomic cloning of the PARG gene

FIGURE 21

genomic PARG locus

targeting vector

Homologous recombination in ES cells:
1. Electroporation of the targeting vector into ES cells.
2. Selection by G418.
3. Identification of clones with targeted PARG allele by PCR and Southern blotting.

targeted allele

mutant allele I

Three types of mutant alleles can be obtained by transfecting the "targeted" ES clones with Cre-expressing vector.

mutant allele II ("floxed" allele)

Excision of exon 2 in mice by crossing mice carrying a "floxed" PARG allele with transgenic mice expressing the Cre recombinase driven by a tissue specific promoter.

mutant allele III

GENES ENCODING SEVERAL POLY (ADP-RIBOSE) GLYCOHYDROLASE (PARG) ENZYMES, THE PROTEINS AND FRAGMENTS THEREOF, AND ANTIBODIES IMMUNOREACTIVE THEREWITH

CROSS REFERENCE TO RELATED APPLICATION

This application is a divisional of application Ser. No. 11/058,995 filed on Feb. 15, 2005, now abandoned which is a divisional of application Ser. No. 09/973,451 filed Oct. 9, 2001, now U.S. Pat. No. 6,906,180, which is a divisional of application Ser. No. 09/302,812, filed on Apr. 30, 1999, now U.S. Pat. No. 6,333,148, which claims the benefits of U.S. Provisional Application No. 60/083,768, filed May 1, 1998. The entire disclosure of U.S. Provisional Application Nos. 60/083,768 and 09/302,812 are incorporated herein by reference.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

TECHNICAL FIELD

The present invention relates to poly(ADP-ribose)glyco-hydrolases (PARGs) and peptides having poly(ADP-ribose) glycohydrolase activity. In addition, the invention also relates to antibodies, including monoclonal antibodies and antibody fragments, that have specific interaction with epitopes present on poly(ADP-ribose) glycohydrolases. Methods of treatment and diagnosis using the poly(ADP-ribose) glycohydrolases, and antibodies specific for poly(ADP-ribose) glycohydro-lases are disclosed. The present invention has implications for the treatment of neoplastic disorder, reperfusion following ischemia, neurological disorders, and related conditions.

BACKGROUND OF THE INVENTION

Genomic damage, if left unrepaired, can lead to malignant transformation, or cell death by senescence (aging), necrosis or apoptosis. Among the variables that can affect the ultimate biological consequence of DNA damage to a particular cell are (i) the amount, type, and location of the DNA damage and (ii) the efficiency and bioavailability of the cellular DNA repair mechanism.

The activation of poly(ADP-ribose) polymerase (PARP) by DNA strand breaks is often one of the first cellular responses to DNA damage. PAR catalyzes the conversion of nicotinamide adenine dinucleotide (NAD) to multi-branched polymers containing up to 200 ADP-ribose residues. Increases in polymer levels of more than 100-fold may occur within minutes of DNA damage. Once synthesized, polymers are rapidly turned over, being converted to free ADP-ribose by the action of poly(ADP-ribose) glycohydrolase (PARG) (1). An ADP-ribosyl protein lyase has been proposed to cata-lyze removal of protein-proximal ADP-ribose monomers (2). FIG. 1 illustrates these processes schematically.

The process of activating PARP upon DNA damage can rapidly lead to energy depletion because each ADP-ribose unit transferred by PARP consumes one molecule of NAD, which in turn, requires six molecules of ATP to regenerate NAD. Additionally, NAD is a key carrier of electrons needed

to generate ATP via electron transport and oxidative phospho-rylation or by glycolysis. The overactivation of PARP due to substantial DNA damage can significantly deplete the cellu-lar pools of NAD and ATP (3). ADP-ribose polymer metabo-lism, and thus PARP and PARG have been linked to the enhancement of DNA repair (4), limitation of malignant transformation (5), enhancement of necrotic cell death (6), and involvement in programmed cell death (7). To date, stud-ies of the structure and function of the enzymes of ADP-ribose polymer metabolism have been mainly limited to PARP (8). Little is known about the function and regulation of PARG.

BRIEF SUMMARY OF THE INVENTION

As embodied and broadly described herein, the present invention is directed to nucleic acids molecules, peptides, methods, vectors and antibodies that are related to the poly (ADP-ribose) glycohydrolase (PARG) enzyme.

One embodiment of the invention is directed to an isolated and purified nucleic acid molecule or nucleic acid molecule analog comprising a sequence that encodes a polypeptide having poly(ADP-ribose) glycohydrolase (PARG) activity. The nucleic acid molecule may encode the complete full-length PARG gene or a fragment of the PARG gene. The nucleic acid molecule may be DNA, RNA or peptide nucleic acid (PNA). The nucleic acid molecule can be linear, such as, for example, an isolated fragment or a linear phage DNA. In addition, the isolated nucleic acid molecule may be circular, such as for example in a plasmid. The nucleic acid molecule may also be a single stranded DNA or RNA such as the single stranded DNA or RNA in a single stranded DNA virus or single stranded RNA virus. The nucleic acid molecule may be of yeast, insect or mammalian origin.

The nucleic acid molecule of the invention, may be of mammalian origin, such as, for example of bovine or murine origin. In a preferred embodiment of the invention, the nucleic acid molecule may be of human origin. While the sequence of the nucleic acid molecule is of mammalian ori-gin, the nucleic acid molecule may be replicated in another organism such as an insert in a viral genome, a plasmid in a bacterium or a 2-micron plasmid in a yeast.

Preferably, the nucleic acid molecule has, a high degree of sequence similarity with a sequence shown in SEQ ID NO: 1 (Genbank Accession Number U78975), SEQ ID NO: 3 (Gen-bank Accession Number AF005043), SEQ ID NO: 5 (Gen-bank Accession Number AF079557), SEQ ID NO: 7 (Gen-bank Accession Number AF079556) or SEQ ID NO: 9 (Genbank Accession Number CEF20C5). The high degree of sequence similarity may be, for example, about 70%, prefer-ably about 80%, even more preferably about 90% and most preferably substantially identical such as for example about 100% identity.

The nucleic acid molecule that encodes a polypeptide hav-ing poly(ADP-ribose)glycohydrolase (PARG) activity may be single or double stranded nucleic acid molecule of any length such as, for example, about 20 bases in length, about 30 bases in length, about 40 bases in length, about 50 bases in length, about 100 bases in length, about 200 bases in length, about 500 bases in length, about 1000 bases in length, about 1500 bases in length, about 2000 bases in length, about 3000 bases in length. It is understood that "bases" in this patent application means "basepairs" when referring to double stranded nucleic acid molecules and bases when referring to single stranded nucleic acid molecules. In a preferred embodiment of the invention, the nucleic acid molecule may be at least about 1000 base or basepairs long and have at least

about 80% sequence similarity with a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9.

In one embodiment of the invention, the nucleic acid molecule may have sequence similarity to one region-of the PARG sequence. The region may be, for example, from about base residue 2113 to about residue 3105 of SEQ ID NO: 3. Alternatively, the region may be, from residue 1240 to about residue 3105 of SEQ ID NO: 3 or from residue 175 to about residue 3105 of SEQ ID NO: 3.

Another embodiment of the invention is directed to the expression and overexpression of PARG in a cell. Expression vectors may mediate the expression of a polypeptide with poly(ADP-ribose) glycohydrolase (PARG) enzyme activity. Expression systems and expression vectors are known in the art. For example, one expression vector may comprise a regulatory sequence which is operatively linked to a nucleotide sequence at least about 1000 base pairs in length, which has at least 70% sequence similarity with a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. In a preferred embodiment, the sequence similarity is at least about 80% identity, more preferably at least about 90% identity and most preferably about 100% identity. The expression vector may be any expression vector that is capable of directing expression of a gene in a host cell including, prokaryotic, eukaryotic, mammalian and viral vector. Examples of such vectors include pCMV-Script cytomeglovirus expression vectors for expression in mammalian cells, pESP and pESC vectors for expression in *S. pombe* and *S. cerevesiae*, pET vectors for expression in bacteria, pSPUTK vectors for high-level transient expression, and pPbac and pMbac vectors for expression in fall army worm (SF9) cells. Such vectors are available commercially from suppliers such as, for example, Invitrogen (Carlsbad, Calif.) or Stratagene (La Jolla, Calif.). In the use of viral vectors, it is understood that defective viral vectors—vectors that are genetically engineered to deliver a gene or gene product to a host but which cannot replicate in a host is preferred. Procedures for the practice of in vitro and in vivo expression are well known to those of skill in the art and are further available with the specific expression products and cell lines from commercial suppliers.

Another embodiment of the invention is directed to a host cell transformed with a vector containing a nucleic acid molecule with a sequence that encodes a polypeptide having poly(ADP-ribose) glycohydrolase (PARG) activity. The host cell may be any eukaryotic or prokaryotic cell such as, for example a human, murine, rattus, bovine, insect, yeast or bacteria. Specific cell lines are well known to those of skill in the art and are available from suppliers such as the American Tissue Type Collection (ATCC, Manassas, Va.) and Stratagene (La Jolla, Calif.) and the like. A preferred embodiment of the invention is directed to cells transformed with the PARG expression vector which shows an elevated level of PARG relative to non-transformed cells. Especially preferred are cells transformed with an inducible PARG expression vector that have normal or slightly elevated PARG levels before induction and have significantly elevated PARG levels after induction.

An embodiment of the invention is directed to an isolated protein having poly(ADP-ribose) glycohydrolase (PARG) activity. The protein may comprise an amino acid sequence with at least 70% sequence similarity with a sequence shown in SEQ ID NO: 2 (Genbank Accession Number U78975), SEQ ID NO: 4 (Genbank Accession Number AF005043), SEQ ID NO: 6 (Genbank Accession Number AF079557), SEQ ID NO: 8 (Genbank Accession Number AF079556), or

SEQ ID NO: 10 (Genbank Accession Number CEF20C5). The sequence similarity is preferably at least about 80%, more preferably at least about 90% and most preferably substantially identical with a sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10. In a preferred embodiment of the invention, the preferred isolated protein having poly(ADP-ribose) glycohydrolase (PARG) activity and has a molecular weight greater than about 100 kDa.

Another embodiment of the invention is directed to an oligonucleotide which is greater than about 10 bases in length and less than about 1000 bases in length which is complementary to a sequence shown SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9. The oligonucleotide may be, for example, greater than about 20 bases in length, greater than about 30 bases in length, greater than about 40 bases in length, greater than about 50 bases in length, greater than about 100 bases in length, greater than about 200 bases in length or greater than about 300 bases in length. The oligonucleotide, which may be optionally labeled with a detectable marker, may be DNA, RNA or PNA. A detectable marker may be, for example, a radioactive isotope such as ^{32}P or ^{125}I, an epitope such as FLAG.

One preferred oligonucleotide is an antisense oligonucleotide directed to the mRNA of PARG. Antisense oligonucleotide as a method of suppression is well known to those in the art. For example, the phosphorothioate oligonucleotide, ISIS 2922, has been shown to be effective against cytomeglovirus retinitis in AIDS patients (9). It is thus well known that oligonucleotides, when administered to animals and humans, can have a useful therapeutic effect. In a preferred embodiment, the oligonucleotide is at least about 10 nucleotides in length, such as, greater than about 20 bases in length, greater than about 30 bases in length, greater than about 40 bases in length, greater than about 50 bases in length, greater than about 100 bases in length, greater than about 200 bases in length or greater than about 300 bases in length. In another preferred embodiment, the oligonucleotide has a ribozyme activity.

Another embodiment of the invention is directed to an isolated polypeptide of at least 6 amino acid residues in length and having a molecular weight less than about 65 kDa, which has at least about 80% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. The polypeptide may be, for example, at least about 10 amino acids in length, at least about 20 amino acids in length, at least about 30 amino acids in length, at least about 40 amino acids in length, at least about 50 amino acids in length, at least about 75 amino acids in length, at least about 100 amino acids in length, at least about 150 amino acids in length, at least about 250 amino acids in length or at least about 500 amino acids in length or more.

In a preferred embodiment, the polypeptide has a molecular weight less than about 40 kDa and has at least about 90% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. The polypeptide preferably has poly(ADP-ribose) glycohydrolase (PARG) activity or is immunogenic and elicits antibodies immunoreactive with a poly(ADP-ribose) glycohydrolase (PARG) enzyme. In a more preferred embodiment, the polypeptide comprises an amino acid sequence substantially identical with SEQ ID NO: 4 from about residue 647 to about residue 977.

Another embodiment of the invention is directed to an isolated polypeptide of at least 10 amino acid residues in length and which has at least about 80% sequence similarity

with a sequence shown in any one of SEQ ID-NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. Preferably, the polypeptide is at least about 20 amino acids in length, such as, for example at least about 30 amino acids, about 40 amino acids, about 50 amino acids, about 100 amino acids, about 200 amino acids and about 500 amino acids in length.

Another embodiment of the invention is directed to an antibody immunoreactive with an isolated polypeptide of at least about 6 amino acid residues in length and having a molecular weight less than about 65 kDa, which has at least about 80% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. In a preferred embodiment, antibody is immunoreactive with a polypeptide with a molecular weight less than about 40 kDa and has at least about 90% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. In another preferred embodiment, the antibody is immunoreactive with a polypeptide comprising an amino acid sequence substantially identical with SEQ ID NO: 4 from about residue 647 to about residue 977.

Another embodiment of the invention is directed to a method of detecting a polypeptide having PARG activity comprising the steps of contacting the polypeptide with an antibody immunoreactive with an isolated polypeptide of at least about 6 amino acid residues in length and having a molecular weight less than about 65 kDa, which has at least about 80% sequence similarity with a sequence shown in any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10, and determining whether the antibody immunoreacts with the polypeptide.

Another embodiment of the invention is directed to a method of preventing, treating, or ameliorating a disease condition or disorder in an individual comprising the step of administering a therapeutically effective amount of a poly (ADP-ribose) glycohydrolase (PARG) inhibitor or activator to the individual. The disease condition or disorder may be any condition associated with responses to DNA damage, examples of which include a neoplastic disorder, a myocardial infarction, a vascular stroke or a neurodegenerative disorder. The PARG inhibitor or activator may be a small molecule inhibitor or activator of PARG or may be an antisense oligonucleotide that can hybridize in vivo to messenger RNA encoded by a PARG gene. PARG based treatment may be directed to new methods for preventing, treating or ameliorating disorders associated with DNA damage. These disorders include neoplastic disorders, inborn genetic errors, myocardial infarctions, vascular strokes, aging, and neurodegenerative disorders such as Alzheimer's disease, Huntington's disease, Parkinson's disease, and neurotoxicity generally.

Another embodiment of the invention is directed to the identification of novel PARG modulators which can activate or inhibit DNA repair and/or apoptosis. A PARG modulator is a compound that can activate or inhibit PARG. These modulators are preferably more efficacious and do not have the known side effects of present modulators. One method of identifying an agent that inhibits or activates poly(ADP-ribose) glycohydrolase (PARG) activity comprise the steps of providing a liquid medium that contains a polypeptide having PARG activity contacting the polypeptide with a candidate agent, in the presence of a reference compound having affinity for the polypeptide, under predetermined assay conditions, and determining the affinity of the candidate agent for the polypeptide relative to the reference compound. Thus, the modulation activity of the candidate agent relative to the

reference compound is determined. In this method, the polypeptide may be immobilized on a solid support. Further, the polypeptide may be generated in vitro by culturing a cell transformed with a nucleic acid molecule encoding PARG under conditions effective to express the polypeptide.

Another embodiment of the invention is directed to a method of identifying a mutant PARG allele in an individual comprising the step of obtaining genomic material from the individual; digesting the genomic material with a restriction enzyme having a recognition site inclusive of the mutant allele; fractionating the restriction fragments obtained from the digestion; and comparing the fractionation pattern with that obtained for a normal allele, thereby determining the presence or absence of the mutant allele. The fractionating step may be performed with electrophoresis.

Another embodiment of the invention is directed to a method of identifying a mutant PARG allele in an individual comprising the steps of hybridizing an oligonucleotide with genomic material from the individual, which oligonucleotide hybridizes under predetermined hybridization conditions to a region immediately 5' of a predetermined mutation site in the PARG alleles with the 3' terminus of the oligonucleotide complementary to an unmutated PARG allele; extending the oligonucleotide using PCR amplification; and determining the degree to which extension occurs, thereby determining the presence or absence of the mutant allele. The PCR extension reaction may be performed at a temperature above about 50° C. The determination may be performed by conducting electrophoresis (using for example, acrylamide at about 4% to about 10% or agarose and low melting temperature agarose from about 0.8% to about 4%) on the products of PCR amplification.

Another embodiment of the invention is directed to a method of screening molecules for PARG modulating activity (inhibition or activation) comprising the steps of providing a purified PARG enzyme; assaying the enzyme in the presence of a molecule to be screened; and comparing the activity of the PARG enzyme in the presence of the molecule to the activity of the PARG enzyme in the absence of the molecule.

Another embodiment of the invention is directed to a method of gene therapy comprising the step of delivering an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme to a cell to be treated. In the method, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. Further, in the gene therapy method, the oligonucleotide may further comprise a ribozyme.

Another embodiment of the invention is directed to a method of delivering to a cell surface, an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme to a cell to be treated. In the method, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. Further, in the method, the oligonucleotide may further comprise a ribozyme. The portion of a polynucleotide encoding a PARG enzyme may be, for example, the polynucleotide encoding the N terminus third of PARG, the middle third of PARG, or the C terminus third of PARG. The portion of a polynucleotide may encode a smaller part of PARG such as the N terminus 10% of PARG, the C terminus 10% of PARG, or any 10% portion in between such as from 10% to 20%, from 20% to 30%, from 30% to 40%, from 40% to 50%, from 50% to 60%, from 60% to 70%, from 70% to 80%, from 80% to 90%. The percent value used means a percent of the linear amino acid sequence. Thus, for a 1000 amino acid protein, the N terminus 10 percent is from

7

amino acid 1 to 100; 10% to 20% percent would be from amino acid 100 to 200 and so on. For a 970 amino acid protein, the N terminal 10% would be from amino acid 1 to 97; 10% to 20% would be from amino acids 98 to 194 amino acids.

Another embodiment of the invention is directed to a method of sensitizing a cell to a chemotherapeutic agent comprising the step of contacting the cell with a molecule that modulates the activity of a PARG enzyme. The molecule may be an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme. For example, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. The portion of a polynucleotide encoding a PARG enzyme may be, for example, the polynucleotide encoding the N terminus third of PARG, the middle third of PARG, or the C terminus third of PARG. The portion of a polynucleotide may encode a smaller part of PARG such as the N terminus 10% of PARG, the C terminus 10% of PARG, or any 10% portion in between such as from 10% to 20%, from 20% to 30%, from 30% to 40%, from 40% to 50%, from 50% to 60%, from 60% to 70%, from 70% to 80%, from 80% to 90%. The oligonucleotide may further comprise a ribozyme. The method may be used, for example, as a method of treating a diseased cell characterized by the presence of DNA strand breaks. In the treatment, the cell is contacted with a molecule that modulates an enzymatic activity of a PARG enzyme.

Another embodiment of the invention is directed to a pharmaceutical composition comprising an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme. The produced molecule may be an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme. For example, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. The oligonucleotide may comprise a ribozyme activity.

Another embodiment of the invention is directed to a virus that causes the production of an oligonucleotide having a sequence complementary to a polynucleotide encoding a PARG enzyme. This may be, for example, a viral vector which after the infection of a host cell, causes the production of an antisense RNA of PARG. The molecule may be an oligonucleotide having a sequence complementary to at least a portion of a polynucleotide encoding a PARG enzyme. For example, the oligonucleotide may have a sequence complementary to a sequence encoding a C-terminal portion of a PARG enzyme. The oligonucleotide may further comprise a ribozyme activity.

Other embodiments and advantages of the invention are set forth, in part, in the description that follows and, in part, will be obvious from this description and may be learned from the practice of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the cellular biochemical process that occurs after DNA damage.

FIG. 2 depicts the SDS-PAGE analysis of purified bovine thymus PARG.

FIG. 3 depicts the alignment of the DNA sequences of two PCR products and eight λgt11 cDNA clones used to identify the cDNA coding for bovine PARG.

FIG. 4 depicts a northern blot analysis of bovine kidney cells mRNA transcripts.

8

FIG. 5 depicts an alignment of the putative bipartite NLS of bovine, human, and murine PARG and comparison with the bipartite NLS of PARP from different organisms.

FIG. 6 depicts expression of bPARG enzyme activity in *E. coli* (10).

FIG. 7 depicts a Southern blot analysis of bovine DNA probed with PARG cDNA.

FIG. 8 depicts activity gel autoradiogram of *E. coli* expressed bovine PARG.

FIG. 9 depicts the analysis by anion exchange HPLC of material released from ADP-ribose polymers by PARG action.

FIG. 10 depicts the SDS-PAGE analysis of the purification of *E. coli* expressed GST-PARG.

FIG. 11 depicts a schematic representation of the portions of the bovine PARG cDNA expressed as GST fusion constructs.

FIG. 12 depicts the cloning of the 1.8 kb PCR EcoRI fragment encoding for the 65 kDa catalytic domain of PARG.

FIG. 13 depicts an autoradiogram of an activity gel of GST-PARG fusion constructs expressed in *E. coli* and PARG expressed in baculovirus.

FIG. 14 depiots a schematic representation of the strategy used to isolate cDNA molecules encoding PARG from various organisms.

FIG. 15 depicts the domain organization of PARGs from different organisms.

FIG. 16 depicts an amino acid sequence alignment of bovine, murine, human, *drosophila* and *C. elegans* PARG enzymes.

FIG. 17 depicts a western blot of recombinant PARGs.

FIG. 18 depicts western blots of natural and recombinant expressed PARG.

FIG. 19 depicts the characterization of PARG by Western Blot in mouse cells of different PARP genotypes.

FIG. 20 depicts a partial restriction map of the mouse PARG locus.

FIG. 21 depicts a schematic representation of the strategy used to create PARG knockout mice.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

List of Abbreviations

ADP adenosine diphosphate
ADPR ADP-ribose
AMP adenosine monophosphate
ASPCR allele-specific PCR
bp base pair(s)
bPARG bovine PARG
CePARG *C. elegans* PARG
dPARG *Drosophila melanogaster* PARG
DTT dithiothreitol
GSH-Sepharose Glutathione-Sepharose 4B
GST glutathione-S transferase
hPARG human PARG
HPLC high pressure liquid chromatography
ICE interleukin-1 b converting enzyme
IPTG isopropyl-β-D-thiogalactoside
kb kilobase pair(s)
MDBK Madin-Darby bovine kidney cells
mPARG murine PARG
NAD nicotinamide adenine dinucloetide
NLS nuclear location signal

9

10

PADPR DHB-Sepharose poly(ADP-ribose)-dihydroxyboro-
nyl-Sepharose
PAGE polyacrylamide-gel electrophoresis
PARG poly(ADP-ribose)glycohydrolase
PARP poly(ADP-ribose)polymerase [EC 2.4.2.30]
PCR polymerase chain reaction
PEG-6,000 polyethylene glycol 6,000
PEG polyethylene glycol
PMSF phenylmethylsulfonyl fluoride
PR-AMP phosphoribosyl-adenosine monophosphate
RFLP restriction fragment length polymorphism
SDS sodium dodecyl sulfate
SSCP single-strand conformation polymorphism
TPCK Trypsin: L-1-tosylamido-2-phenylethyl chloromethyl
ketone.

An "agonist" as defined herein refers to a molecule which,
when bound to PARG, increases or prolongs the effect of
PARG. Agonist may include proteins, nucleic acid molecules,
carbohydrates, or any other molecules that bind to and modu-
late the effect of PARG.

An "allele" or "allelic sequence", as defined herein refers
to an alternative form of PARG. Alleles may result from at
least one mutation in the nucleic acid molecule sequence and
may result in altered mRNAs or polypeptides whose structure
or function may or may not be altered. Any given natural or
recombinant gene may have none, one, or many allelic forms.
Common mutational changes which give rise to alleles, are
generally ascribed to natural deletions, additions, or substi-
tutions of nucleotides. Each of these types of changes may
occur alone, or in combination with the others, one or more
times in a given sequence.

An "ortholog" as defined herein refers to a nucleotide or
amino acid sequence that is related to a reference nucleotide
or amino acid sequence through speciation, and is therefore
identical or structurally similar to the reference sequence.

A given nucleotide or amino acid sequence is said to be
"substantially identical" with another sequence when the
compared sequences have the same residues in the same
order, excepting for any degeneracy (nucleotides) and con-
servative substitutions (amino acids).

A "regulatory sequence" of an expression vector is a DNA
sequence necessary for inducing transcription of a gene, and
includes a functional promoter and/or enhancer sequence.
The term "operatively linked" as used herein means that a first
nucleotide sequence, such as a regulatory element, is fused in
frame with a second nucleotide sequence so as to afford a
faithful transcription of the entire nucleotide sequence, which
upon translation yields the desired protein.

The term "immunoreactivity" and related terms refers to
the ability of antibodies and fragments thereof to bind to
particular regions (antigens) presented by polypeptides and
proteins, presented to the antibodies either as immunogens or
targets. Typically, the binding affinity of the antibodies for
their antigen is in the range 10^5 to 10^{11}, with higher affinities
being preferred.

The term "specific immunoreactivity" refers to the ability
of antibodies and fragments thereof to bind to particular
regions (antigens) presented by polypeptides and proteins,
presented to the antibodies either as immunogens or targets
and not to unrelated antigens. For example, an antibody with
specific immunoreactivity to actin will bind actin but would
not bind another protein, such as a polymerase, which do not
share epitopes with actin.

The term "nucleic acid molecule" refers to DNA, RNA and
nucleic acid molecule analogs such as PNA and the like. PNA
or "Peptide Nucleic Acid" is a nucleic acid molecule analog
that has a neutral "peptide-like" backbone with nucleobases

that allow the molecule to hybridize to complementary RNA
or DNA with higher affinity and specificity than correspond-
ing oligonucleotides. PNA can be made to be more resistant to
normal nucleases and are especially desirable, for example, in
gene therapy. PNA is known to one of skill in the art and can
be purchased or custom synthesized in numerous commercial
laboratories including PerSeptive Biosystems, Inc. (Framing-
ham, Mass.).

The term "modulate" means to activate or inhibit. For
example, a PARG modulator may activate or inhibit PARG
activity. "Modulation activity" means the amount of activa-
tion or inhibition. For example, a compound that increase
PARG (or any other enzyme) activity by. 10% will have a
modulation activity of 10%. Conversely, a compound that
decreases PARG activity by 10% will have a modulation
activity of –10%.

As used herein, a given nucleotide or amino acid sequence
is said to have a defined percentage of sequence similarity
with another sequence when the two sequences differ by no
more than the specified sequence similarity, including con-
servative substitutions, insertions, and deletions. Degenerate
codons do not result in a change in amino acid upon transla-
tion, therefore, it is appreciated that identical amino acids-can
be encoded by several equivalent codons. The term "homol-
ogy" and "sequence similarity" should have the same mean-
ing for the purpose of this patent. Similarity parameters may
be any generally acceptable parameter. For the purposes of
this patent, percent similarity between two polymers such as
nucleic acid molecules and polypeptides is preferably defined
by Karlin and Altschul (11). The similarity algorithms of
Karlin and Altschul are well known to those of skill in the art
as exemplified by their adoption by the National Center for
Biological Information. For nucleic acid molecule sequence
searching, one desirable set of parameters would M (score for
a pair of matching residues) at 5; N (score for mismatching
residues) at –4; W (word length) at 11. For proteins, it is well
known that some amino acids are similar and that substitution
would be conservative. That is, for example, the replacement
of an acidic amino acid with another acidic acid would be
consider a conservative mismatch while the replacement of
an acidic amino acid with a basic amino acid would be con-
sider a more divergent mismatch. Preferably, the parameters
for a desirable protein similarity determination are expressed
in the sequence similarity matrix BLOSUM62 as described in
Henikoff & Henikoff (12). Other similarity matrixes that are
also preferred in the invention are PAM40, PAM120 and
PAM250 as described in Altschul (13).

The rapid synthesis of ADP-ribose polymers that occurs in
response to DNA strand breaks is accompanied by very rapid
polymer turnover, indicating that PARP and PARG activities
are closely coordinated as cells respond to DNA damage.
While PARP has been widely studied, information concern-
ing structure and function relationships of PARG is much
more limited. The present invention discloses the isolation of
a cDNA encoding the bovine, human, murine and *drosophila*
PARG and their deduced amino acid sequences.

The availability of PARP cDNA has allowed a number of
molecular genetic approaches to study the function(s) of
ADP-ribose polymer metabolism and the availability of
PARG cDNA should allow the design of additional molecular
genetic approaches for studying this metabolism. For
example, disruption of the gene encoding PARG in mice
containing a normal PARP gene will allow the determination
of whether other cellular enzymes can replace PARG in the
turnover of ADP-ribose polymers and/or whether develop-
ment of animals will occur in the absence of PARG. Alterna-
tively, disruption of the PARG gene in mice containing a

disrupted PARP gene may provide insights for the coordinated function of PARP and PARG.

One embodiment of the invention is directed to a deoxyribonucleic acid (DNA) molecule that encodes a polypeptide having poly(ADP-ribose) glycohydrolase (PARG) activity. Preferably, the molecule is of mammalian origin, such as, for example, of human origin.

In a preferred embodiment, a DNA molecule of the invention comprises a nucleotide sequence with at least about 70% sequence similarity with a sequence shown in a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. Higher degrees of sequence similarity, such as about 80%, about 90%, and about 100% are preferred. Most preferred is a DNA molecule comprising a nucleotide sequence substantially identical with any one of sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. It is preferred that a DNA molecule of the present invention comprises at least about 1000 nucleotides and has a nucleotide sequence with at least 80% sequence similarity with a sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. Most preferably, the DNA molecule consist of a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9.

For a DNA molecule of the present invention based on a human PARG gene it is preferred that the molecule comprises a nucleotide sequence that shows similarity to the sequence shown in SEQ ID NO: 3 from about residue 2113 to about residue 3105. More preferably, the sequence similarity is from about residue 1240 to about residue 3105. Still more preferably, the DNA molecule comprises a nucleotide sequence similarity to the coding sequence for the full-length hPARG as shown in SEQ ID NO: 3 from about residue 175 to about residue 3105.

A DNA molecule of the present invention affords probes and primer molecules that can be used in hybridization assays and PCR amplification. An exemplary oligonucleotide is less than about 1000 residues in length and comprises a nucleotide sequence at least about 10 residues long to ensure hybridization. Preferably, the at least about 10 residue region of the oligonucleotide is complementary to a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9. Typically, the oligonucleotide will be a DNA molecule, which can be labeled by any method as desired, for example, with a radiolabel, a fluorescence label, or chemi-luminescent label.

Another embodiment of the invention is directed to a nucleic acid molecule that hybridizes to in a nucleic acid blot (Southern blot, Northern blot) to a sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9 under stringent hybridization conditions. A nucleic acid blot may be made using techniques defined in Molecular Cloning, Second Edition, Sambrook et al., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. DNA to be analyzed may be separated in agarose or acrylamide gels. The DNA may be transferred to nylon or nitrocellulose membrane using techniques known to those in the art. Stringent hybridization condition may be for example, prehybridizations 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA for 10 hours, 100 ug denatured salmon sperm DNA, hybridization at 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, 100 ug denatured salmon sperm DNA, pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA, 1 ng/ml probe with a specific activity of 10^9 cpm/ug DNA, for 16 hours. The probe may comprise any contiguous sequence from SEQ ID NO: 1, SEQ ID NO: 3,

SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9. Preferably, said contiguous sequence is at least about 50 bases long, more preferably, the contiguous sequence is at least about 75 bases long, such as at least about 100 bases, at least about 200 bases long or at least about 300 bases long. The complete sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, or SEQ ID NO: 9. Methods of labeling probes to with radioactive labels are known to those of skill in the art.

Method of washing after stringent hybridization are known. A stringent washing may comprise, for example, two washes at in 2×SSC, 0.1% SDS. for 15 minutes each at room temperature; two washes in 0.2×SSC, 0.1% SDS for 15 minutes each at room temperature; and a final three washes in 0.2×SSC, 0.1% SDS for 15 minutes each at 60° C. The final wash may be increased in temperature for reduced background. For example, the final wash may be a final three washes in 0.2×SSC, 0.1% SDS for 15 minutes each at 65° C. or a final three washes in 0.2×SSC, 0.1% SDS for 15 minutes each at 68° C.

If a radioactive probe is used, hybridization may be monitored using known techniques such as autoradiogram or a two dimensional measurement of radioactivity.

An anti-sense oligonucleotide is also afforded by the present invention. The anti-sense molecule is typically less than about 1000 residues in length to ensure ease of synthesis, and hybridizes to an RNA molecule, e.g., messenger RNA, which has at least 70% sequence similarity with a sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9. Preferably, the anti-sense molecule is at least about 10 nucleotides in length to ensure hybridization with mRNA. Even more preferably, the anti-sense molecule may be at least about 15 nucleotides in length such as, for example, at least about 20 nucleotides in length; at least about 30 nucleotides in length; at least about 50 nucleotides in length; at least about 75 nucleotides in length; at least about 100 nucleotides in length; at least about 150 nucleotides in length; at least about 200 nucleotides in length; at least about 500 nucleotides in length; at least about 1000 nucleotides in length; or at least about 1500 nucleotides in length. It is also preferred that the molecule has a ribozyme activity so that it can degrade the mRNA that it binds to.

An antisense oligonucleotide may be used therapeutically to inhibit translation of mRNA encoding PARG. Synthetic antisense oligonucleotides may be produced, for example, in a commercially available oligonucleotide synthesizer. This invention provides a means to therapeutically alter levels of expression of a human or other mammalian PARG by the use of a synthetic antisense oligonucleotide drug that inhibits translation of mRNA encoding PARG. Synthetic antisense oligonucleotides, or other antisense chemical structures designed to recognize and selectively bind to mRNA, are constructed to be complementary to portions of the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 and SEQ ID NO: 9. An antisense oligonucleotide may be designed to be stable in the blood stream for administration to patients by injection, or in laboratory cell culture conditions, for administration to cells removed from the patient. The antisense may be designed to be capable of passing through cell membranes in order to enter the cytoplasm and nucleus of the cell by virtue of physical and chemical properties of the antisense oligonucleotide which render it capable of passing through cell membranes (e.g., by designing small, hydrophobic antisense oligonucleotide chemical structures) or by virtue of specific transport systems in the cell which recognize and transport the antisense oligonucleotide into the cell. In addition, the antisense oligonucleotide can be designed for administration only to

certain selected cell populations by targeting the antisense oligonucleotide to be recognized by specific cellular uptake mechanisms which bind and take up the antisense oligonucleotide only within certain selected cell populations. For example, the antisense oligonucleotide may be designed to bind to transporter found only in a certain cell type, as discussed-above. The antisense oligonucleotide may be designed to inactivate the PARG mRNA by (1) binding to the PARG mRNA and thus inducing degradation of the mRNA by intrinsic cellular mechanisms such as RNase I digestion, (2) by inhibiting translation of the mRNA target by interfering with the binding of translation-regulating factors or of ribosomes, or (3) by inclusion of other chemical structures, such as ribozyme sequences or reactive chemical groups, which either degrade or chemically modify the target mRNA. Synthetic antisense oligonucleotide drugs have been shown to be capable of the properties described above when directed against mRNA targets (14). In addition, coupling of ribozymes to antisense oligonucleotides is a promising strategy for inactivating target mRNA (15). In this manner, an antisense oligonucleotide directed to PARG may serve as a therapy to reduce PARG expression in particular target cells of a patient and in any clinical condition that may benefit from reduced expression of PARG.

It is known by those in the art that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences encoding PARG, some bearing minimal homology to the nucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates a nucleic acid molecule that encodes a polypeptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO:6, SEQ ID NO: 8 and SEQ ID NO: 10. The invention contemplates each and every possible variation of nucleotide sequence that could be made by selecting combinations based on possible codon choices that would encode the oligopeptides disclosed herein. These combinations are made in accordance with the standard triplet genetic code as applied to the nucleotide sequence of naturally occurring PARG and all such variants are to be considered as being specifically disclosed.

Although nucleic acid molecules which encode PARG and its variants preferably hybridizes under high stringency conditions to the nucleotide sequence of the naturally occurring PARG gene under appropriate conditions of stringency, it may be advantageous to produce nucleotide sequences encoding PARG or its derivatives possessing a substantially different codon usage. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding PARG and its derivatives and variants without altering the produced amino acid sequence include the production of RNA transcripts having more desirable properties, such as greater half-life, than transcripts produced from the naturally occurring sequence.

In order to express a biologically active or immunologically active PARG, the nucleic acid molecule encoding PARG or functional equivalents, may be inserted into appropriate expression vector, such as, for example a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. Thus, another aspect of the present invention is an expression vector comprising a regulatory sequence operatively linked to nucleic acid molecule comprising a nucleotide sequence disclosed herein. For example, an expression vector can contain a nucleotide

sequence at least about 1000 base pairs in length, which has at least about 70%, about 80%, or higher, sequence similarity with a sequence shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, and SEQ ID NO: 9.

Methods that are known to those skilled in the art may be used to construct expression vectors containing sequences encoding PARG and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination.

A variety of expression vector/host systems may be utilized to contain and express sequences encoding PARG. These include, for example, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with virus expression vectors (e.g., baculovirus), insects infected with virus expression vectors (e.g., fall army worm infected with baculovirus); plant cell systems transformed with virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus; TMV) or with bacterial expression vectors (e.g., Ti or bacterial plasmids); or animal cell systems. The invention is not limited by the host cell employed.

Prokaryotic expression systems are commercially available from a number of suppliers worldwide. Prokaryotic expression vectors provide a convenient system to synthesize proteins. If it is desired to express a protein with characteristics such as immunogenic properties, 3D conformation, and other features exhibited by authentic PARG, the protein may be expressed in an eukaryotic protein expression system. The eukaryotic expression systems are numerous and include mammalian, amphibian, plant, insect, and yeast expression systems.

Yeast hosts that can be used for expression include *Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastois, Hansela polymorpha, Kluyveromyces lactis*, and *Yarrowia lipolytica*. Yeast hosts offer the advantages of rapid growth on inexpensive minimal media and ease in large-scale production using bioreactors. Another advantage of yeast is the ability to direct expression to cytoplasmic localization or for extracellular export.

Most yeast vectors for protein expression are derivatives of the *S. cerevisiae* 2μ (two micron) plasmid. Yeast vectors include pYES and pEST from Stratagene (La Jolla, Calif.). Constitutive gene expression by the yeast plasmid cassette can be mediated by well known promoters such as the glyceraldehyde-3-phosphate dehydrogenase promoter (TDH3); the triose phosphate isomerase promoter (TPI1); the phosphoglycerate isomerase promoter (PGK1); the alcohol dehydrogenase isozyme II (ADH2) gene promoter; GAL1 and GAL10 promoters; the metallothionein promoter from the CUP1 gene (induced by copper sulfate); and the PHO5 promoter (induced by phosphate limitation). Proper termination of yeast transcripts is known to those in the art. Termination signals may include the MF-alpha-1, TPI1, CYC1, and PGK1 genes. These termination signals may be spliced onto the 3' end of the insert to provide proper termination.

Insect expression systems include baculovirus based vectors designed to express foreign proteins in a number of insect hosts and insect cell line hosts. Insect and insect cell lines may be of *Drosophila melanogaster, Aedes albopictus, Spodoptera frugiperda*, and *Bombyx mori* origin. Numerous expression systems comprising cells, vectors, hosts and the like can be purchased from a variety of commercial sources.

The control elements or regulatory sequences necessary for the proper expression of the insert, in this case PARG, may comprises promoters, enhancers (including both proximal

and distal control elements) which interact with the host proteins to carry out transcription and translation. Such elements may vary in their strength and specificity and are known to those in the art. Depending on the vectors system and host utilized, any number of suitable transcription and translation elements, including constitutive and inducible promoters, may be used. For example, the LacZ promoter may be used in a bacterial cell; the baculovirus polyhedrin promoter may be used in an insect cell; plant promoters such as heat shock promoters, and storage protein promoters, plant virus promoters and the like may be used in a plant cell. In a mammalian cell expression system, an SV40 promoter or EBV promoter may be used.

Methods and protocols for both prokaryotic and eukaryotic expression systems are generally known to those in the art. Further, the cells, vectors, growth medium may be purchased from commercial suppliers. The catalogs and product literature of commercial suppliers provide detailed protocols to enable the expression of proteins in prokaryotic and eukaryotic systems including bacterial, yeast, insect, insect cell, and mammalian cell systems. The product literature and catalogs of Clontech (Palo Alto, Calif.), Invitrogen (Carlsbad, Calif.), Life Technologies (Rockville, Md.), Novagen (Madison, Wis.), Pharmigen (San Diego, Calif.), Quantum Biotechnotogies (Montreal, Quebec, Canada), and Stratagene (La Jolla, Calif.) are incorporated herein by reference.

A further aspect of the invention is isolated proteins and protein fragments having poly(ADP-ribose) glycohydrolase (PARG) activity. Such a protein can comprise an amino acid sequence with sequence similarity of at least about 70%, about 80% or higher to a sequence shown SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. For example, the full-length bovine PARG has a molecular weight greater than about 100 kDa, thereby distinguishing it from previously known PARGs. The protein may be purified, for example, from cell lysates using the antibodies of the invention. The purification may be through an antibody column.

PARG polypeptides are another aspect of the invention. Polypeptides of PARG may be used, for example, to generate antibodies in an immunogenic procedure. To be effective it is preferred that the polypeptides are at least about 6 amino acid residues in length, such as for example, at least about 10 amino acids in length, at least about 20 amino acids in length, at least about 30 amino acids in length, at least about 50 amino acids in length, at least about 75 amino acids in length, at least about 100 amino acids in length, at least about 150 amino acids in length, at least about 200 amino acids in length, or at least about 400 amino acids in length. In one embodiment, the polypeptide has a molecular weight less than about 65 kDa and with at least about 80% sequence similarity with a sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. The polypeptide may consist of the sequence set forth in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 10.

The polypeptide of the invention may be conjugated to a larger molecule, such as, for example, keyhole lymphet hemocyanin (KLH), to increase the immunogenicity of the polypeptide. The increased immunogenicity of the polypeptide will, in turn, increase the yield of antibody. Preferably, the polypeptide has a molecular weight less than about 40 kDa and with at least about 90% sequence similarity with a sequence shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. The polypeptide can also be used in a wide variety of assays, e.g., as a competitor of antigen in a liquid sample in an antibody-based assay. Therefore, it is preferred that the polypeptide has poly

(ADP-ribose)glycohydrolase (PARG) activity. A particularly preferred polypeptide is of human origin and comprises an amino acid sequence substantially identical with SEQ ID NO: 4 from about residue 647 to about residue 977—the C terminus catalytic region of the enzyme. Longer sequences more inclusive of the natural molecule are of course also contemplated.

The invention also encompasses PARG variants and alleles. A preferred PARG variant is one having at least 80% and more preferably at least 90% amino acid similarity to the amino acid of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO: 10 and which retains at least one biological, immunological or other functional characteristic or activity of PARG. A most preferred PARG variant is one having at least 95% amino sequence similarity or identity to human PARG (SEQ ID NO: 3).

Antibodies to PARG may be generated using numerous established methods that are well known in the art. One example of such a method is described in the Examples. Generated antibodies may include, for example, polyclonal, monoclonal, chimeric, single chain, Fab fragments, Fab' fragments, Fab'(2) fragments, and fragments produced by a FAB expression library. Humanized antibodies and single chain antibodies may also be produced after the amino acid sequence of effective antibodies are determined.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others, may be immunized by injection with PARG or any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, for example, Freund's mineral gels such as aluminum hydroxide, and surface-active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvant used in humans, BCG (*bacilli* Calmette-Guerin) and *Corynebacterium parvum* are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to PARG have an amino acid sequence consisting of at least five amino acids and more preferably at least about 10 amino acids, such as for example about 20 amino acids or about 40 amino acids. It is also preferable that they are identical to a portion of the amino acid sequence of the natural PARG. Short stretches of PARG amino acids may be fused with those of another protein such as keyhole limpet hemocyanin and antibodies may be produced against the chimeric molecule.

Antibodies may be produced by inducing in vivo production in the lymphocyte population of a living animal or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in published procedures (16).

Antibody fragments that contain specific binding sites for PARG may be generated. For example, such fragments include the F(ab')$_2$ fragment, Fab fragment, Fab' fragment which can be produced by enzymatic digestion of the antibody molecule. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity (Huse, W. D. (1989) Science 254, 1275-1281).

Therapeutic Methods

A method of preventing, treating, or ameliorating a disease condition in a patient, which disease state is affected by the level of PARG expression is also contemplated. This method entails administering a therapeutically effective amount of a poly(ADP-ribose)glycohydrolase (PARG) inhibitor or acti-

vator to the individual. Particularly, implicated disease states are neoplastic disorder, myocardial infarction, vascular stroke and neurodegenerative disorders.

In one embodiment, antisense oligonucleotides for PARG may be used alone or in combination with other chemotherapeutic agents to treat neoplastic disorder. The anti-sense oligo is designed to hybridize in vivo to messenger RNA expressed by the organism. The use of anti-sense molecules in a therapeutic setting is described, for example, by S. Agrawal, *Antisense Therapeutics*, Humana Press. Currently favored protocols call for the oligo to have ribozyme activity in an effort to degrade the mRNA. These methods are described, for example, in *Therapeutic Application of Ribozymes*, K. Scanlon, ed., Humana Press. Therefore, in one embodiment, an antagonist of PARG may be administered to a subject to prevent or treat neoplastic disorder.

PARG levels may be enhanced to suppress DNA repair and increase a cell's susceptibility to chemotherapy drugs. Therefore, in another embodiment, an PARG enhancer is administered to a subject along with a chemotherapeutic drug as a treatment for neoplastic disorder.

Neoplastic disorders that can be treated by PARG elevation and chemotherapy include benign and malignant neoplasm such as, for example, adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, hyperplasia and hypertrophy. Neoplastic disorders may include, in particular, neoplastic disorders of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus. For the purposes of this invention, a neoplastic disorder is any new and abnormal growth; specifically a new growth of tissue in which the growth is uncontrolled and progressive. Malignant cancer is a subset of neoplastic disorders which show a greater degree of anaplasia and have the properties of invasion and metastasis.

The synthesis of effective anti-sense inhibitors is known. Numerous approaches have been previously described and generally involve altering the backbone of the polynucleotide to increase its stability in-vivo. Exemplary oligonucleotides and methods of synthesis are described in U.S. Pat. Nos. 5,661,134; 5,635,488; and 5,599,797 (phosphorothioate linkages), U.S. Pat. Nos. 5,587,469 and 5,459,255 (N-2 substituted purines), U.S. Pat. No. 5,539,083 (peptide nucleic acids) and U.S. Pat. Nos. 5,629,152; 5,623,070; and 5,610,289 (miscellaneous approaches). The disclosures of each of these references are incorporated herein by reference.

Significantly, the present invention discloses a method of identifying an agent that inhibits or activates poly(ADP-ribose) glycohydrolase (PARG) activity. Such method comprises (i) providing a liquid medium that contains a polypeptide of the present invention; (ii) contacting the polypeptide with a candidate agent, in the presence of a reference compound having affinity for the polypeptide, under predetermined assay conditions; and (iii) determining the affinity of the candidate agent for the polypeptide relative to the reference compound, thereby determining the inhibition or activation activity of the candidate agent relative to the reference compound. These determinations can be facilitated by immobilizing the polypeptide on a solid support. Alternatively, the polypeptide can be generated in vitro by culturing a cell transformed with a PARG gene under conditions effective to express the polypeptide.

Combination therapies are also afforded by the present invention in which a PARG inhibitor or activator is administered in combination with a chemotherapeutic or a "clot-

busting" drug. The clot-busting drug may be, for example, tissue plasminogen activator (t-PA) or streptokinase.

In some cases it may be desired to overexpress PARG in the cells of an organism in order to achieve the correct PARP/PARG balance. In this context of gene therapy, it is desired to stably transfect target cells with a vector, such as, for example, a viral or a DNA (nucleic acid) vector, so that the desired gene is overexpressed. Gene therapy vector systems and protocols are well known and are described, for example, in the *Internet Book of Gene Therapy* (17) Anti-sense and ribozyme approaches to cancer gene therapy are described in chapters 7-9 of the *Internet Book of Gene Therapy*, and are incorporated herein by reference. Another reference is *Gene Therapy Protocols*, P. Robbins, ed., Humana Press. Furthermore, gene therapy methods have advanced greatly and are well documented in numerous issued US patents. Gene therapy may be practiced, for example, by substituting a nucleic acid molecule of the invention with the nucleic acid molecule described in the methods referred to in any issued US patents directed to gene therapy (18).

Any of the therapeutic methods described above may be applied to any subject in need of such therapy, including, for example, mammals such as dogs, cats, cows, horses, rabbits, monkeys, and most preferably, humans.

Diagnostic Methods

Methods of genotyping an individual for a mutant PARG allele are also afforded by the present invention. A number of protocols are available for identifying a mutant allele as described herein once the nucleotide sequence encoding PARG is known. Some exemplary methods are restriction fragment length polymorphism (RFLP), allele-specific PCR (ASPCR) and single-strand conformation polymorphism (SSCP). Armed with this information, the genetic susceptibility of an individual to an above-mentioned disease condition can be assessed.

An allele-specific method for identifying point mutations by differential PCR amplication is described by (19). A non-electrophoretic method of genotyping with allele-specific PCR employs a dye specific for double-stranded DNA (20). A method of detecting mutations referred to as single-stranded conformation polymorphism (SSCP) is presently widely employed (21). A hybrid of SSCP and Sanger dideoxy sequencing, called dideoxy fingerprinting (ddF) has recently been described (22).

Other methods of identifying allelic mutations are known to the skilled artisan. Probably the most commonly used method of genotyping is restriction fragment length polymorphism (RFLP) (23), which is employs one or more restriction enzymes to identify mutant alleles occurring within a restriction site. This method has been used extensively in forensic applications and is employed commercially by such companies as Helix Biotech, Inc. Reliagene Technologies, Inc. and GenTest Laboratories, Inc. Accordingly, an instant mutant PARG allele can be detected by RFLP methods, optionally by one of these commercial entities. The above methods are most effective in the detection of homozygotes for the defective allele.

An RFLP method of identifying a mutant PARG allele in an individual entails: (i) obtaining genomic material from the individual; (ii) digesting the genomic material with a restriction enzyme having a recognition site inclusive of the mutant allele; (iii) fractionating the restriction fragments obtained from the digestion, e.g., by electrophoresis; and (iv) comparing the fractionation pattern with that obtained for a normal allele, thereby determining the presence or absence of the mutant allele.

An ASPCR method of identifying a mutant PARG allele in an individual entails: (i) hybridizing an oligonucleotide with genomic material from the individual; (ii) attempting to extend the oligonucleotide using PCR amplification; and (iii) determining the degree to which extension occurs, thereby determining the presence or absence of the mutant allele. In this method, it is preferred that the oligonucleotide hybridizes under predetermined hybridization conditions to a region immediately 5' of a predetermined mutation site in the PARG allele with the 3' terminus of the oligonucleotide complementary to an unmutated PARG allele. In these protocols, the PCR extension reaction is generally attempted at a temperature above about 50° C., more preferably above about 60° C.

A variety of protocols including ELISA, RIA and FACS for measuring PARG levels are known in the art and provide a basis for diagnosing altered or abnormal levels of PARG expression. Normal or standard values for PARG expression may be established by combining body fluids and tissue biopsies from normal mammalian subjects, rupturing the cells or permeating the cells, combining the cells with antibody under conditions suitable for complex formation. The amount of standard complex formation may be quantified by various methods but preferably by photometric means. Quantities of PARG expressed in subject, control, and disease sample are compared to standard values to determine between normal, reduced or enhanced levels of PARG.

A still further aspect of the invention pertains to an antibody immunoreactive with a polypeptide of the present invention. Preferably the antibodies are specifically immunoreactive with the polypeptides of this invention such as, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, and SEQ ID NO: 10. Frequently it is desired to label the antibody, e.g., with a radiolabel, fluorescent or epitope label, to permit visualizing the antibody. Thus, antibodies immunoreactive with the PARG of this invention are afforded, which can be used to study features of PARG heterogeneity and possible modes of regulation. The high degree of sequence similarity between bovine PARG, human PARG and murine PARG permits eliciting antibodies to PARG of one species, which are found to be cross-reactive with PARGs from other organisms. These antibodies are valuable in characterizing PARG in-vivo under defined physiological conditions in many different organisms.

Accordingly, a method of detecting a polypeptide having PARG activity, for example, a diagnostic assay, entails: (i) contacting the polypeptide with an aforementioned antibody of the invention; and (ii) determining whether the antibody immunoreacts with the polypeptide. Binding can be ascertained in an sandwich assay, as is well known, due to the ability of the antibodies to immunoreact with an epitope of PARG. Preferably, monoclonal antibodies, such as those prepared by the method of Kohler and Milstein (24) and labeled antigens effective in competing with the polypeptide, are employed. Exemplary assays are disclosed in U.S. Pat. No. 4,375,110, the disclosure of which is incorporated herein by reference.

The present invention includes immunoreactive fragments of a PARG enzyme. Immunoreactive fragments can be fragments that can elicit an immune response that recognizes a PARG enzyme. Alternatively, immunoreactive fragments can be fragments that are specifically bound by an antibody that specifically binds a PARG enzyme. Any of variety of methods may be employed in order to identify contiguous peptide fragments of a PARG enzyme that comprise immunoreactive sequences. PARG enzymes may be fractionated by proteases, cyanogen bromide, etc. and the resultant fragments assessed for their capacity to specifically bind anti-PARG antibodies.

In an alternative embodiment, one or more synthetic peptides may be prepared in order to locate contiguous amino acid sequences that are immunoreactive. The peptides may have a sequence that includes a series of contiguous amino acids that are identical to a series of contiguous amino acids of a PARG enzyme. The peptides may be of about six amino acids to about 500 amino acids in length. The peptide may also include sequences that are not identical to sequences of a PARG so long as it includes at least about six contiguous amino acids that are identical to about six contiguous amino acids of a PARG enzyme. In a preferred embodiment, the peptide will be about 50 amino acids in length. In other preferred embodiments the length of the peptide may be from about six amino acids to about 30 amino acids.

The peptides of the present invention may comprise amino acid sequences that elicit antibodies that specifically bind to the peptide or to a PARG enzyme. Alternatively, the peptides may contain sequences that are specifically bound by anti-PARG antibodies. Peptides that are bound by anti-PARG antibodies may identified through the use of Epitope Scanning™ strategy (Cambridge Research Biochemicals, Inc.). Thus, the linear sequence of amino acids of a particular PARG enzyme is used to construct a set of peptides of defined length which overlap other members of the set by one or more residues. The peptides may be any length; however, lengths of from about 6 to 25 amino acids are preferred. In selecting the length, a general consideration is that antibodies that recognize linear native epitopes constitute approximately 60-70% of the anti-protein antibody population (25).

The number of overlapping amino acids will generally be more than half of the length of the peptides. That is, if the peptides are about 20 amino acids long, the overlap may be 11 or more amino acids long. In preferred embodiments, each peptide will be selected such that the number of overlapping amino acid residues in adjacent peptides is from about (n-1) to (n-3), where "n" is the number of amino acids in the peptide. An overlap of (n-1) is particularly preferred. Thus, in a particularly preferred embodiment, a first peptide may have the amino acid sequence of residues 1-10 of a PARG enzyme, a second peptide may have the amino acid sequence of residues 2-11 of the same PARG enzyme, a third peptide may have the sequence of residues 3-12 of the same PARG enzyme and so on until the entire sequence of the PARG enzyme has been synthesized in fragments.

The peptides may be synthesized using any means known to those of skill in the art. In a preferred embodiment, the peptide will be synthesized using an automated synthesizer such as a multipin peptide synthesis system. Such systems or peptides synthesis services are commercially available from suitable providers known to those skilled in the art.

To identify suitable peptides, each peptide is introduced into a well of a microtiter plate, and assayed for its ability to bind to antibodies elicited by a PARG enzyme. Such assays may be conducted in various ways known to those skilled in the art. One suitable assay is conducted by immobilizing a peptide on the surface of a well and then contacting the peptide with a solution containing an anti-PARG antibody. After washing, the well is contacted with a labeled antibody that specifically binds to the anti-PARG antibody. Thus, the presence of label in the well indicates that the anti-PARG antibody bound to the immobilized peptide. Another preferred method of determining the ability of the peptide to be specifically recognized by anti-PARG antibodies is a competitive ELISA.

Once a particular peptide has been found to bind to anti-PARG antibodies, the peptide can be used to elicit monospecific antibodies. By immunizing an experimental animal with

a single peptide containing a single antigenic determinant, the antibodies elicited will all specifically bind to the same antigenic determinant even though the antibodies are not monoclonal.

Where desired, the peptides can be modified to increase their immunogenicity. Thus, they may be modified to contain an amino-terminal and/or a carboxyl-terminal cysteine or lysine residue with or without spacer arms. The peptides may be conjugated to carriers such as bovine serum albumin, ovalbumin, human serum albumin, KLH (keyhole limpet hemocyanin) or tetanus toxoid. The use of human serum albumin is preferred over ovalbumin or bovine serum.

The peptides, alone or conjugated to a carrier, may be themselves capable of eliciting an antibody response when administered to an experimental animal. Alternatively, the peptides, alone or conjugated to a carrier, may be administered in conjunction with an adjuvant. Those skilled in the art will understand that a variety of materials may function as adjuvants. Examples of possible adjuvants include, but are not limited to, Freund's complete adjuvant, Freund's incomplete adjuvant, lipopolysaccharide (LPS) and the like. Any material that increases the immune response to a fragment of a PARG enzyme may be used as an adjuvant.

The ability to produce large amounts of active PARG enzyme permits, for the first time, the large scale screening of chemical libraries for molecules capable of inhibiting or activating PARG enzymatic activity. The screening may be conducted using any assay for PARG known to those skilled in the art. In a preferred embodiment, the screen may be conducted using the TLC based assay described by Ménard, et al. (26). A known amount of PARG will be incubated under standardized conditions with [^{32}P]-poly(ADPR) in the presence of inhibitor or activator. After an appropriate period of time, the reaction will be stopped and the reaction mixture separated on PEI-F cellulose TLC plates. The TLC plates may be developed in an appropriate solvent system such as methanol followed by 0.3N LiCl. The amount of ADPR released in the reaction will be quantified and the effect of the inhibitor or activator on enzymatic activity will be determined. Typical reaction conditions are 50 mM potassium phosphate (pH 7.5) at 37° C. in the presence of 25 μM [^{32}P]-poly(ADPR). The concentration of the inhibitor or activator can be varied as necessary to determine the K_i value of the inhibitor or activator according to standard procedures.

Another embodiment of the invention is directed to a method of altering the response of the cell to a genotoxic stress by modulating the concentration of ADPR polymers. As discussed above, the metabolism of ADPR polymers is critical in determining the fate of cells subjected to genotoxic stress. The modulation can be either an increase or a decrease in the concentration of the polymers. In one embodiment of the present invention, the concentration of ADPR polymers can be decreased by the use of a gene therapy vector expressing a high level of PARG. In another embodiment of the present invention, the concentration of polymers can be increased by inhibiting the enzymatic activity of the PARG enzyme by the addition of inhibitors or activators identified as described above. Alternatively, the concentration of ADPR polymers can be increased by interfering with the endogenous expression of PARG enzymes using antisense oligonucleotide technology.

Knowledge of the nucleotide sequence of the PARG gene permits the preparation of antisense therapeutics containing sequences complimentary to the mRNA of PARG gene. The preparation and delivery of antisense therapeutics is well known to those skilled in the art. For example, antisense therapeutics have been used to treat neoplastic disorder as

exemplified by Smith, U.S. Pat. No. 5,248,671, specifically incorporated herein by reference. Additional examples of antisense therapeutics are provided by Miller, U.S. Pat. Nos. 4,511,713 and 4,757,055, specifically incorporated herein by reference.

In the present invention, an oligonucleotide having a sequence complimentary to the mRNA of the PARG gene will be prepared. Such an oligonucleotide is said to be an antisense oligonucleotide with respect to the PARG gene. The oligonucleotide may be RNA or DNA or a may contain both RNA and DNA portions. The oligonucleotide may contain modified bonds so as to enhance the stability of the oligonucleotide and render it more resistant to the action of cellular nucleases. For example, the oligonucleotide may be constructed with phosphorothioate nucleotides, phosphonate nucleotides and other types of modified nucleotides known to those skilled in the art. The structure of the oligonucleotide may be altered so as to include other types of bonds that do not naturally occur in oligonucleotides. For example, adjacent nucleosides might be joined using linear alkyl chains, peptide bonds or other types of structures. The only limitation is that the resulting oligonucleotide remains capable of hybridizing to the target PARG mRNA.

The antisense oligonucleotides may be delivered by any means customarily used in the art. For example, the oligonucleotide may be delivered in neutral liposomes, cationic liposomes or by ballistic high speed injection. Alternatively the DNA sequence encoding the antisense oligonucleotide may be inserted into a gene vector and the vector may be introduced into target cells. The vector may be any type of gene therapy vector known to those skilled in the art. Preferred embodiments include, plasmid vectors and viral vectors. Viral vectors are seen to include those vectors customarily used for gene therapy applications including, but not limited to, retroviral vectors, vaccinia virus vectors, herpes virus vectors, adenovirus vectors and adeno-associated virus vectors. Upon introduction of the vector into target cells, the vector will direct expression of a nucleic acid molecule comprising the appropriate sequence to hybridize with the mRNA encoding a PARG enzyme. In a preferred embodiment, introduction of the vector into the target cell will result in the production of an RNA molecule that hybridizes with the mRNA of a PARG enzyme and also includes one or more additional RNA sequences capable of functioning as a ribozyme. The ribozyme portion of the molecule will cause the cleavage of the mRNA encoding the PARG enzyme thereby preventing the production of PARG.

Therapeutics of this type may be used to treat a wide variety of conditions. In one embodiment, an antisense therapeutic will be used to treat neoplastic disorder. In a preferred embodiment, an antisense therapeutic of the present invention will be delivered in combination with a currently known chemotherapeutic agent. In general, chemotherapeutic agents function by disrupting the integrity of DNA in target cells. Since the recovery of a cell from such DNA disruption is highly dependent upon the normal ADPR polymer metabolism, the presence of the antisense therapeutic will have the effect of chemosensitizing the neoplastic cells by disturbing the ratio PARG and PARP.

In another preferred embodiment, the antisense oligonucleotides of the present invention may be used to treat a variety of conditions caused by genotoxic oxidative stress. Examples include cardiac disorders, neuronal disorders, reperfusion injury, neurotoxicity, Alzheimer's disease, Huntington's disease and Parkinson's disease. It has been shown that inhibition of ADPR polymer synthesis provides protection against cellular damage caused by nitric oxide injury. Zhang,

et al,. U.S. Pat. No. 5,587,384, specifically incorporated herein by reference, teach that decreasing the amount of ADPR polymers formed can result in protection against nitric oxide induced neurotoxicity. As discussed above, decreasing the amount of ADPR polymers in the cell can be accomplished by the introduction of gene therapy vector expressing PARG, thus, the present invention can be used to treat neurodegenerative conditions resulting from oxidative stress.

CONCLUSION

The synthesis and rapid turnover of ADP-ribose polymers is an immediate cellular response to DNA damage. Reported here is the isolation and characterization of cDNAs encoding various poly(ADP-ribose) glycohydrolase (PARG) enzymes responsible for ADP-ribose polymer turnover. PARG was isolated from bovine thymus, yielding a protein of approximately 59 kDa. Based on the sequence of oligopeptides derived from the enzyme, polymerase chain reaction products and partial cDNA clones were isolated and used to construct a putative full-length cDNA. The cDNA of approximately 4.1 kb pairs predicts expression of a protein of approximately 111 kDa, nearly twice the size of the isolated protein. A single transcript of approximately 4.3 kb pairs is detected in bovine kidney poly(A)$^+$ RNA, consistent with expression of a protein of 111 kDa. Expression of the cDNA in *Escherichia coli* results in an enzymatically active protein of 111 kDa and an active fragment of 59 kDa. Analysis of restriction endonuclease fragments from bovine DNA by Southern hybridization indicate that PARG is encoded by a single copy gene. Taken together, the results indicate that previous reports of multiple PARGs can be explained by proteolysis of an 111-kDa enzyme. The deduced amino acid sequence of the bovine PARG shares little or no sequence similarity with differing types of known proteins; however, it contains a putative bipartite nuclear location signal as would be predicted for a nuclear protein. The availability of cDNA clones for PARG should facilitate structure-function studies of the enzyme and its involvement in cellular responses to genomic damage.

Other embodiments and advantages of the invention are set forth, in part, in the description that follows and, in part, will be obvious from this description and may be learned from practice of the invention.

EXAMPLES

Example 1

Purification of Bovine PARG

PARG was purified from bovine thymus tissue (Pel-Freez, Rogers, A K) by modifications of previously published procedures (27). The enzyme was isolated up to the polyethylene glycol (PEG)-6,000 fractionation step as described previously (28). However, DNA-agarose and heparin-Sepharose chromatographic steps used previously were omitted, and the PEG-6,000 fraction was applied directly to an affinity matrix of poly(ADP-ribose)-dihydroxyboronyl-Sepharose (PADPR DHB-Sepharose). The active fractions eluted from PADPR DHB-Sepharose (25 ml) were pooled, placed in dialysis tubing, concentrated against dry PEG-20,000 to approximately 12 ml, and dialyzed against 2 liters of 20 mM potassium phosphate buffer, pH 8.0, 0.1% Triton X-100, 5 mM β-mercaptoethanol, 0.1 mM thioglycolic acid, 0.4 M KC1 (buffer A). The sample was loaded onto a 1.0×11-cm Toyopearl AF-Red (Supelco) column, and PARG was eluted with an 80-ml linear gradient of 0.4-2 M KCl in buffer A. The active

fractions, eluting at approximately 1.25 M KCl, were pooled, placed in dialysis tubing, concentrated against solid sucrose to approximately 9 ml, and dialyzed against 20 mM potassium phosphate buffer, pH 7.2, 0.75 M KCl, 0.1% Triton X-100, 10% glycerol, 5 mM β-mercaptoethanol, 0.1 mM thioglycolic acid. PARG activity was determined as described by Menard and Poirier (29), and protein content was determined by the method of Bradford (30). The final preparation was quantified by SDS-PAGE (31) and Coomassie Blue staining to compare the intensity of the protein band with a known amount of bovine serum albumin (32).

The purification procedure for the bovine thymus PARG summarized in Table 1 is typical for results obtained from six separate preparations of the enzyme. Purification from 500 g of bovine thymus achieved approximately 50,000-fold purification and yielded approximately 20 µg of purified protein. An aliquot of the purified enzyme was precipitated with trichloroacetic acid, washed with acetone, resuspended in SDS-PAGE sample buffer, separated on a 10% SDS-PAGE gel, and stained with Coomassie Blue. Analysis of the final preparation of SDS-PAGE revealed that more than 95% of the protein migrated at an apparent molecular mass of approximately 59 kDa (FIG. 2). In FIG. 2, an aliquot of the purified enzyme was precipitated by TCA, washed with acetone, resuspended in SDS-PAGE sample buffer, separated on a 10% SDS-PAGE gel and stained with Coomassie blue. The positions of molecular weight marker proteins are shown.

TABLE 1

Purification of PARG from bovine thymus					
Step	Protein mg	Total activity units	Specific activity units/mg protein	Yield %	Purification -fold
Crude extract	27,800	57,400	2.06	100	1.0
Protamine sulfate	12,500	58,000	4.64	101	2.3
Ammonium sulfate	4,480	30,000	6.70	52	3.3
CM-Sepharose	171	19,100	112	33	55
PEG 6000	23.0	7,530	327	13	160
PADPR-DHB-Sepharose	1.30	6,730	5,180	12	2,500
Toyopearl AF-Red	0.023	2,260	98,300	4	48,000

Example 2

Peptide Sequencing

Prior to proteolytic fragmentation, the purified bPARG (40 µg in 100 µl of 0.4 M ammonium bicarbonate buffer, pH 8.0, 8 M urea) was incubated in a final concentration of 2.2 mM dithiothreitol at 56° C. for 15 min. Iodoacetamide was added to a final concentration of 2.0 mM, and the sample was incubated at 25° C. for 15 min. After dilution with an equal volume of water, 1.5 units of immobilized L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin (Pierce Chemical, Rockford, Ill.) was added, and the sample was incubated at 37° C. for 18 h with gentle rotary shaking. Finally, the mixture was subjected to centrifugation at 16,000×g for 5 min to separate the tryptic fragments from the immobilized trypsin. The tryptic fragments were adjusted to 0.05% in trifluoroacetic acid and separated on a 4.6 mm×25 cm, Microsorb MV, C_4 reversed-phase HPLC column (Rainin) eluted with an 80-min linear gradient from 4 to 44%

acetonitrile in 0.05% trifluoroacetic acid. Four oligopeptide fractions, with approximate elution times of 61, 63, 68, and 75 min, were selected for peptide sequence analysis by the Edman degradation method. Amino acid sequence data of four oligopeptides, designated by their approximate HPLC elution times from the reversed-phase column, are shown in Table II.

TABLE II

Amino acid sequence of oligopeptides derived from bPARG

Oligopeptide	Amino Acid Sequence			SEQ ID NO:
	10	20	30	
68	LFTEVLDHNE	CLIITGTEQY	SEYTGYAETY R	SEQ ID NO: 11
63	AYCGFLRPGV	SSENLSAVAT	GNXGCGAFG	SEQ ID NO: 12
61	FLINPELIVS	R		SEQ ID NO: 13
75	IALXLPNIXT	QPIPLL		SEQ ID NO: 14

Example 3

cDNA Cloning

To obtain cDNA clones encoding bovine PARG, PCR amplification experiments were followed by the screening of two different bovine cDNA libraries. FIG. 3 depicts the alignment of the DNA sequences of two PCR products and eight λ gt11 cDNA clones used to identify the cDNA coding for bovine PARG. The two PCR products and clones 1 and 2 were obtained from the bovine thymus cDNA library. Clones 3-8 were obtained from the bovine kidney cDNA library. The positions of restriction sites used in this study are shown, and the top diagram shows the consensus clone, denoting the relative location of the coding regions for oligopeptides, 75, 61, 68, and 63 as well as the open reading frame and noncoding regions. For each of the cDNA inserts characterized, the sequence of both strands was determined by the dideoxynucleotide chain termination method using Sequenase™ (U.S. Biochemical Corp., Cleveland, Ohio).

The first step leading to the isolation of cDNA clones was to synthesize two multi-degenerate 17-mer primers, GAYCAYAAYGARTGYYT (SEQ ID NO: 15) and CKRTANGTYTCNGCRTA (SEQ ID NO: 16) (where Y represents T/C, R is A/G, K is T/G, and N is A/T/C/G), based on two regions of the SEQ ID NO: 11; "DHNECL" (amino acids 7 to 12 of SEQ ID NO: 11) and "YAETYR" (amino acid 26 to amino acid 31 of SEQ ID NO: 11) (Table II). Using the multidegenerate primers and an oligo(dT)-primed bovine thymus cDNA λgt11 library BL1019b from Clontech (Palo Alto, Calif.), PCR amplification generated a 74-bp DNA fragment with a deduced amino acid sequence identical to the corresponding region of oligopeptide 68. Next, two specific 24-mer oligonucleotide primers, ATCATCACAGGTACTGAGCAGTAC (SEQ ID NO: 17) and GCCTGTGTATTCACTGTACTGCTC (SEQ ID NO: 18), based on the sequence of this 74-bp DNA were used in combination with λgt11 forward and reverse primers to amplify PCR products 1 and 2 from the bovine thymus library. PCR product 1 contained 231 bp of sequence including the region encoding the N-terminal region of oligopeptide 68 (SEQ ID NO: 11) and the entire

sequence of oligopeptide 61 (SEQ ID NO: 13). PCR product 2 contained 757 bp, which included a sequence encoding the C-terminal region of oligopeptide 68 (SEQ ID NO: 11) and the entire sequence of oligopeptide 63 (SEQ ID NO: 12).

The sequence information obtained from PCR products 1 and 2 was used to isolate cDNA clones obtained by the screening of bovine thymus and bovine kidney cDNA libraries. A 518-bp EcoRI-HindIII fragment from PCR product 2 was used as a probe to screen approximately 1×10^6 independent clones from the bovine thymus library. Two positive cDNA clones (clones 1 and 2) were isolated, which overlapped PCR products 1 and 2. However, attempts to obtain clones from the bovine thymus library that contained sequence 5' to clone 2 were unsuccessful. Thus, a 231-bp EcoRI-KpnI fragment from clone 2 was used as a probe to screen approximately 5×10^5 independent clones of the bovine kidney 5' stretch plus cDNA λgt11 library BL3001b (Clontech, Palo Alto, Calif.). Three positive cDNA clones (clones 3-5) were obtained, all of which contained sequence 5' to clone 2. Each of these clones also contained a sequence encoding oligopeptide 75. Clones 1-5 provided multiple overlapping sequences in the 3'-terminal portion of a consensus cDNA, but additional clones were sought to obtain overlapping sequences for the 5'-terminal region. Thus, a 436-bp EcoRI-KpnI fragment located at the 5' end of clone 3 was used as a probe to screen approximately 6×10^5 independent clones of the bovine kidney library. Clones 6-8 provided overlapping sequences for the 5'-terminal region. The full-length cDNA was constructed by ligating a 3.9-kb XbaI-NsiI fragment from pWL11 (clone 1 cDNA insert in pTZ18R (33)) and a 3.0-kb NsiI-XbaI fragment from pWL13 (clone 4 cDNA insert in pTZ 18R). The resulting plasmid, termed pWL30, contained the 4,070-bp full-length cDNA.

FIG. 3 shows an alignment of the DNA sequences of two PCR products and eight λgt11 cDNA clones used to identify the cDNA coding for bovine PARG. The two PCR products and Clones 1 and 2 were obtained from the bovine thymus cDNA library. Clones 3 through 8 were obtained from the bovine kidney cDNA library. The position of restriction sites used in this study is shown and the top diagram shows the consensus clone, denoting the relative location of the coding regions for oligopeptides 75, 61, 68, and 63 as well as the open reading frame and non coding regions.

The nucleotide sequence of cDNA coding for bovine PARG is shown in the sequence listing as SEQ ID NO: 1. The deduced amino acid sequence of the enzyme is shown in the sequence listing as SEQ ID NO: 2. The four oligopeptides sequenced from purified enzyme is within SEQ ID NO: 2. They are IALCLPNICTQPIPLLK (amino acid 601 to 617, SEQ ID NO: 2); LINPELIVSR (amino acid 761 to 770, SEQ ID NO: 2); LFTEVLDHNECLIITGTEQYSEYTGYAETYR (amino acid 771 to 801, SEQ ID NO: 2) and AYCGFLRPGV PSENLSAVAT GNWGCGAFGGDAR (amino acid 849 to 880, SEQ ID NO: 2). The combined nucleotide sequence of Clones 1 through 8 predicted a full-length cDNA clone of 4,070 bp containing 257 bp of 5'-non-coding sequence, a single open reading frame of 2,931 bp (beginning at the ATG at position 258 of SEQ ID NO: 1) and a 3'-non-coding region of 882 bp. and the deduced amino acid sequence which predicts a protein of 977 amino acids and a molecular weight of 110.8 kDa.

Example 4

Analysis of the Sequence of Bovine PARG

The cDNA clone (SEQ ID NO: 1) has features typical of cDNAs that code for mammalian proteins. These include (i) an oligo A (putative poly(A)+) sequence at the 3'-end, (ii) a polyadenylation signal (AATAAA) 12 bp upstream from the oligo A sequence, (iii) a sequence of ATTTA in the 3'-untranslated region thought to play a role in selective mRNA degradation in mammalian cells (34), (iv) a single open reading frame, and (v) a nucleotide sequence around the first start codon commonly found at known sites of initiation of translation (35). The evidence that the cDNA clone constructed represents a full-length or nearly full-length clone for PARG is shown by the observation that hybridization of poly(A)+ RNA from bovine kidney cells with the cDNA showed a single band of hybridization of approximately the same size as the cDNA under stringent hybridization conditions (set forth above) (FIG. 4).

The nucleotide sequence encoding bovine PARG indicates that PARG shares little or no sequence similarity with other known sequences. A search of sequence data banks has failed to reveal significant sequence similarity with any sequences coding for known proteins. A strong sequence similarity has been observed with human and rat cDNA clones that likely represent partial clones for PARG from these species. Examination of protein sequence databases such as Genbank and SwissPro also has shown that the deduced amino acid sequence of PARG lacks any sequence similarity with known proteins. However, the amino acid sequence shares a significant similarity with a protein sequence from *Caenorhabditis elegans* that may represent the PARG protein from this organism (36).

The deduced amino acid sequence of PARG has been examined for a number of structural motifs that can be predicted from the primary amino acid sequence. The expressed PARG protein was observed to be able to form dimers stable to SDS-PAGE conditions. In that regard, residues 871-907 show significant homologies to known leucine zipper dimerization sequences (37).

Another motif identified is a putative bipartite nuclear location signal (NLS) (38). It is interesting that PARP also contains a bipartite NLS (39). FIG. 5 compares deduced amino acid sequences in the NLS region of the bovine PARG, and regions of putative PARG sequences from human, mouse and *C. elegans*, with the NLS region of PARP from seven different organisms. Conserved residues are noted in bold and the amino acid distances are from the amino terminal methionine residue. Abbreviations and references for the sequences shown are as follows: bPARG, bovine PARG (SEQ ID NO: 19); hPARG, human PARG (SEQ ID NO: 20); mPARG, murine PARG (SEQ ID NO: 21); CePARG, *Caenorhabditis elegans* PARG (SEQ ID NO: 22); hPARP, human PARP (SEQ ID NO: 23; 40); mPARP, murine PARP (SEQ ID NO: 24; 41); bPARP, bovine PARP (SEQ ID NO: 25, 42); aPARP, chicken PARP (SEQ ID NO: 26; 43); XlPARP, *Xenopus laevis* PARP (SEQ ID NO: 27; 44); DmPARP, *Drosophila melanogaster* PARP (SEQ ID NO: 28; 45); SpPARP, *Sarcophaga peregrina* PARP (SEQ ID NO: 29; 46). In FIG. 5, conserved residues are noted in boldface type, and the amino acid distances are from the amino-terminal methionine residue. Sequence alignment of putative bipartite nuclear localization signal of bovine, human and murine PARG compared to the nuclear localization signal of PARP from different organisms. The putative NLS of PARG fulfills the criteria for bipartite NLS in that it contains conserved acidic and basic amino acid residues at

two different locations each within the region of sequence similarity to the NLS of PARP (47).

A surprising finding was that the bovine PARG cDNA clone codes for a protein of approximately 111 kDa, which is nearly twice the size of the PARG protein isolated from bovine thymus (FIG. 2). It indicates that PARG contains a protease sensitive site that, following proteolysis, yields a protein fragment of approximately 59 kDa that still retains enzymatic activity. Several pieces of evidence favor this possibility. (i) Expression of the carboxyl terminal portion of the cDNA resulted in enzymatic activity (FIG. 6, bar 5). (ii) All of the oligopeptides sequenced were located in the carboxyl terminal half of the protein (FIG. 3, FIG. 6 and Table 2). (iii) The only protein, other than 59 kDa protein detected in the thymus preparation was approximately 111 kD (FIG. 2). (iv) The PARG activity expressed in bacteria was sensitive to proteolysis, yielding a protein of approximately 56 kD (FIG. 6). (v) The cleavage site in PARG is in the region of the putative NLS and the PARP NLS is located in a protease sensitive site (48). Taken together with the data suggesting that bovine PARG appears to be coded for by a single copy gene (FIG. 7), proteolysis seems likely to explain the presence of PARG activity of molecular weight of approximately 74 kDa and 59 kDa in bovine thymus preparations (49). Likewise, a similar mechanism could explain previous reports of a PARG of 74 kDa isolated from nuclear fractions of guinea pig liver and human placenta (50) and a PARG of 59 kDa isolated from postnuclear fractions of guinea pig liver (51).

While proteolysis of a larger protein to yield smaller proteins retaining PARG activity seems likely to explain the size heterogeneity of PARG previously reported, it remains to be determined if proteolysis normally occurs in vivo or whether it occurs during purification of the enzyme. While the results presented here show that a full-length protein can be expressed containing PARG activity (FIG. 8), the molecular size of PARG in vivo also remains to be determined. If PARG occurs as a larger protein, an interesting possibility is that the amino terminal region may be involved in the regulation of enzymatic activity.

Example 5

Expression of bPARG in *Escherichia coli*

To determine whether the isolated cDNA encoded PARG, bPARG was express using two different bacterial expression systems, the pTrcHis Xpress System™ (Invitrogen, Carlsbad, Calif.), in which the expressed protein contains a leader polyhistidine sequence, and the glutathione S-transferasae (GST) gene fusion system (Pharmacia Biotech Inc., Piscataway, N.J.). For expression in the pTrcHis Xpress system, three different DNA fragments were amplified and inserted into the pTrcHis expression plasmid. Constructs A and B contained the entire opening reading frame of 110.8 kDa, which together with the fusion partner predicted a protein of about 115 kDa. Construct B also contained the 3'-untranslated region of the clone. Construct A, containing the cDNA sequence-3 to 2,946, was prepared by subcloning a 2.9kb XhoI-EcoRI DNA fragment amplified from pWL30 with primers WIN34 (GCTGCGGGTCTCGACGATGAGT-GCGGGC) (SEQ ID NO: 30) and WIN15 (GCGTCTA-GAATTCACTTGGCTCCTCAGGC) (SEQ ID NO: 31). Construct B, containing the cDNA sequence-3 to 3,813, was prepared by subcloning a 3.8-kb XhoI-EcoRI DNA fragment amplified from pWL30 with primers WIN34 (SEQ ID NO: 30) and WIN33 (CCGGAATTCGGGTTTTTTGTTAAT-

GAAAATTTATTAAC) (SEQ ID NO: 32). Construct C, containing cDNA sequence 964-2,946, was prepared by subcloning a 2.0-kb DNA fragment amplified from pWL13 with primers WIN14 (TCAGAGCAGATGAACTCGAGCAGTC-CAGG) (SEQ ID NO: 33) and WIN15 (SEQ ID NO: 31). Since the isolated PARG of approximately 59 kDa contained enzymatic activity, construct C contained only the 75-kDa carboxyl-terminal region of the PARG, which predicted a fusion protein of approximately 79 kDa.

For expression experiments of bPARG as a GST fusion protein, an insert containing the cDNA sequence from position 1138 to 2946 was prepared by subcloning a 1.8-kb EcoRI-EcoRI fragment amplified from pWL30 with the oligonucleotide CCAATTTGAAGGAGGAATTCCCGCCGC-CACCATGAATGATGTGAATGCCAAACGACCTGGA (SEQ ID NO: 34) and WIN15 (SEQ ID NO: 31) as primers. The resulting DNA fragment was inserted into the EcoRI site of the pGEX-2T expression vector, and the plasmid was used to transform E. coli NM522 cells.

For expression experiments, bacterial cultures were grown at 37° C. in 1% Bacto-tryptone, 0.5% yeast extract, and 0.5% NaCl to a density of approximately 0.6 A_{600}/ml and were induced with 1 mM isopropyl-β-D-thiogalactoside (IPTG). Cells were-collected by centrifugation, and crude extracts were prepared by sonication (10 A_{600}/ml) in 10 mM sodium phosphate buffer, pH 7.2, 150 mM NaCl, 0.5 mg/ml lysozyme, 0.1 mg/ml phenylmethylsulfonyl fluoride, 1 mM EDTA, 0.7 µg/ml pepstatin A, 0.5 µg/ml leupeptin, and 1 µg/ml aprotinin. Cell extracts were subjected to centrifugation, and the supernatant fraction was used for assay. PARG assay conditions were as described previously (52). Following incubations, portions of reaction mixture were analyzed by thin layer chromatography or subjected to anion exchange HPLC.

Using a thin layer chromatography assay that measures release of [^{32}P]ADP-ribose from [^{32}P]ADP-ribose polymers (53), PARG activity was detected in extracts from cells transformed by each of the constructs. FIG. 6 shows results obtained with constructs B and C. Reaction mixtures contained approximately 15,000 cpm of [^{32}P]ADP-ribose polymers, and the cpm shown represent ADP-ribose released from the ADP-ribose polymers. Bar 1, a strain transformed by pTrcHis without an insert but induced with 1 mM IPTG for 5 h at 37° C. A strain containing construct B is shown without the addition of IPTG (bar 2) or after the addition of 1 mM IPTG for 1.5 h (bar 3) or 5 h (bar 4). A strain containing construct C 5 h after induction by IPTG is shown in the absence (bar 5) and presence (bar 6) of 167 µm ADP-hydroxymethylpyrrolidine diol (54). No activity was detected in cells transformed with the empty vector, but activity was detectable without induction by IPTG, indicating a leaky lac promoter. The addition of IPTG resulted in a time-dependent increase of up to approximately 4.5-fold in enzymatic activity. FIG. 6 also shows that the enzymatic activity was strongly inhibited by the presence of ADP-hydroxymethylpyrrolidine diol, a specific inhibitor of PARG (55).

In FIG. 9, material released from ADP-ribose polymers by anion exchange HPLC was analyzed. Extracts from a strain containing construct B were incubated with [^{32}P]ADP-ribose polymers (56), and a portion was analyzed by anion exchange HPLC as described. The elution times for AMP, ADPR, and PR-AMP are indicated by arrows. The material analyzed was PARG expressed in E. coli. The results indicated that the material released from ADP-ribose polymers is exclusively ADP-ribose by strong anion exchange HPLC (FIG. 9), demonstrating that the cell extracts did not contain any other

ADP-ribose polymer-degrading enzymes such as phosphodiesterase, which catalyzes the formation of AMP and phosphoribosyl-AMP (57).

Anion exchange HPLC utilized a Whatman Partisil SAX column equilibrated with 7 mM potassium phosphate buffer pH 4.0, at a flow rate of 1 ml/min. The sample was diluted in the same buffer, applied to the column, and eluted with a 30-min linear gradient from 7 mM potassium phosphate buffer, pH 4.0 to 250 mM potassium phosphate buffer, 0.5 M KCl, pH 4.0.

To determine the size of the expressed enzymatic activity, an activity gel assay (58) was used. Activity gel assays for bPARG were done by casting polyacrylamide gels with auto-modified PARP containing [^{32}P]ADP-ribose polymers as described previously (59). Following electrophoresis, PARG was renatured by incubating the gels at 25° C. in 5 volumes of 50 mM sodium phosphate buffer, pH 7.5, 50 mM NaCl, 10% glycerol, 1% Triton X-100, 10 mM β-mercaptoethanol, changing the buffer every 3 h for a total of five changes. After an additional incubation at 37° C. for 3 h, gels were dried, and PARG activity was detected following autoradiography as a clear band on a black background. Cell extracts containing PARG fused to GST were examined for binding to glutathione-Sepharose 4B (GSH-Sepharose) (Pharmacia Biotech Inc.) according to the specifications of the manufacturer. No bands were produced from extracts from the IPTG-induced pTrcHisB vector that did not contain an insert. Extracts from cells transformed with a construct containing a PARG insert showed bands at approximately 1 15 and 59 kDa (FIG. 8). During storage at 4° C., cell extracts lost activity migrating at the higher molecular weight, while the activity at approximately 59 kDa increased.

Expression of bPARG in the pTrcHisB expression vector did not result in detectable amounts of protein by staining the Coomassie Blue. Thus, another construction was designed to overexpress a 69-kDa carboxyl-terminal region of the PARG as a fusion with GST, which allows convenient protein purification by affinity chromatography on a GSH-Sepharose column. Two hours after induction with IPTG, strong expression of a protein migrating at approximately 90 kDa was observed. This protein bound to GSH-Sepharose and was eluted by GSH. The construct contained a thrombin cleavage site between the GST and the 69-kDa region of PARG, and the treatment of-the material bound to GSH-Sepharose with thrombin resulted in the release of a protein that migrated at approximately 59 kDa. This result suggests that the protein purified from the bovine thymus may be larger than suggested by its migration on SDS-PAGE. The result of this experiment is presented in FIG. 10. Lane 1 shows extract from uninduced cells; lane 2 shows extract from cells induced with 1 mM IPTG for 2 hours; lane 3 shows proteins in extracts from cells shown in lane 2 that bound to GSH-Sepharose; lane 4 shows material released from GSH-Sepharose by treatment with thrombin.

In addition to the GST fusion construct described above, several other GST fusion proteins have been made. FIG. 11 shows the portions of the bovine PARG gene that have been expressed. The top line represents the structure of bovine PARG mRNA containing the open reading frame encoding the 111 kDa PARG protein. The different parts of PARG that have been cloned in expression vectors are represented with the size of the resulting expressed recombinant proteins. The expression of the 65 kDa catalytic domain of PARG (starting at the amino acid MNDV) in pGEX-2T as a fusion protein with glutathione-S-transferase (29 kDa) is detailed. Among the constructs, only the clone designed to express a protein of 69 kDa starting at amino acid +380 from the sequence of

bovine PARG (bPARC$_{MNDV}$) allowed high level expression as a fusion protein with glutathione-S transferase (GST). A 1.8 kb PCR EcoRI fragment encoding for the 65 kDa catalytic domain of PARG was cloned into the EcoRI site of pGEX-2T giving pGEX-2T-bPARG$_{MNDV}$. This construction results in the expression of a fused polypeptide consisting of the sequence of GST. Amino acids derived from the polylinker and thrombin site and the 65 kDa domain (FIG. **12**).

In addition to various constructs designed to express PARG in *E. coli*, a recombinant baculovirus expressing a functional PARG has been constructed using the methodology of Summers and Smith as set out in U.S. Pat. No. 4,879,236 which is specifically incorporated herein by reference.

bPARG$_{MNDV}$ was cloned in baculovirus transfer vector pVL1393 using the EcoRI site. The recombinant vector was constructed as follows. An insert containing the cDNA sequence from position 1138-2946 of bovine PARG was prepared by subcloning a 1.8 kb EcoRI fragment amplified from pWL30 using oligonucleotides CCAATTTGAAGGAG-GAATTCCCGCCGCCACCATGAATGATGT-GAATGCCAAACG ACCTGGA (SEQ ID NO: 34) and GCGTCTAGAATTCACTTGGCTCCTCAGGC (SEQ ID NO: 31, WIN15). The resulting fragment was inserted into the EcoRI site of the pVL1393 baculovirus transfer vector. The amplification introduced a Kozak consensus sequence (gaattcccgccgccaccATGAA SEQ ID NO: 35) at the start site of translation to enhance expression of the recombinant protein. The resulting recombinant plasmid was cotransfected with linearize Baculogold™ baculovirus DNA (Pharmingen, San Diego, Calif.) into SF9 cells according to the manufacturers instructions. Recombinant viruses isolated using standard techniques. Overexpression of the recombinant protein was confirmed by Western blot and the results displayed in FIG. **13** demonstrate that the 65 kDa domain expressed in *E. coli contained enzymatic activity (lane* 2) migrating with the same apparent molecular weight as the enzyme purified from bovine thymus (lane 1). Likewise, a construct expressing bPARG$_{MNDV}$ domain in SF9 insect cells infected with recombinant baculovirus showed activity (lane 4) migrating with the same apparent molecular weight.

Example 6

Northern Blot Analysis

An surprising feature of the consensus full-length cDNA clone was that it predicted expression of a protein of approximately 111 kDa (FIG. **3**, SEQ ID NO: 1, and SEQ ID NO: 2), while the enzymatically active PARG from thymus had a molecular weight of approximately 59 kDa (FIG. **2**). To determine the size of the RNA transcript for PARG, total RNA and poly(A)+ RNA were isolated from bovine kidney (MDBK) cells and annealed using Clone 4 as the hybridization probe.

Total cytoplasmic RNA and poly(A)+ RNA were isolated from bovine kidney MDBK cells (ATCC #CCL22) using TRIzol reagent (Gibco/BRL) following the manufacturer's recommendations. After the RNA was fractionated, it was then transferred to nylon membranes and hybridized with Clone 4 (FIG. **3**) radiolabeled by a random hexamer priming method (21). The results are presented in FIG. **4**. Total RNA (5 μg, lanes 1A and 1B) and poly(A)+ RNA (4 μg, lanes 2A and 2B) were separated on a denaturing agarose gel (60). Panel A shows the ethidium bromide stained gel and panel B shows the autoradiogram of a Northern blot analysis using a random primed, ^{32}P-labeled DNA probe constructed from Clone 4 (FIG. **3**). A single transcript of approximately 4.3 kb

was detected in the poly(A)+ RNA (FIG. **4**, lane 2). Thus, the transcript size was consistent with the expression of a 111 kDa PARG protein.

Example 7

Southern Blot Analysis of PARG Genomic Complexity

Previous studies have reported that PARG isolated from nuclear fractions had a molecular weight of approximately 75 kDa (61), while PARG isolated from whole cell homogenates or postnuclear supernatant fractions had a molecular weight of approximately 59 kDa (62). These results suggest that either two or more genes may code for PARG or that proteolysis generates lower molecular weight forms from higher molecular weight forms. The cDNA isolated encoded a protein considerably larger than any PARG proteins previously described, consistent with the possibility that the different forms of PARG are derived from a single form by proteolytic cleavage. To test the hypothesis that PARG is encoded by a single copy gene, the genomic complexity of the PARG gene was analyzed by a Southern hybridization experiment.

Total genomic DNA was prepared from bovine thymus tissue as described previously (63) and DNA (10 μg) was digested with EcoRI, BglII, XbaI or PstI, fractionated on a 1% agarose gel, transferred to a nylon membrane (Hybond N+, Amersham), and hybridized using an 828 bp HindIII fragment of Clone 1 radiolabeled as described for clone 4 above (64). Pre-hybridizations and hybridizations were carried out at 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, pH 7.2, 0.25 M NaCl, 7% SDS, 1 nM EDTA. The blot was annealed with a ^{3}P-labeled DNA probe corresponding to the carboxyl terminal region of the PARG protein.

The results of the Southern blot analysis are presented in FIG. **7**. Genomic DNA was digested with four different restriction enzymes, EcoRI (lane 1), BglII (lane 2), XbaI (lane 3) and PstI (lane 4), none of which cleave within the carboxyl terminal region of the PARG cDNA. Following electrophoresis, the restriction digests were subjected to hybridization with a probe that corresponded to the carboxyl terminal region of the PARG cDNA. The analysis displayed in FIG. **7** shows that, in each restriction digest, the probe hybridized primarily with a single restriction fragment. The fainter signals likely reflect the presence of introns in the PARG gene. This result indicates that PARG is encoded by a single copy gene in the bovine genome.

Example 8

Isolation and Characterization of PARGs from Other Species

The isolation and characterization of bovine cDNA encoding poly(ADP-ribose)glycohydrolase (PARG) has been described above. Using the information provided by the sequencing of bovine PARG, various tools were used, including public sequence databases searches and screening of cDNA libraries using PARG specific probes, to clone and sequence the cDNA and determine the primary structure of PARG from human, mouse, *Drosophila* and *Caernorhabditis elegans*. Mammalian sequences newly obtained using this combined strategy show high sequence similarity to bovine PARG (bPARG), whereas the sequences of *Drosophila* and *C. elegans* only display significant homologies in the region responsible of the catalytic activity of the protein.

The strategy followed to obtain cDNAs coding for proteins with sequence similarity to bovine PARG is summarized in FIG. **14**. dBEST, GenBank, SwissProt and PIR databases were searched for PARG like-sequences at the nucleotide or amino acid level using the programs BLASTn, TBLASTn (Altschul et al., 1990) respectively, available at the NIH site on the Worldwide Web, and also included in the sequence analysis package from the Genetic Computer Group, Inc. (GCG) (Madison, Wis.), version 9.1. Both programs perform pair-wise sequence comparisons on multiple nucleotide or amino acid sequences. PARG multiple sequence comparisons obtained with these programs are very similar. Box-shading of the amino acids in the multi-sequence alignment was obtained using the program BOXSHADE (K. Hofmann and M. D. Baron). The first step involved extensive searching for sequences with bPARG similarity in various databases. As a result of this search several partial nucleotide sequences sharing extensive homologies with bPARG cDNA were obtained from the dBEST database (65). These sequences were the result of random cloning and sequencing of partial cDNAs clones obtained from mRNAs expressed in various tissues and organisms. Among them, partial cDNAs coding for PARG from human and mouse were available. One of these human clones was particularly interesting as its sequence (2500 bp long) overlapped the coding sequence of bovine PARG from aa470 to aa977 (Carboxy terminus end) and contained all the 3' untranslated region of the human PARG cDNA. This clone (No. 50859; GenBank accession number: H17209) was requested and freely obtained from the IMAGE Consortium (in collaboration with Washington University School of Medicine in St. Louis, Mo. and Merck & Co., info@image.llnl.gov). The sequence of the clone was then completed. This partial cDNA permitted design of a radiolabeled probe (fragment HindIII—KpnI of 677 bp) specific to human PARG (SEQ ID NO: 36).

Example 9

Cloning and Sequencing

The cloning procedures used in this work generally known and are also described in details in the book, *Molecular Cloning: A Laboratory Manual* (Maniatis et al., 1982). DNA sequencing was performed using the dideoxynucleotide method of Sanger (Sanger et al., 1977). Chemical reagents were purchased from Sigma (St. Louis, Mo.). Restriction enzymes, T4 DNA ligase were from New England Biolabs, Inc. (Beverly, Mass.), T7 DNA polymerase Sequenase from US Biochemical (Cleveland, Ohio), Calf Intestine Phosphatase from Boehringer, Manheim (Indianapolis, Ind.). The phagemid pTZ18/19R is from Pharmacia (Piscataway, N.J.). The labeled nucleotides α-[^{35}S]-dATP and α-[^{32}P]-dCTP were purchased from ICN (Costa Mesa, Calif.). Human thymus and murine liver 5'-stretch cDNA libraries cloned in the vector λgt 10 were from Clontech (Palo Alto, Calif.).

A single, isolated colony of C600Hfl *E. coli* strain was picked and grown in 5 ml of Luria-Bertani medium (LB)+10 mM MgSO$_4$+0.2% maltose overnight at 37° C. in a shaker. The bovine library lysate was diluted 1:250,000 and incubated with the C600Hfl bacterial overnight culture and 1× lambda dilution buffer. Next, LB soft top agar+10 mM MgSO$_4$ was added, and the entire mixture was quickly poured onto 90 mm LB agar+10 mM MgSO$_4$ plates. The plates were cooled briefly at room temperature to allow the inoculum to soak into the agar before they were incubated at 37° C. for 6-7 hr. The number of clear plaques was counted to determine the titer.

Plaques containing the entire library that had been plated were transferred to nitrocellulose or nylon membranes. The filters were then washed in a 1.5 M NaCl/0.5 M NaOH solution to lyse the cells. This was followed by a 5 min wash in neutralizing solution (1.5 M NaCl/1 M Tris buffer pH 8). Finally, the filters were rinsed in 0.2×SSPE (30 mM NaCl/2 mM sodium phosphate buffer pH 7.2/0.2 mM EDTA) (Sambrook et al., 1992). The filters were then dried and baked in a 80° C. oven for 2 hr to fix the lysed plaques onto the filters.

Radioactive probes were prepared using a random hexamer priming method. Pre-hybridizations and hybridizations were carried out at 42° C. in 50% formamide, 0.25 M sodium phosphate buffer, pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA.

Example 10

Specific Methods Used for Library Screening

All the cloning procedures used in obtaining the additional PARG cDNAs and determining their sequences were performed essentially as described for the bovine PARG cDNA and sequence. Human thymus and murine liver 5'-stretch cDNA libraries cloned in the vector λgt 10 were from Clontech (Palo Alto, Calif.).

Library plating and titering: A single, isolated colony of C600Hfl *E. coli* strain was picked and grown in 5 ml of Luria-Bertani medium (LB)+10 mM MgSO4+0.2% maltose overnight at 37° C. in a shaker. The library lysate was diluted 1:250000 and incubated with the C600Nfl bacterial overnight culture and 1× lambda dilution buffer. Next, LB soft top agar+10 mM MgSO4 was added, and the entire mixture was quickly poured onto 90 mm LB agar+10 mM MgSO4 plates. The plates were cooled briefly at room temperature to allow the inoculum to soak into the agar before they were incubated at 37° C. for 6-7 hr. The number of clear plaques was counted to determine the titer.

Plaque lifts: Plaques containing the entire library that have been plated are transferred to nitrocellulose or nylon membranes. The filters are then washed in a 1.5 M NaCl/0.5 M NaOH solution to lyse the cells. This is followed by a 5 min wash in neutralizing solution (1.5 M NaCl/1 M Tris buffer pH 8). Finally, the filters are rinsed in 0.2×SSPE (30 mM NaCl/2 mM sodium phosphate buffer pH 7.2/0.2 mM EDTA) (66). The filters are then dried and baked in a 80° C. oven for 2 hr to fix the lysed plaques onto the filters.

Making a radioactive probe and Hybridizations: Radioactive probes were prepared using a random hexamer priming method. Pre-hybridizations and hybridizations were carried out at 42° C. in 50% formrnamide, 0.25 M sodium phosphate buffer, pH 7.2, 0.25 M NaCl, 7% SDS, 1 mM EDTA. This partial cDNA allowed to design a radiolabeled probe (fragment HindIII—KpnI of 750 bp long) specific to human PARG.

Example 11

Screening of a Human Thymus 5'-stretch cDNA Libraries

Multiple screenings of a human thymus 5'-stretch cDNA library were performed to complete the cloning of human PARG cDNA. For each screening a new probe was designed and used to screen approximately one million recombinants of the library. During each round of screening, overlapping clones were isolated at high stringency conditions and subcloned into the EcoRI site of pTZ18/19R phagemid using

standard techniques. The different positive clones (J5, C, E1, E2, M, M', M'', P', P'', Of, O2) were characterized by restriction analysis, subcloned into the appropriate restriction sites of pTZ18/19R as necessary and sequenced in both strand using the dideoxynucleotide method. The probe used to complete the cloning of the human cDNA library is shown is SEQ ID NO: 37. Finally, a full-length cDNA sequence was assembled which encodes the human PARG. The sequence of the cDNA encoding human PARG is presented in the sequence listing as SEQ ID NO: 3 and the amino acid sequence of human PARG is presented in the sequence listing as SEQ ID NO: 4.

The human PARG sequence shares extensive amino acid sequence homologies with bovine PARG with more than 89% identity. The sequence similarity is also high at the nucleotide level particularly in the region coding for the protein (174ATG-TGA3104). Surprisingly the 5'-untranslated region of the human sequence displays a completely different sequence with an extensive sequence similarity with highly repeated polymorphic DNA sequences found in the human genome such as Alu repetitive elements or variable number of tandem repeats (VNTR).

Example 12

Screening of Mouse Liver 5'-stretch cDNA Libraries

To isolate a PARG cDNA from the mouse liver cDNA library, a probe was designed from the human cDNA clone coding for PARG. Analysis of the bovine and human sequences revealed that PARG was highly conserved between these two species, suggesting that it might also be conserved in the mouse. Based on the restriction map of the human cDNA clone, a region in the human clone was selected, located where the active site of the protein is encoded, that exhibited near identity to its counterpart in the bovine clone. This region, consisting of approximately 800 bases, was excised from the entire human clone by digestion with the restriction endonuclease, HindIII, then purified by agarose gel separation and radiolabeled by random priming.

This probe was used to screen a mouse liver 5'-stretch cDNA library. One clone consistently hybridized with the probe. After two rounds of screening to ensure the purity of the clone the 2.5 kb insert was subcloned into the plasmid pTZ19R and sequenced. Comparison with the sequence of bovine and human PARG showed that this clone had the partial sequence that has extensive similarities to the two other mammalian sequences covering almost entirely the coding region from nucleotide −10 to a few nucleotides from the end of the coding region. A second screen was performed to obtain the missing part of the cDNA using a radioactive probe specifically designed to hybridize with the region the most 3' of the previous clone to increase the chance to get the missing part of the cDNA.

With this new probe, the same mouse liver cDNA library was screened to obtain a second clone, containing an insert that was about 3 kb. This clone was purified, subcloned and sequenced. The sequence showed that this second clone starts at amino acids 634, extends toward the stop codon to approximately 900 nucleotides into the 3' non-coding region.

A search of the dBEST database turned up one significant match to a 400 bp fragment cloned from mouse muscularis. This fragment had an exact match to the very tail end of the second clone and exceeded it by 34 bases. This extra extension contained the oligo A sequence as well as the polyadenylation signal. Because there was an exact match, the cDNA sequence was completed using this information coming from the database. The complete cDNA sequence of murine PARG is presented in the Sequence Listing as SEQ ID NO: 5 and SEQ ID NO: 6.

Example 13

Obtaining the *Drosophila* PARG cDNA

Among the clones obtained from DNA databases searches were several clones from the *Drosophila* genome sequencing project (European *Drosophila* Genome Sequencing Consortium) as well as the *Drosophila* expression sequence TAG sequencing project (67). The EST clone was requested from the University of California Berkeley and obtained. Because the sequence published in the dBEST database was only partial, its sequence was completed in our laboratory and compared to a genomic sequence, part of the distal X chromosome of *Drosophila melanogaster* submitted by Murphy et al., August 1997 which presumably contains the gene of *Drosophila* PARG. The 768 aa shares less homologies with only 40% identity (48% similarity) mainly located in the catalytic domain of the protein. The domain organization of the protein is also very different with an unknown domain of 20 kDa located Carboxy terminus of the highly conserved active domain. (See FIG. 15). The sequence of the cDNA encoding the *Drosophila* PARG is presented in the Sequence Listing as SEQ ID NO: 7 and the amino acid sequence of the *Drosophila* PARG is presented in the Sequence Listing as SEQ ID NO: 8.

Example 14

Obtaining the *C. elegans* PARG Sequence

This sequence has been obtained by searching the GenBank database with the mammalian PARG protein sequence. A sequence with PARG similarity was found in the cosmid F20C5 (Accession number: Z68161, SEQ ID NO: 38) derived from the *C. elegans* genomic DNA (68). The overall sequence conservation (726aa, MW 83129 Da) with the other PARG sequences is as follows: 32% similarity and 22% identity with the mammalian PARG and 39% similarity and 30% identity with the *Drosophila* PARG. The sequence is presented in the Sequence Listing as SEQ ID NO: 38 (Genbank accession number CEF20C5). SEQ ID NO: 38 contains 12 exons as follows: exon 1 from 3591 to 3635; exon 2 from 3681 to 4121; exon 3 from 5065 to 5235; exon 4 from 5930 to 6152; exon 5 from 6200 to 6267; exon 6 from 7246 to 7338; exon 7 from 7386 to 7553; exon 8 from 7738 to 7853; exon 9 from 8153 to 8435; exon 10 from 8487 to: 8610; exon 11 from 8662 to 8952; and exon 12 from 9383 to: 9540. The coding sequence of the CePARG protein, which is publicly available from Accession number: Z68161, is referred to in the Sequence Listing as SEQ ID NO: 9. Its corresponding amino acid sequence is referred to in the Sequence Listing as SEQ ID NO: 10. The amino acid sequence of the *C. elegans* PARG is presented on the alignment (FIG. 16)

Example 15

Cloning and Overproduction of the Carboxyl-terminus 69 kDa Domain of Bovine PARG (bPARG) in *E. coli*

As described, above, bovine PARG is encoded by a messenger of 4 kb predicting a protein of 110 kDa, almost twice the size of the purified enzyme (65 kDa). It is also demon-

strated that bPARG can be expressed in *E. coli* as an active enzyme either as a 110 kDa or a 65 kDa protein. This result combined with other evidence implies that the active site of PARG is located in the carboxyl-terminal part of the protein. FIG. **11** is a schematic representation of the different clones we have expressed in bacteria. Among them, only the clone designed to express a protein of 69 kDa starting at the amino acid +380 from the sequence of bovine PARG (bPARG$_{MNDV}$) allowed high level expression as a fusion protein with glutathione-S transferase (GST).

The heterologous expression of bPARG$_{MNDV}$ was conducted as represented in FIG. **12**. The 1.8 kb cDNA encoding the 69 kDa carboxyl-terminal part of bovine PARG was amplified by PCR and cloned in the EcoRI site-of pGEX-2T vector (Pharmacia) in fusion with GST giving the pGEX-2T-bPARG$_{MNDV}$ plasmid. *E. coli* NM522 cells transformed with the pGEX-2T-bPARG$_{MNDV}$ were induced by addition of IPTG, resulting in expression of a 90 kDa fusion protein. The fusion protein can be conveniently purified using Glutathione-Sepharose and the bPARG$_{MNDV}$ can be released by treatment with thrombin while the GST protein remains bound to the beads of GSH-Sepharose. In this manner milligram amounts of protein can be routinely obtained.

Example 16

Characterization of the Purified 65 kDa Domain and the Generation of Antibodies

The purified bPARG$_{MNDV}$ was characterized by activity gel assays (69) by casting polyacrylamide gels with automodified PARP containing [^{32}P]ADP-ribose polymers. The results demonstrate that the 65 kDa domain expressed in *E. coli* contained enzymatic activity migrating with the same apparent molecular weight as the enzyme purified from bovine thymus. Likewise, a construction expressing bPARG$_{MNDV}$ domain in SF9 insect cells infected with recombinant baculovirus showed activity migrating with the same apparent molecular weight.

The availability of PARG cDNA allows the development of new molecular tools to study this enzyme in its cellular context. Until this work, it was not possible to obtain PARG in sufficient quantities to produce antibodies against the protein. The antibody raised against bovine PARG is able to recognize PARG from other organisms and, thus, will be valuable in characterizing PARG in vivo under defined physiological conditions in many different organisms.

Antibodies against bPARG$_{MNDV}$ overexpressed in *E. coli* were raised in rabbits using the procedure described by Vaitukaitis (70). Specific high affinity antibodies are generated by administration of small doses of immunogens intradermally over a wide anatomic area of the animal. Rabbits were immunized by three injections of 10-50 μg of the Mr 65,000 protein band excised from a preparative SDS polyacrylamide gel. Titer and affinity of sera harvested weekly were followed by conventional methods. Peak affinity was attained in 8 to 10 weeks after primary immunization. For each animal, a pre-immune serum was retained as a control.

FIG. **17** shows a Western blot experiment demonstrating the specificity of the resulting. PARG anti-serum against the purified bPARG from thymus (lane 1), SF9 protein extract expressing 65 kDa-bPARG$_{MNDV}$ in recombinant baculovirus (lane 2), recombinant 65 kDa-PARG$_{MNDV}$ purified by treatment with thrombin from GSH-Sepharose (lane 3), and an *E. coli* crude extract expressing the fusion protein GST-65 kDa-

PARG$_{MNDV}$ (lane 4). The pre-immune serum did not show reactivity against any of these fractions even at a low dilution (1/250).

Antibodies directed against the 45 kDa -terminal have also been generated using the same strategy used to generate antibodies against the catalytic domain. This involved the overexpression of the 45 kDa protein domain in *E. coli* in a construct designed for easy purification, followed by injection of the purified protein into rabbits. The heterologous expression of PARG45 was conducted by cloning a part (1.1 kb) of the coding region of the cDNA, generated by PCR amplification of the region located between the ATG(267) codon and nucleotide 1400 in the bovine sequence, into the Eco RI site of the bacterial expression vector pGEX-2T (Pharmacia) in fusion with glutathione-S-transferase. *E. coli* NM522 cells transformed with this construct were induced by addition of IPTG, resulting in expression of a 72 kDa fusion protein. The fusion protein was purified using glutathione Sepharose and the PARG45 was released by treatment with thrombin, while the GST protein remained bound to the GSH Sepharose beads. In this manner milligram amounts of protein were obtained. Antibodies against PARG45 overexpressed in *E. coli* were raised in rabbits using the procedure described (71). Specific high affinity antibodies were generated by administration of small doses of immunogens subcutaneously over a wide area of the animal. Rabbits were immunized by three injections of 10-50 μg of the 45 kDa protein band excised from a preparative SDS-polyacrylamide gel. Titer and affinity of sera harvested weekly were followed by conventional methods. Peak affinity was attained in 8 to 10 weeks after primary immunization. For each animal, a pre-immune serum was retained as a control.

Example 17

Conservation of PARG in Tissues and Organisms

Tissue and cell extracts from different origins were homogenized in a cold hypotonic lysis buffer containing a cocktail of protease inhibitors and sonicated. SDS and β-mercaptoethanol were added to insure inactivation of any remaining active proteases. Thirty μg of protein from each extract was analyzed by Western-blot using the anti-PARG antibody (FIG. **18**). In all of the fractions from bovine tissues, PARG was observed as a major band at 65 kDa. However, less intense, discrete proteins of higher molecular weight were also detected. These proteins may correspond to different forms of PARG; the band of highest molecular weight (about 115 kDa) found in thymus extract likely corresponds to the full-length of PARG (111 kDa) as deduced from the cDNA. Multiple species were detected in cell extracts from mouse fibroblasts, rat PC 12 cells, and SF9 insect cells. This result shows that the sequence of PARG is well conserved phylogenetically. Moreover, the conservation includes multiple molecular forms of the protein.

Example 18

Regulation of the Expression of PARG

In the metabolism of ADP-ribose polymers, the activities of PARP and PARG are closely related. Soon after polymer has been synthesized by PARP following DNA damage, it is extensively degraded by PARG. The net result is that the polymer has a very short half life. The close relationship between the two proteins suggests a possible mode of regulation in which PARG expression depends on the presence of

PARP. In order to test if the presence or the absence of PARP influences the expression of PARG, a Western Blot experiment was performed with cell extracts from mouse fibroblasts of different PARP genotypes (72).

Cell extract (30 μg) from mouse cells with PARP+/+, PARP+/− and PARP−/− genotypes were separated by SDS-PAGE, transferred to a membrane and probed with the antibodies indicated. The results are shown in FIG. 19. In FIG. 19, purified PARG (50 ng) from bovine thymus (lane 1), 30 μg of protein of a total extract from PARG recombinant baculovirus infected SF9 cells (lane 2), 150 ng of purified recombinant PARG produced in the bacteria (lane 3) and 30 μg of protein of a crude extract from *E. coli* NM522 transformed with pGEX-2T-bPARG$_{MNDV}$ 2 h after induction by IPTG (lane 4) were separated on a 0.1% SDS-12% polyacrylamide gel, then transferred on nitrocellulose, and incubated with a ⅕₀₀₀ dilution of the rabbit polyclonal antiserum raised against the 65 kDa domain of bPARG. Proteins were revealed by immunofluorescence with the ECL detection kit (Amersham) and autoradiography. Panel A is a western blot of PARP in cells of varying PARP genotype showing the results of the analysis using anti-PARP antibodies. The amount of PARP expressed varies as expected dependant upon the genotype of the cell line with the PARP−/− cell line producing no detectable amount of PARP. Panel B is western blot of PARG from various tissues using an anti-PARG antibody. It shows that the level of PARP is variable. The amount of PARG present in the cell extracts was not dependent upon the PARG genotype of the cell. Further support for this view is provided by the results of the PARG activity assay presented in panel C. The specific activity of PARG detected in the extracts showed no significant difference among the three genotypes.

Example 19

Preparation PARG Gene Ablation (Knockout) Animals

One embodiment of the present invention is experimental animals with targeted mutations in the PARG gene. These animals may be constructed using standard techniques and the cDNA sequence of the PARG. In the following example, a mouse containing a targeted mutation in the PARG gene is constructed. Those skilled in the art will readily appreciate that other experimental animals, including but not limited to rats, guinea pigs, hamsters and the like, may be constructed using similar techniques. The construction of animals with disrupted genes may be accomplished using standard techniques such as those described by Moreadith (73). Further, cells lines, construction kits, and protocols for knockout mice are available from commercial suppliers such as Stratagene (Stratagene 1999 catalog, La Jolla, Calif.). Commercial services such as Lexicon Genetics (The Woodlands, Tex.) and Chrysalis DNX Transgenic Sciences (Princeton, N.J.) also offer complete ES cell knockout mice production services.

A genomic clone of the murine PARG enzyme may be isolated from a genomic library by screening with a probe derived from the cDNA sequence of PARG. A mouse 129/SV genomic library (Stratagene) containing mouse genomic sequences in λ phage was screened using a 2.49 kb fragment of the mouse PARG cDNA as a probe. A partial restriction map of one positive clone thus isolated, R1, is provided in FIG. 20. The R1 clone contains the genomic sequence corresponding to the 5'-most end of the murine cDNA. The clone was subcloned into pBluescript as three fragments. The plasmid containing the 5'-end contained a 2.8 kb NotI-EcoRI fragment and was designated p2.8R. The fragment containing the central portion contained a 3.5 kb EcoRI fragment and was designated p3.5R. The plasmid containing the 3'-end of the gene contained a 7.0 kb EcoRI-NotI fragment and was

designated 7.0R. Sequencing the resulting plasmids revealed that p2.8R contained no sequences corresponding to the cDNA, p3.5R contains a 1.5 kb promoter region and/or untranslated region and exon 1 coding for 72 amino acids including the initiation ATG codon and p7.0R contains at least 4 additional exons. Gene targeting vectors may be constructed using both p3.5R and p7.0R.

A gene targeting vector may contain one or more selection genes flanked by genomic sequences. The targeting vector is introduced into the genome by homologous recombination resulting in the incorporation of the selection gene into the genome of the cell. The mouse PARG gene was targeted using a "conditional" inactivation procedure outlined in FIG. 21. This approach allows the production of viable animals even if the disrupted gene results in a lethal phenotype since the gene is not disrupted until a second "conditional" recombination event is induced.

A lox-P sequence may be inserted into the first intron. A cassette expressing the neomycin resistance gene (neo) and the thymidine kinase gene (TK) flanked by two additional lox-P sites may be placed in intron 2. In the presence of Cre recombinase, recombination will occur between two lox-P sites thereby deleting the genomic sequences present between the sites. A MC1-DTA cassette is ligated at the 3'-end of the vector to reduce random integration of the vector into the genome.

The targeting vector may be introduced into embryonic stem cells by any method known to those skilled in the art such as transfection, lipofection or electroporation. In a preferred embodiment, the targeting vector will be introduced into embryonic stem cells by electroporation. After homologous recombination, cells containing the neo gene will be selected for using G418. Selected cells will then be analyzed by PCR and Southern blot.

To generate mutant alleles of PARG, the positive embryonic stem cell clones identified will be transfected with a plasmid expressing Cre recombinase. The action of Cre recombinase will result in three different mutant alleles. Mutant allele I contains a deletion in exon 2 but still maintains the selection genes neo and TK. Mutant allele II contains the genomic sequence for exon 2 flanked by two lox-P sites (exon 2 is said to be "floxed") and does not contain the selection genes. Mutant allele III has a deletion of the genomic sequences and does not contain the selection genes.

Mice containing each of the three mutant alleles may be constructed by microinjecting embryonic stem cells containing the mutant allele into blastocytes resulting in the production of chimeric and mutant mice. Mice homozygous in mutant allele I or III will be null mutants in that they will be unable to express a functional PARG enzyme due to the loss of required genomic sequences. In the absence of Cre recombinase, mice containing mutant allele II will express a wild type protein. In the presence of the Cre recombinase, the PARG will lose exon 2, thus producing an inactive protein. To inactivate the gene, these mice will be bred to mice expressing Cre recombinase under the control of a tissue specific promoter. This will result in mice expressing PARG in some tissues and not expressing PARG in others. Mice homozygous in mutant allele II, will be valuable for evaluating the role of PARG in specific tissues.

Although the present invention has been described with reference to certain examples for purposes of clarification and illustration. It should be appreciated that certain obvious improvements and modifications can be practiced within the scope of the appended claims and their equivalents. Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification

US 7,538,194 B2

41

and practice of the invention disclosed herein. All U.S. patents GenBank sequence listings, and other references noted herein for whatever reason are specifically incorporated by reference. The specification and examples should be considered exemplary only with the true scope and spirit of the invention indicated by the following claims.

1. Miwa, M. et al. (1971) J. Biol. Chem. 246, 6362-6364; Ueda, K. et al. (1972) Biochem. Biophys. Res. Commun. 46, 516-523
2. Oka, J. et al. (1984) J. Biol. Chem. 259, 986-995.
3. Gaal, J. et al. (1987) Trends in Biol. Sci., 12, 129.
4. Nudka, N. et al. (1980) Eur. J. Biochem. 105, 525-530; Jacobson, E. et al. (1985) Carcinogenesis 6, 715-718; Küipper, J. et al. (1990) J. Biol. Chem: 265, 18721-18724; Ding, R. et al. (1992) J. Biol. Chem. 267, 12804-12812.
5. Jacobson, E. et al. (1985) in ADP-ribosylation of Proteins (Althaus, F. R., Hilz, H., and Shall, S., eds) pp. 277-283, Springer-Verlag, Berlin; Lubet, R. et al: (1986) Carcinogenesis 7, 71-75; Kasid, U. et al. (1986) Carcinogenesis 7, 327-330.
6. Berger, N. (1985) Radiat. Res. 101, 4-15.
7. Kaufmann, S. et al. (1993) Cancer Res. 53, 3976-3985; Lazebnik, Y. et al. (1994) Nature 371, 346-347.
8. de Murcia, G. et al. (1994) Trends Biochem. Sci. 19, 172-176.
9. BioWorld Today, Apr. 29, 1994, p. 3.
10. Thomassin, H. et al. (1990) Nucleic Acids Res. 18, 4691-4694.
11. Karlin, Samuel and Stephen F. Altschul (1993). Proc. Natl. Acad. Sci. USA 90:5873-7
12. Henikoff and Henikoff Proc. Natl. Acad. Sci. USA 89:10915-19, 1992
13. Altschul, Stephen F. (1991). J. Mol. Biol. 219:555-65.
14. Cohen, J. S., 1989; Weintraub, H. M., 1990
15. N. Sarver et al., 1990
16. Orlandi, R. et al., (1989) Proc. Natl. Acad. Sci. 86, 3833-3837; Winter, G et al., (1991) Nature 349, 293-299
17. R. Sobol and K. Scanlon eds., available at www.appleton-lange.com.
18. e.g., at least, but not limited to U.S. Pat. No. 5,797,870, U.S. Pat. No. 5,804,383, U.S. Pat. No. 5,670,161, U.S. Pat. No. 5,645,829, U.S. Pat. No. 5,741,486, U.S. Pat. No. 5,836,905, U.S. Pat. No. 5,843,069, U.S. Pat. No. 5,827,216, U.S. Pat. No. 5,871,464, U.S. Pat. No. 5,702,384, U.S. Pat. No. 5,810,888, U.S. Pat. No. 5,787,900, U.S. Pat. No. 5,752,515, U.S. Pat. No. 5,674,192, U.S. Pat. No. 5,658,955, U.S. Pat. No. 5,656,465, U.S. Pat. No. 5,547,932, U.S. Pat. No. 5,873,904, U.S. Pat. No. 5,792,651, U.S. Pat. No. 5,772,888, U.S. Pat. No. 5,641,750, U.S. Pat. No. 5,641,749, and U.S. Pat. No. 5,626,561
19. Kaltenbock, B. et al. (1998) Biotechniques, 24, 202-206.
20. Moran, P. et al. (1998) Biotechniques, 24, 206-212.
21. Orita, M. et al. (1989) PNAS USA, 86, 2766-2770.
22. Liu, Q. et al. (1998) Biotechniques, 24, 140-147.
23. Proceeding from the Sixth International Symposium on Human Identification 1995 (ISBN 1-882274-55-5).
24. Kohler and Milstein, Nature, 256:495-497 (1975).
25. Geysen, et al. (1984) Proc. Natl. Acad. Sci. USA 81:3998-4002.
26. Ménard, et al. (1987) Biochem. Cell Biol. 65, 668-673.
27. Hatakeyama, K. et al. (1986) J. Biol. Chem. 261, 14902-14911.
28. Thomassin, H. et al. (1990) Nucleic Acids Res. 18, 4691-4694.
29. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
30. Bradford, M. (1976) Anal. Biochem. 72, 248-254.
31. Laemmli, U. (1970) Nature 227, 680-685.

42

32. Althaus, F. et al. (1987) Molecular Biology, Biochemistry and Biophysics, Vol. 37, Springer-Verlag, Berlin.
33. Mead, D. et al. (1986) Protein Eng. 1, 67-74.
34. Shaw, et al. (1986) Cell 46, 659-667.
35. Kozak (1987) Nucleic Acids Res. 1.5, 8125-8148.
36. Wilson, et al. (1994) Nature (London) 368, 32-38.
37. Brendel, et al. (1992) Proc. Natl. Acad. Sci. USA 89, 2002-2006.
38. Robbins, et al. (1991) Cell 64, 615-623.
39. Schreiber, et al. (1992) EMBO J. 11, 3263-3269.
40. Uchida, K. et al. (1987) Biochem. Biophys. Res. Commun. 148, 617-622, Cherney, B. et al. (1987) Proc. Natl. Acad. Sci. U.S.A. 84, 8370-8374; Kurosaki, T. et al. (1987) J. Biol. Chem. 262, 15990-15997.
41. Huppi, K. et al. (1989) Nucleic Acids Res. 17, 3387-3401.
42. Saito, I. et al. (1990) Gene (Amst.) 90, 249-254.
43. Ittel, M.-E. et al. (1991) Gene (Amst.) 102, 157-164.
44. Saulier-Le Drean, B. (1992) Poly(ADP-ribose) Polymerase in Xenopus lae-vis, Ph.D. thesis, Université De Rennes, France.
45. Uchida, K. et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 3481-3485.
46. Masutani, M. et al. (1994) Eur. J. Biochem. 220, 607-614.
47. Schreiber, et al. (1992) EMBO J. 11, 3263-3269.
48. Lazebnik, et al. (1994) Nature (London) 371, 346-347.
49. Brochu, et al. (1994) Biochem. Biophys. Acta 1219, 342-350.
50. Tanuma, et al. (1986) J. Biol. Chem. 261,965-969; Uchida, et al. (1993) J. Biol. Chem. 268, 3194-3200.
51. Maruta, et al. (1991) Biochemistry 30, 5907-5912.
52. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
53. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
54. Slama, J. et al. (1995) J. Med. Chem. 38,389-393; Slama, J. et al. (1995) J. Med. Chem. 38, 4332-4336.
55. Slama, J. et al. (1995) J. Med. Chem. 38, 389-393; Slama, J. et al. (1995) J. Med. Chem. 38, 4332-4336.
56. Ménard, L. et al. (1987) Biochem. Cell Biol. 65, 668-673.
57. Althaus, F. et al. (1987) Molecular Biology, Biochemistry and Biophysics, Vol. 37, Springer-Verlag, Berlin.
58. Brochu, G. et al. (1994) Anal. Biochem. 218, 265-272.
59. Brochu, G. et al. (1994) Anal. Biochem. 218, 265-272.
60. Moreadith, et al. (1997) J. Mol. Med. 75, 208-216.
61. Tanuma, et al. (1986) J. Biol. Chem. 261, 965-969 and Uchida, et al. (1993) J. Biol. Chem. 268, 3194-3200.
62. Hatakeyama, et al. (1986) J. Biol. Chem. 261, 14902-14911; Thomassin, et al. (1990) Nucleic Acids Res. 18, 4691-4694; and Maruta, et al. (1991) Biochemistry 30, 5907-5912.
63. Sambrook, et al. (1992) MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Cold Spring harbor, N.Y.
64. Feinberg, et al. (1983) Anal. Biochem. 132, 6-13.
65. Boguski, 1995
66. Sambrook, et al. (1992) MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory Cold Spring Harbor, N.Y.
67. BDGP/HHMI Drosophila EST Project, University of California Berkeley, EST@fruitfly.berkeley.edu
68. Nematode Sequencing Project, Sanger Centre, Hinzton, Cambridge CB10 1RQ, England and Department of Genetics, Washington University, St. Louis, Mo. 63110, USA. E-mail: jes@sanger.ac.uk
69. Brochu G. et al. (1994) Anal. Biochem. 218, 265-272.
70. Vaitukaitis (1981) Methods in Enzymology 73, 46-52.
71. Vaitukaitis (1981) Methods in Enzymology 73, 46-52.
72. Wang, et al. (1995) Genes & Dev. 9, 509-520.
73. Moreadith, et al. (1997) J. Mol. Med. 75, 208-216.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 38

<210> SEQ ID NO 1
<211> LENGTH: 4070
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 1

```
accggaaagt gaacgaagcc cgaatcagaa cggctcatcc tgaggctggt agggtgccgg       60

tggaagaggg aaggcaggcg tctggatagg gcctggttcg ggaggctgtc agagcaggag      120

ctgcagaagc agtcagcggc agagggggca tggtgccggg aggcaccgag gagggggcgc      180

agtccgtccc tcccagggtt agtgaatgag gctctacgcc cgggctggcc cggagactca      240

gtgctgcggg tcccagcatg agtgcgggcc ccggctgtga gccctgcacc aagcgacccc      300

gctgggacgc cgctgcaact tctccgccgg ccgcctcgga cgcccggagc ttccccggca      360

ggcagaggcg cgtcctcgat tccaaggacg ctccggtgca gttcagggtc ccgccgtcct      420

cgtcaggctg cgccctgggc cgggcgggac agcaccgagg cagcgccacc tctcttgttt      480

tcaaacagaa gactataacc agttggatgg acactaaagg aatcaagaca gttgaatcag      540

aaagtttgca tagtaaagaa aacaacaata caagagaaga atccatgatg agttctgtac      600

aaaaagataa cttttatcaa cataacatgg aaaaattaga aaatgtttct cagctaggtt      660

ttgataagtc accagttgaa aaaggtacac agtatttgaa gcagcatcag actgcggcta      720

tgtgtaagtg gcagaatgaa gggccacact cagaacggct tttggaaagt gaacctccag      780

cggtaactct ggtaccagag cagttcagta atgctaatgt cgatcagtcg tccccaaagg      840

atgatcacag tgacacaaat agtgaggaga gtagagataa tcagcagttt ttgacacatg      900

taaagcttgc gaatgcaaag cagacgatgg aagatgaaca gggcagagaa gccagaagcc      960

accagaagtg tggcaaggct tgccatcctg cagaagcctg tgcagggtgt cagcaggagg     1020

agacagacgt ggtgtccgag agcccccttgt cggacactgg ctctgaggat gttggtactg     1080

gactgaaaaa tgccaacaga ttgaatagac aagaaagtag tctaggaaat tctcctccat     1140

ttgagaaaga aagtgaacct gagtcaccaa tggatgtaga taattccaaa aatagttgtc     1200

aggattcaga agcagatgaa gagacaagtc caggttttga tgaacaggaa gatagcagtt     1260

ctgctcaaac agcaaataaa ccttcaaggt tccaaccaag agaagctgac actgagttga     1320

ggaagcggtc ctctgctaag ggaggtgaga ttcgattaca tttccaattt gaaggaggag     1380

agagtcgagc tggaatgaat gatgtgaatg ccaaacgacc tggaagtact tctagcctga     1440

atgtagagtg cagaaattct aagcaacatg ggagaaagga ttctaaaatc acagatcatt     1500

tcatgagagt gcccaaagca gaggacaaaa gaaaagaaca atgtgaaatg aaacatcaaa     1560

gaacagaaag gaagatccct aaatacattc cacctcacct ttctccagat aagaaatggc     1620

ttggaactcc tattgaggag atgaggagaa tgccaaggtg tgggatccgg ctgcctccct     1680

tgagaccatc tgccaatcac acagtgacta ttcgggtaga tcttttgcga ataggagaag     1740

ttcctaaacc tttcccaaca cattttaaag atttgtggga caacaagcat gttaagatgc     1800

cttgttcaga acaaaacttg taccctgtgg aagatgagaa tggtgagcga gctgcaggca     1860

gccggtggga actcattcag actgcacttc tcaacaggct cactcggccc cagaacctga     1920

aggatgctat tctgaagtac aatgtggcat attctaagaa atgggacttt acagctttga     1980
```

-continued

```
ttgatttctg ggataaggta ctagaagaag cagaagctca acacttgtat cagtccatct      2040

tgcctgatat ggtgaaaatt gcactctgtc tgccaaatat ttgtacccag ccaataccac      2100

tcctgaaaca gaagatgaat cattccatca caatgtcaca ggaacagatt gccagtcttt      2160

tagctaatgc tttcttctgc acgtttccac gacgcaatgc caagatgaaa tcagagtatt      2220

ccagttatcc agatattaac ttcaatcggt tgtttgaagg acgttcatca aggaaaccag      2280

agaagcttaa aacgctcttc tgctacttta gaagagtcac agagaaaaaa cccactgggt      2340

tggtgacatt cacaagacag agtcttgaag attttccaga gtgggaaaga tgtgaaaaac      2400

tcctgactcg actgcatgtc acttacgaag gtaccataga aggaaacggc cagggcatgc      2460

tacaggtgga ttttgcaaac cgtttcgttg gaggtggtgt aaccagtgca ggacttgtgc      2520

aagaagaaat ccgcttttta atcaaccctg agttgattgt ttcacggctc ttcactgagg      2580

tgctggatca caatgaatgt cttatcatca caggtactga gcagtacagt gaatacacag      2640

gctatgccga aacataccgc tgggcccgga gccatgaaga caggagcgaa agggacgact      2700

ggcagaggcg cacgactgag atcgtcgcca tcgacgccct ccacttcaga cgctacctcg      2760

accagtttgt gcccgagaag atcagacggg agcttaacaa ggcttactgt ggatttcttc      2820

gtcctggagt ttcttcagag aacctgtctg cagtggctac aggaaactgg ggctgtggtg      2880

cctttggggg tgatgctaga ctaaaagcct aatacagat cctggcagct gctgtagctg      2940

agcgagacgt ggtttatttc acctttgggg actcagaact gatgagagac atttacagca      3000

tgcatacatt cctcactgag aggaaactga ctgttggaga agtatataag ctgctgctac      3060

gatattacaa tgaagaatgc agaaactgct ccacccccgg accagacatc aagctttatc      3120

cattcatata ccatgcagtt gagtcctgta cacagaccac caaccagccg ggacaaagga      3180

cggggggcctg aggagccaag tgactagacg ctccccactt gtgtaacaag aaggtgtgac      3240

gtgtgaactg acatgatatc catgtgtata taatccgcgt ttgtaggcaa ggatgcagtc      3300

ccttccgccc atgcagctgt cagtacatct gcgcctcctc catcccgact tacatagact      3360

gagacatact ttgtttcttt ttttttctat ttcagccctg attcttttat ttttctttct      3420

tttgcccatc agacttcttg tgaaatttca tcagagtttg tgctcagcct ggcaggtgtc      3480

tttttgatg cctaaatata caaatcacct ctgcagctag cagatgccac ggaaggtggt      3540

ggaaccctag gagctgtaac tgagtctgct gcagatctcc ctctgagcct ctcaccccta      3600

ccctattatc attgtggtgg tggaggtttt ttgattttttg aaataagagt tgggtttgtt      3660

aaataataca gatctcctag gttaagagtt ttatatttaa gaatactttt caaaaagtta      3720

ttttgagata tcacctttat ttgtaatggt aatttgcctg tcccttttcc cctgatcaat      3780

ttgtattgac tgttttttgga aattgaccca aatgaaagga aatatgagaa taagagtttc      3840

ccaaatggtg tttaaaaaca aacaggttca agacacgcga aggacctcgt ttcctgggat      3900

tttttttctt tttctttttt tgaattagga ttattgtttg ttccttggtg cttgagacat      3960

attcatataa ccaaagttta ggaactggga acttcgtggt gatttgtaca tattgaagtt      4020

tctctggtac tcaaaggtta tgtagttaat aaattttcat taacaaaaaa                 4070
```


<210> SEQ ID NO 2
<211> LENGTH: 977
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 2

-continued

```
Met Ser Ala Gly Pro Gly Cys Glu Pro Cys Thr Lys Arg Pro Arg Trp
1               5                   10                  15

Asp Ala Ala Ala Thr Ser Pro Pro Ala Ala Ser Asp Ala Arg Ser Phe
            20                  25                  30

Pro Gly Arg Gln Arg Arg Val Leu Asp Ser Lys Asp Ala Pro Val Gln
        35                  40                  45

Phe Arg Val Pro Pro Ser Ser Ser Gly Cys Ala Leu Gly Arg Ala Gly
    50                  55                  60

Gln His Arg Gly Ser Ala Thr Ser Leu Val Phe Lys Gln Lys Thr Ile
65                  70                  75                  80

Thr Ser Trp Met Asp Thr Lys Gly Ile Lys Thr Val Glu Ser Glu Ser
            85                  90                  95

Leu His Ser Lys Glu Asn Asn Asn Thr Arg Glu Glu Ser Met Met Ser
            100                 105                 110

Ser Val Gln Lys Asp Asn Phe Tyr Gln His Asn Met Glu Lys Leu Glu
        115                 120                 125

Asn Val Ser Gln Leu Gly Phe Asp Lys Ser Pro Val Glu Lys Gly Thr
    130                 135                 140

Gln Tyr Leu Lys Gln His Gln Thr Ala Ala Met Cys Lys Trp Gln Asn
145                 150                 155                 160

Glu Gly Pro His Ser Glu Arg Leu Leu Glu Ser Glu Pro Pro Ala Val
            165                 170                 175

Thr Leu Val Pro Glu Gln Phe Ser Asn Ala Asn Val Asp Gln Ser Ser
            180                 185                 190

Pro Lys Asp Asp His Ser Asp Thr Asn Ser Glu Glu Ser Arg Asp Asn
        195                 200                 205

Gln Gln Phe Leu Thr His Val Lys Leu Ala Asn Ala Lys Gln Thr Met
    210                 215                 220

Glu Asp Glu Gln Gly Arg Glu Ala Arg Ser His Gln Lys Cys Gly Lys
225                 230                 235                 240

Ala Cys His Pro Ala Glu Ala Cys Ala Gly Cys Gln Gln Glu Glu Thr
            245                 250                 255

Asp Val Val Ser Glu Ser Pro Leu Ser Asp Thr Gly Ser Glu Asp Val
            260                 265                 270

Gly Thr Gly Leu Lys Asn Ala Asn Arg Leu Asn Arg Gln Glu Ser Ser
            275                 280                 285

Leu Gly Asn Ser Pro Pro Phe Glu Lys Glu Ser Glu Pro Glu Ser Pro
    290                 295                 300

Met Asp Val Asp Asn Ser Lys Asn Ser Cys Gln Asp Ser Glu Ala Asp
305                 310                 315                 320

Glu Glu Thr Ser Pro Gly Phe Asp Glu Gln Glu Asp Ser Ser Ser Ala
            325                 330                 335

Gln Thr Ala Asn Lys Pro Ser Arg Phe Gln Pro Arg Glu Ala Asp Thr
            340                 345                 350

Glu Leu Arg Lys Arg Ser Ser Ala Lys Gly Gly Glu Ile Arg Leu His
        355                 360                 365

Phe Gln Phe Glu Gly Gly Glu Ser Arg Ala Gly Met Asn Asp Val Asn
    370                 375                 380

Ala Lys Arg Pro Gly Ser Thr Ser Ser Leu Asn Val Glu Cys Arg Asn
385                 390                 395                 400

Ser Lys Gln His Gly Arg Lys Asp Ser Lys Ile Thr Asp His Phe Met
            405                 410                 415

Arg Val Pro Lys Ala Glu Asp Lys Arg Lys Glu Gln Cys Glu Met Lys
```

-continued

```
                 420              425              430

His Gln Arg Thr Glu Arg Lys Ile Pro Lys Tyr Ile Pro Pro His Leu
             435              440              445

Ser Pro Asp Lys Lys Trp Leu Gly Thr Pro Ile Glu Glu Met Arg Arg
         450              455              460

Met Pro Arg Cys Gly Ile Arg Leu Pro Pro Leu Arg Pro Ser Ala Asn
465              470              475              480

His Thr Val Thr Ile Arg Val Asp Leu Leu Arg Ile Gly Glu Val Pro
                 485              490              495

Lys Pro Phe Pro Thr His Phe Lys Asp Leu Trp Asp Asn Lys His Val
             500              505              510

Lys Met Pro Cys Ser Glu Gln Asn Leu Tyr Pro Val Glu Asp Glu Asn
             515              520              525

Gly Glu Arg Ala Ala Gly Ser Arg Trp Glu Leu Ile Gln Thr Ala Leu
         530              535              540

Leu Asn Arg Leu Thr Arg Pro Gln Asn Leu Lys Asp Ala Ile Leu Lys
545              550              555              560

Tyr Asn Val Ala Tyr Ser Lys Lys Trp Asp Phe Thr Ala Leu Ile Asp
                 565              570              575

Phe Trp Asp Lys Val Leu Glu Glu Ala Glu Ala Gln His Leu Tyr Gln
             580              585              590

Ser Ile Leu Pro Asp Met Val Lys Ile Ala Leu Cys Leu Pro Asn Ile
             595              600              605

Cys Thr Gln Pro Ile Pro Leu Leu Lys Gln Lys Met Asn His Ser Ile
         610              615              620

Thr Met Ser Gln Glu Gln Ile Ala Ser Leu Leu Ala Asn Ala Phe Phe
625              630              635              640

Cys Thr Phe Pro Arg Arg Asn Ala Lys Met Lys Ser Glu Tyr Ser Ser
                 645              650              655

Tyr Pro Asp Ile Asn Phe Asn Arg Leu Phe Glu Gly Arg Ser Ser Arg
             660              665              670

Lys Pro Glu Lys Leu Lys Thr Leu Phe Cys Tyr Phe Arg Arg Val Thr
             675              680              685

Glu Lys Lys Pro Thr Gly Leu Val Thr Phe Thr Arg Gln Ser Leu Glu
         690              695              700

Asp Phe Pro Glu Trp Glu Arg Cys Glu Lys Leu Leu Thr Arg Leu His
705              710              715              720

Val Thr Tyr Glu Gly Thr Ile Glu Gly Asn Gly Gln Gly Met Leu Gln
                 725              730              735

Val Asp Phe Ala Asn Arg Phe Val Gly Gly Gly Val Thr Ser Ala Gly
             740              745              750

Leu Val Gln Glu Glu Ile Arg Phe Leu Ile Asn Pro Glu Leu Ile Val
             755              760              765

Ser Arg Leu Phe Thr Glu Val Leu Asp His Asn Glu Cys Leu Ile Ile
         770              775              780

Thr Gly Thr Glu Gln Tyr Ser Glu Tyr Thr Gly Tyr Ala Glu Thr Tyr
785              790              795              800

Arg Trp Ala Arg Ser His Glu Asp Arg Ser Glu Arg Asp Asp Trp Gln
                 805              810              815

Arg Arg Thr Thr Glu Ile Val Ala Ile Asp Ala Leu His Phe Arg Arg
             820              825              830

Tyr Leu Asp Gln Phe Val Pro Glu Lys Ile Arg Arg Glu Leu Asn Lys
             835              840              845
```

-continued

```
Ala Tyr Cys Gly Phe Leu Arg Pro Gly Val Ser Ser Glu Asn Leu Ser
    850              855              860

Ala Val Ala Thr Gly Asn Trp Gly Cys Gly Ala Phe Gly Gly Asp Ala
865              870              875              880

Arg Leu Lys Ala Leu Ile Gln Ile Leu Ala Ala Ala Val Ala Glu Arg
                885              890              895

Asp Val Val Tyr Phe Thr Phe Gly Asp Ser Glu Leu Met Arg Asp Ile
            900              905              910

Tyr Ser Met His Thr Phe Leu Thr Glu Arg Lys Leu Thr Val Gly Glu
        915              920              925

Val Tyr Lys Leu Leu Leu Arg Tyr Tyr Asn Glu Glu Cys Arg Asn Cys
    930              935              940

Ser Thr Pro Gly Pro Asp Ile Lys Leu Tyr Pro Phe Ile Tyr His Ala
945              950              955              960

Val Glu Ser Cys Thr Gln Thr Thr Asn Gln Pro Gly Gln Arg Thr Gly
            965              970              975

Ala
```

```
<210> SEQ ID NO 3
<211> LENGTH: 4069
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:

<400> SEQUENCE: 3
```

```
ggcgtctggg aagtgaggag cgtctctgcc tggcagaggc tgcaatctct gcactttggg      60

gggccaaggc aggcgctgag aaggacgcgc agtccatctc tctcaggtta gtgaaatgag     120

gctctccgcg gggccggccc ggggacagtg cgctgctggt cccagcatga atgcgggccc     180

cggctgtgaa ccctgcacca aagcgacccg ctggggcgcc gctacaactt cgccggctgc     240

ttcggacgcc cggagctttc cgagcaggca gaggcgcgtc ctcgacccca aggacgctca     300

cgtgcagttc agggtcccac cgtcctcgcc agcctgcgtc ccagggcagg cgggacagca     360

cagaggcagc gccacctcgc ttgttttcaa acaaaagact attaccagtt ggatggacac     420

taaaggaatc aagacagcgg aatcagaaag tttggatagt aaagaaaaca acaatacaag     480

aatagaatcc atgatgagtt ctgtacaaaa agataacttt taccaacata atgtagaaaa     540

attagtaaat gtttctcagc taagtcttga taagtcactc actgaaaaaa gtacacagta     600

tttgaaccag catcagactg cagcaatgtg taagtggcaa aatgaaggga acacacgga     660

gcagcttttg aaagtgaac ctcaaacagt aaccctggta ccagagcagt ttagtaatgc     720

taacattgat cggtcacctc aaaatgatga tcacagtgac acagatagtg aagagaatag     780

agacaatcaa cagtttctca caactgtaaa gcttgcaaat gcaaagcaga ctacggaaga     840

tgaacacgcc agagaagcca aaagccacca gaagtgcagc aagtcttgcc atcctgggga     900

agactgtgca agttgtcagc aagatgagat agacgtggtg ccaaagagtc cattgtcaga     960

tgttggctct gaggatgttg gtactgggtc aaaaaatgac aacaaattga ttagacaaga    1020

aagttgccta ggaaattctc ctccatttga gaaggaaagt gaacccgaat caccgatgga    1080

tgtggataat tctaaaaata gttgtcaaga ctcagaagca gatgaggaga caagtccagg    1140

ttttgatgaa caagaagatg gtagttcctc ccaaacagca aataaacctt caaggttcca    1200

agcaagagac gctgacattg aatttaggaa acggtactct actaagggcg gtgaagttag    1260

attacatttc caatttgaag gaggagagag tcgcactgga atgaatgatt taaatgctaa    1320
```

```
actacctgga aatatttcta gcctgaatgt agaatgcaga aattctaagc aacatggaaa   1380

aaaggattct aaaatcacag atcatttgat gagactgccc aaagcagagg acagaagaaa   1440

agaacagtgg gaaaccaaac atcaaagaac agaaaggaag atccctaaat acgttccacc   1500

tcacctttct ccagataaga agtggcttgg aactcccatt gaggagatga gaagaatgcc   1560

tcggtgtggg atccggctgc ctctcttgag accatctgcc aatcacacag taactattcg   1620

ggtagatctt ttgcgagcag gagaagttcc taaacctttt ccaacacatt ataaagattt   1680

gtgggataac aagcatgtta aaatgccttg ttcagaacaa aatttgtacc cagtggaaga   1740

tgagaatggt gagcgaactg cggggagccg gtgggagctc attcagactg cacttctcaa   1800

caaatttaca cgaccccaaa acttgaagga tgctattctg aaatacaatg tggcatattc   1860

taagaaatgg gactttacag ctttgatcga tttctgggat aaggtacttg aagaagcaga   1920

agctcaacat ttatatcagt ccatcttgcc tgatatggtg aaaattgcac tctgtctgcc   1980

aaatatttgc acccagccaa taccactcct gaaacagaag atgaatcatt ccatcacaat   2040

gtcgcaggaa cagattgcca gtcttttagc taatgctttc ttctgcacat ttccacgacg   2100

aaatgctaag atgaaatcgg agtattctag ttacccagac attaacttca atcgattgtt   2160

tgagggacgt tcatcaagga aaccggagaa acttaaaacg ctcttctgct actttagaag   2220

agtcacagag aaaaaaccta ctgggttggt gacatttaca agacagagtc ttgaagattt   2280

tccagaatgg gaaagatgtg aaaaaccctt gacacgattg catgtcactt acgaaggtac   2340

catagaagaa aatggccaag gcatgctaca ggtggatttt gcaaatcgtt ttgttggagg   2400

tggtgtaacc agtgcaggac ttgtgcaaga agaaatccgc ttttttaatca atcctgagtt   2460

gattatttca cggctcttca ctgaggtgct ggatcacaat gaatgtctaa ttatcacagg   2520

tactgagcag tacagtgaat acacaggcta tgctgagaca tatcgttggt cccggagcca   2580

cgaagatggg agtgaaaggg acgactgcga gcggcgctgc actgagatcg ttgccatcga   2640

tgctcttcac ttcagacgct acctcgatca gtttgtgcct gagaaaatga gacgcgagct   2700

gaacaaggct tactgtggat ttctccgtcc tggagtttct tcagagaatc tttctgcagt   2760

ggccacagga aactggggct gtggtgcctt tgggggtgat gccaggttaa aagccttaat   2820

acagatattg gcagctgctg cagctgagcg agatgtggtt tatttcacct ttggggactc   2880

agaattgatg agagacattt acagcatgca cattttcctt actgaaagga aactcactgt   2940

tggagatgtg tataagctgt tgctacgata ctacaatgaa gaatgcagaa actgttccac   3000

ccctggacca gacatcaagc tttatccatt catataccat gctgtcgagt cctgtgcaga   3060

gaccgctgac cattcagggc aaaggacagg gacctgagga gccgagcgaa tagcatctcc   3120

tcccacctcc caccagagac gtcctgtttg agctgtcagg tgtaatatat gaattgactt   3180

aagttaatat aaatgtgtac ataatccaca tttgtagtca aggacgcaat ctcttccaca   3240

catgtgcagt tgtcagttgg tacatctaaa ctccctccat cctgactcac gtggacttag   3300

atatgttttg tttctatttt cttctatttc agttttttcat tctttgatgt ttatttcttt   3360

tgtccatcag atctcttgtg aaatcccatg gaaggttgtg ctcagctgtc gggtctcttt   3420

cttcctgccc atatattata ccagttgctt ctgcagcccg cagatgccca gcgatgccca   3480

ggaaacaagt tgaaatccca ggaatctctt taactgattt tgctaaaaat ctccctgtga   3540

gccttccact caactcttaa tatgcttgca ttgtttaagt ttttaaattc tgaaaattaa   3600

taattagggt ttttttcata tgtgttgcat aatgcaaacc tcctaggtta aaatagtttc   3660
```

-continued

```
tttatttaag atagaataat ttccagaaat tgtacttttg aggtatcatt tttatctgta    3720

atggtttgtc tgtctttttt cctctgatca gtattttttt ataccagttt tggagactgc    3780

ctgagatgaa aggaaatgtg gaataaaagg aggtttttcct gatgtggtgt aaagaaaaca    3840

gattccaaga gaattgaaga ttttttttgt ttccttggta cttttttctt tttaaattag    3900

gactaatgtt tcttttgtgg tgcttgaggc atattcatat aaccaaagtt tgagaactgg    3960

gaacttcatg ctgatttgta catattgaag tttctctggt attcaaaggt tatatagtga    4020

atgaattttc attaataaat cactttgtca gaaaaaaaaa aaaaaaaaa    4069
```

<210> SEQ ID NO 4
<211> LENGTH: 976
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:

<400> SEQUENCE: 4

```
Met Asn Ala Gly Pro Gly Cys Glu Pro Cys Thr Lys Ala Thr Arg Trp
1               5                   10                  15

Gly Ala Ala Thr Thr Ser Pro Ala Ala Ser Asp Ala Arg Ser Phe Pro
            20                  25                  30

Ser Arg Gln Arg Arg Val Leu Asp Pro Lys Asp Ala His Val Gln Phe
        35                  40                  45

Arg Val Pro Pro Ser Ser Pro Ala Cys Val Pro Gly Gln Ala Gly Gln
    50                  55                  60

His Arg Gly Ser Ala Thr Ser Leu Val Phe Lys Gln Lys Thr Ile Thr
65                  70                  75                  80

Ser Trp Met Asp Thr Lys Gly Ile Lys Thr Ala Glu Ser Glu Ser Leu
                85                  90                  95

Asp Ser Lys Glu Asn Asn Asn Thr Arg Ile Glu Ser Met Met Ser Ser
            100                 105                 110

Val Gln Lys Asp Asn Phe Tyr Gln His Asn Val Glu Lys Leu Val Asn
        115                 120                 125

Val Ser Gln Leu Ser Leu Asp Lys Ser Leu Thr Glu Lys Ser Thr Gln
    130                 135                 140

Tyr Leu Asn Gln His Gln Thr Ala Ala Met Cys Lys Trp Gln Asn Glu
145                 150                 155                 160

Gly Lys His Thr Glu Gln Leu Leu Glu Ser Glu Pro Gln Thr Val Thr
                165                 170                 175

Leu Val Pro Glu Gln Phe Ser Asn Ala Asn Ile Asp Arg Ser Pro Gln
            180                 185                 190

Asn Asp Asp His Ser Asp Thr Asp Ser Glu Glu Asn Arg Asp Asn Gln
        195                 200                 205

Gln Phe Leu Thr Thr Val Lys Leu Ala Asn Ala Lys Gln Thr Thr Glu
    210                 215                 220

Asp Glu His Ala Arg Glu Ala Lys Ser His Gln Lys Cys Ser Lys Ser
225                 230                 235                 240

Cys His Pro Gly Glu Asp Cys Ala Ser Cys Gln Gln Asp Glu Ile Asp
                245                 250                 255

Val Val Pro Lys Ser Pro Leu Ser Asp Val Gly Ser Glu Asp Val Gly
            260                 265                 270

Thr Gly Ser Lys Asn Asp Asn Lys Leu Ile Arg Gln Glu Ser Cys Leu
        275                 280                 285

Gly Asn Ser Pro Pro Phe Glu Lys Glu Ser Glu Pro Glu Ser Pro Met
    290                 295                 300
```

-continued

```
Asp Val Asp Asn Ser Lys Asn Ser Cys Gln Asp Ser Glu Ala Asp Glu
305                 310                 315                 320

Glu Thr Ser Pro Gly Phe Asp Glu Gln Glu Asp Gly Ser Ser Ser Gln
                325                 330                 335

Thr Ala Asn Lys Pro Ser Arg Phe Gln Ala Arg Asp Ala Asp Ile Glu
                340                 345                 350

Phe Arg Lys Arg Tyr Ser Thr Lys Gly Gly Glu Val Arg Leu His Phe
            355                 360                 365

Gln Phe Glu Gly Gly Glu Ser Arg Thr Gly Met Asn Asp Leu Asn Ala
    370                 375                 380

Lys Leu Pro Gly Asn Ile Ser Ser Leu Asn Val Glu Cys Arg Asn Ser
385                 390                 395                 400

Lys Gln His Gly Lys Lys Asp Ser Lys Ile Thr Asp His Leu Met Arg
                405                 410                 415

Leu Pro Lys Ala Glu Asp Arg Arg Lys Glu Gln Trp Glu Thr Lys His
                420                 425                 430

Gln Arg Thr Glu Arg Lys Ile Pro Lys Tyr Val Pro Pro His Leu Ser
            435                 440                 445

Pro Asp Lys Lys Trp Leu Gly Thr Pro Ile Glu Glu Met Arg Arg Met
    450                 455                 460

Pro Arg Cys Gly Ile Arg Leu Pro Leu Leu Arg Pro Ser Ala Asn His
465                 470                 475                 480

Thr Val Thr Ile Arg Val Asp Leu Leu Arg Ala Gly Glu Val Pro Lys
                485                 490                 495

Pro Phe Pro Thr His Tyr Lys Asp Leu Trp Asp Asn Lys His Val Lys
                500                 505                 510

Met Pro Cys Ser Glu Gln Asn Leu Tyr Pro Val Glu Asp Glu Asn Gly
            515                 520                 525

Glu Arg Thr Ala Gly Ser Arg Trp Glu Leu Ile Gln Thr Ala Leu Leu
    530                 535                 540

Asn Lys Phe Thr Arg Pro Gln Asn Leu Lys Asp Ala Ile Leu Lys Tyr
545                 550                 555                 560

Asn Val Ala Tyr Ser Lys Lys Trp Asp Phe Thr Ala Leu Ile Asp Phe
                565                 570                 575

Trp Asp Lys Val Leu Glu Glu Ala Glu Ala Gln His Leu Tyr Gln Ser
                580                 585                 590

Ile Leu Pro Asp Met Val Lys Ile Ala Leu Cys Leu Pro Asn Ile Cys
            595                 600                 605

Thr Gln Pro Ile Pro Leu Leu Lys Gln Lys Met Asn His Ser Ile Thr
    610                 615                 620

Met Ser Gln Glu Gln Ile Ala Ser Leu Leu Ala Asn Ala Phe Phe Cys
625                 630                 635                 640

Thr Phe Pro Arg Arg Asn Ala Lys Met Lys Ser Glu Tyr Ser Ser Tyr
                645                 650                 655

Pro Asp Ile Asn Phe Asn Arg Leu Phe Glu Gly Arg Ser Ser Arg Lys
            660                 665                 670

Pro Glu Lys Leu Lys Thr Leu Phe Cys Tyr Phe Arg Arg Val Thr Glu
            675                 680                 685

Lys Lys Pro Thr Gly Leu Val Thr Phe Thr Arg Gln Ser Leu Glu Asp
    690                 695                 700

Phe Pro Glu Trp Glu Arg Cys Glu Lys Pro Leu Thr Arg Leu His Val
705                 710                 715                 720
```

-continued

```
Thr Tyr Glu Gly Thr Ile Glu Glu Asn Gly Gln Gly Met Leu Gln Val
             725                 730                 735

Asp Phe Ala Asn Arg Phe Val Gly Gly Gly Val Thr Ser Ala Gly Leu
             740                 745                 750

Val Gln Glu Glu Ile Arg Phe Leu Ile Asn Pro Glu Leu Ile Ile Ser
             755                 760                 765

Arg Leu Phe Thr Glu Val Leu Asp His Asn Glu Cys Leu Ile Ile Thr
         770             775                 780

Gly Thr Glu Gln Tyr Ser Glu Tyr Thr Gly Tyr Ala Glu Thr Tyr Arg
785                 790                 795                 800

Trp Ser Arg Ser His Glu Asp Gly Ser Glu Arg Asp Asp Cys Glu Arg
             805                 810                 815

Arg Cys Thr Glu Ile Val Ala Ile Asp Ala Leu His Phe Arg Arg Tyr
             820                 825                 830

Leu Asp Gln Phe Val Pro Glu Lys Met Arg Arg Glu Leu Asn Lys Ala
         835                 840                 845

Tyr Cys Gly Phe Leu Arg Pro Gly Val Ser Ser Glu Asn Leu Ser Ala
         850                 855                 860

Val Ala Thr Gly Asn Trp Gly Cys Gly Ala Phe Gly Gly Asp Ala Arg
865                 870                 875                 880

Leu Lys Ala Leu Ile Gln Ile Leu Ala Ala Ala Ala Glu Arg Asp
             885                 890                 895

Val Val Tyr Phe Thr Phe Gly Asp Ser Glu Leu Met Arg Asp Ile Tyr
             900                 905                 910

Ser Met His Ile Phe Leu Thr Glu Arg Lys Leu Thr Val Gly Asp Val
         915                 920                 925

Tyr Lys Leu Leu Leu Arg Tyr Tyr Asn Glu Glu Cys Arg Asn Cys Ser
         930                 935                 940

Thr Pro Gly Pro Asp Ile Lys Leu Tyr Pro Phe Ile Tyr His Ala Val
945                 950                 955                 960

Glu Ser Cys Ala Glu Thr Ala Asp His Ser Gly Gln Arg Thr Gly Thr
             965                 970                 975
```

<210> SEQ ID NO 5
<211> LENGTH: 3814
<212> TYPE: DNA
<213> ORGANISM: Mus musculus
<220> FEATURE:

<400> SEQUENCE: 5

gggggactgt gtgctgcggg tcccagcatg agtgcgggcc ccggctggga gccctgcacg   60

aaagcgcgct ggggcgccgc tggaacttct gcgccgactg cctcggactc ccggagcttc   120

cctggcaggc agaggcgtgt tctcgacccc aaggacgctc ccgtccagtt cagggtccct   180

ccgtcctcgc cagcctgcgt ctcggggcgg gcgggaccgc acagaggcaa cgccacctcg   240

tttgttttca aacaaaagac tattactact tggatggata ctaaaggacc caagacagct   300

gaatcagaaa gtaaagaaaa caacaataca agaattgact ccatgatgag ttctgtgcag   360

aaagataact tttacccaca taaggtggaa aaattggaaa atgttcctca gctaaatctt   420

gataaatcac ccacagaaaa gagttcacag tatttgaacc aacagcagac tgcgagtgtg   480

tgcaagtggc agaatgaagg gaagcatgca gaacagcttt tggcaagtga gcctcccgcg   540

gggactccgc taccaaagca gcttagtaat gctaacattg gtcagtcacc ccacactgat   600

gaccacagtg acacagatca tgaagaagac agagacaatc agcagtttct tacacctata   660

-continued

```
aaacttgcaa atacaaagcc aacagtagga gatgggcagg ccagaagcaa ctgtaagtgc      720

agtggatctc gccagtctgt gaaagactgt acaggctgtc aacaggagga ggtggatgtg      780

ctaccagaga gtcctttgtc agatgttggt gccgaggaca ttggaactgg accaaaaaat      840

gacaacaaat tgactggaca agaaagcagc ctaggtgatt cgcctccatt tgagaaagaa      900

agtgagcctg agtcaccaat ggatgtagac aactcgagaa acagttgtca agattcagaa      960

gcagatgaag aaacaagtcc agtctttgat gagcaagatg atcgttcctc ccaaacagca     1020

aataaacttt caagttgcca agcaagagaa gctgatggcg atcttaggaa acggtatttg     1080

actaagggaa gtgaagttag attgcatttc caatttgaag gagaaaataa tgctgggacc     1140

agtgacttaa atgccaagcc atctggaaac tcttctagcc ttaatgtaga gtgtagaagt     1200

tccaagcagc atggaaaaag ggattctaaa attacagatc atttcatgag aatttccaag     1260

tcagaggaca gaagaaaaga acaatgtgaa gtcagacatc aaagaacaga aaggaagatt     1320

ccaaaataca tcccacctaa cctccctcca gagaagaagt ggctgggaac tcctattgag     1380

gaaatgagaa aaatgcctcg gtgtgggatc catttgcctt ccttaagacc atctgcaagt     1440

cacacagtga ctgttcgggt agaccttctg agagcaggag aggttccgaa accttttcca     1500

acacattaca aagatttgtg ggataacaaa catgtgaaaa tgccttgttc ggaacaaaac     1560

ttgtaccctg tggaagatga gaatggtgag cgaactgcag ggagtaggtg ggagctcatt     1620

cagactgcac ttctcaacaa attcacacga ccccagaact tgaaggatgc gattctgaaa     1680

tacaatgtgg catattctaa gaaatgggac tttacagctt tggttgattt ctgggataag     1740

gtacttgaag aagcagaggc ccaacattta tatcagtcca ttttacctga catggtgaaa     1800

attgcactct gtctgccaaa tatttgcacc cagccaatac cactcctgaa acagaagatg     1860

aatcattctg tcacgatgtc acaggaacag atcgccagtc ttttagctaa tgctttcttc     1920

tgcacatttc cccgacggaa tgccaagatg aaatcggagt attctagtta cccagacatt     1980

aacttcaatc ggttgtttga aggacgttca tcaaggaaac cagaaaaact gaaaacactc     2040

ttctgctact ttcgaagagt cacagagaaa aaacctacag gattggtgac atttacaaga     2100

cagagtcttg aagatttcc agaatgggaa aggtgtgaaa agcctctgac acgcttacac     2160

gtcacttacg agggtaccat agaaggcaac ggccgaggca tgctacaggt ggattttgca     2220

aatcgttttg ttggaggtgg tgtgactggt gcgggacttg tacaagaaga aatcagattt     2280

ttaatcaatc ctgaattgat tgtttcacgg ctgttcactg aggtgctgga tcacaatgag     2340

tgtcttatta tcacaggtac tgaacagtac agtgaataca caggctatgc tgaaacttat     2400

cgttgggccc gaagccatga agatgggagt gaaaaggacg attggcagcg gcgctgcacg     2460

gagatcgttg ccattgacgc acttcacttc agacgctacc tcgatcagtt tgtgcctgag     2520

aaagtgagac gtgagcttaa caaggcttac tgcggattcc tccgtcctgg agttccttct     2580

gaaaatcttt ctgcagtggc cacgggaaac tggggctgtg gtgcctttgg gggtgacgct     2640

agattaaaag ccttaataca gatcctggca gctgctgcgg ctgaacgtga cgtggtttat     2700

ttcacctttg gggactcaga gttgatgaga gacattaca gcatgcacac tttccttacc     2760

gagaggaagc tggatgttgg aaaagtgtac aagttattgc ttagatacta caatgaagaa     2820

tgcagaaact gttccacccc tggaccagac atcaagcttt atccattcat ataccatgct     2880

gttgagtcaa gtgcagagac cactgacatg ccaggacaga aggcaggcac ctgaggaaca     2940

agtgactagg acctcctctc aaagagacat cctatttgaa atgtggggtg tgatgtctga     3000

attgactgaa tctgatctaa gtgtgtatat aatccacatt tgtaatcaag gatgcagtct     3060
```

-continued

```
cttctgcata tgcagttgtt tcttgttcat cctggtggac atgcctttag acatggcttc    3120

ttcaattttt cttctccttc agtctttatt ctttgatttt tttttttccaa cttgatttct    3180

tgggaaaact caagaaaggt tgcactcagc ttctagatct ttctcttcct gtctgtgtgt    3240

tgtccagact gctttggtgg ctagcagata ccatcacact tggaggaagt tacaaatcca    3300

gaaatctgag tttgctgcag atttacctgt gagcttctca ctcccaaccc ttgttaggct    3360

tgtgttgtct acattttcaa ttttggaagt tgaagttttt cttatgttac ttaatgctag    3420

tatcttttag gctaaaacta ttttctattt aaggcagact aatttccagt ttctcttttg    3480

aaacatcatc cctataagta acggtttttt tcgtcctttt ttccccagcg ctattttaga    3540

agctggccaa gaggaaagaa aatgtagaat aaaaggattt tcctcggatg ctataaagaa    3600

gccaggttca agagcgttgg ggttttttgtt tttttcaaga cttgtttttc ctttgcagct    3660

agggtgagtg cttgttctgt ggtgctgagg gcatagtcct gtaaccaaag gtctttgctg    3720

gagacttgat gctgatttgt acatatggaa gtttctctgg caggaaatat tagagttaat    3780

aaatttcatt aataaatcat ttgtcagaaa aaaa                                3814
```

<210> SEQ ID NO 6
<211> LENGTH: 968
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<220> FEATURE:

<400> SEQUENCE: 6

```
Met Ser Ala Gly Pro Gly Trp Glu Pro Cys Thr Lys Ala Arg Trp Gly
1               5                   10                  15

Ala Ala Gly Thr Ser Ala Pro Thr Ala Ser Asp Ser Arg Ser Phe Pro
            20                  25                  30

Gly Arg Gln Arg Arg Val Leu Asp Pro Lys Asp Ala Pro Val Gln Phe
        35                  40                  45

Arg Val Pro Pro Ser Ser Pro Ala Cys Val Ser Gly Arg Ala Gly Pro
    50                  55                  60

His Arg Gly Asn Ala Thr Ser Phe Val Phe Lys Gln Lys Thr Ile Thr
65                  70                  75                  80

Thr Trp Met Asp Thr Lys Gly Pro Lys Thr Ala Glu Ser Glu Ser Lys
                85                  90                  95

Glu Asn Asn Asn Thr Arg Ile Asp Ser Met Met Ser Ser Val Gln Lys
            100                 105                 110

Asp Asn Phe Tyr Pro His Lys Val Glu Lys Leu Glu Asn Val Pro Gln
        115                 120                 125

Leu Asn Leu Asp Lys Ser Pro Thr Glu Lys Ser Ser Gln Tyr Leu Asn
    130                 135                 140

Gln Gln Gln Thr Ala Ser Val Cys Lys Trp Gln Asn Glu Gly Lys His
145                 150                 155                 160

Ala Glu Gln Leu Leu Ala Ser Glu Pro Pro Ala Gly Thr Pro Leu Pro
                165                 170                 175

Lys Gln Leu Ser Asn Ala Asn Ile Gly Gln Ser Pro His Thr Asp Asp
            180                 185                 190

His Ser Asp Thr Asp His Glu Glu Asp Arg Asp Asn Gln Gln Phe Leu
        195                 200                 205

Thr Pro Ile Lys Leu Ala Asn Thr Lys Pro Thr Val Gly Asp Gly Gln
    210                 215                 220

Ala Arg Ser Asn Cys Lys Cys Ser Gly Ser Arg Gln Ser Val Lys Asp
```

-continued

```
225                  230                  235                  240

Cys Thr Gly Cys Gln Gln Glu Glu Val Asp Val Leu Pro Glu Ser Pro
                245                  250                  255

Leu Ser Asp Val Gly Ala Glu Asp Ile Gly Thr Gly Pro Lys Asn Asp
                260                  265                  270

Asn Lys Leu Thr Gly Gln Glu Ser Ser Leu Gly Asp Ser Pro Pro Phe
                275                  280                  285

Glu Lys Glu Ser Glu Pro Glu Ser Pro Met Asp Val Asp Asn Ser Arg
          290                  295                  300

Asn Ser Cys Gln Asp Ser Glu Ala Asp Glu Glu Thr Ser Pro Val Phe
305                  310                  315                  320

Asp Glu Gln Asp Asp Arg Ser Ser Gln Thr Ala Asn Lys Leu Ser Ser
                325                  330                  335

Cys Gln Ala Arg Glu Ala Asp Gly Asp Leu Arg Lys Arg Tyr Leu Thr
                340                  345                  350

Lys Gly Ser Glu Val Arg Leu His Phe Gln Phe Glu Gly Glu Asn Asn
          355                  360                  365

Ala Gly Thr Ser Asp Leu Asn Ala Lys Pro Ser Gly Asn Ser Ser Ser
          370                  375                  380

Leu Asn Val Glu Cys Arg Ser Ser Lys Gln His Gly Lys Arg Asp Ser
385                  390                  395                  400

Lys Ile Thr Asp His Phe Met Arg Ile Ser Lys Ser Glu Asp Arg Arg
                405                  410                  415

Lys Glu Gln Cys Glu Val Arg His Gln Arg Thr Glu Arg Lys Ile Pro
          420                  425                  430

Lys Tyr Ile Pro Pro Asn Leu Pro Pro Glu Lys Lys Trp Leu Gly Thr
          435                  440                  445

Pro Ile Glu Glu Met Arg Lys Met Pro Arg Cys Gly Ile His Leu Pro
          450                  455                  460

Ser Leu Arg Pro Ser Ala Ser His Thr Val Thr Val Arg Val Asp Leu
465                  470                  475                  480

Leu Arg Ala Gly Glu Val Pro Lys Pro Phe Pro Thr His Tyr Lys Asp
                485                  490                  495

Leu Trp Asp Asn Lys His Val Lys Met Pro Cys Ser Glu Gln Asn Leu
          500                  505                  510

Tyr Pro Val Glu Asp Glu Asn Gly Glu Arg Thr Ala Gly Ser Arg Trp
          515                  520                  525

Glu Leu Ile Gln Thr Ala Leu Leu Asn Lys Phe Thr Arg Pro Gln Asn
          530                  535                  540

Leu Lys Asp Ala Ile Leu Lys Tyr Asn Val Ala Tyr Ser Lys Lys Trp
545                  550                  555                  560

Asp Phe Thr Ala Leu Val Asp Phe Trp Asp Lys Val Leu Glu Glu Ala
                565                  570                  575

Glu Ala Gln His Leu Tyr Gln Ser Ile Leu Pro Asp Met Val Lys Ile
                580                  585                  590

Ala Leu Cys Leu Pro Asn Ile Cys Thr Gln Pro Ile Pro Leu Leu Lys
                595                  600                  605

Gln Lys Met Asn His Ser Val Thr Met Ser Gln Glu Gln Ile Ala Ser
          610                  615                  620

Leu Leu Ala Asn Ala Phe Phe Cys Thr Phe Pro Arg Arg Asn Ala Lys
625                  630                  635                  640

Met Lys Ser Glu Tyr Ser Ser Tyr Pro Asp Ile Asn Phe Asn Arg Leu
                645                  650                  655
```

-continued

```
Phe Glu Gly Arg Ser Ser Arg Lys Pro Glu Lys Leu Lys Thr Leu Phe
            660                 665                 670

Cys Tyr Phe Arg Arg Val Thr Glu Lys Lys Pro Thr Gly Leu Val Thr
            675                 680                 685

Phe Thr Arg Gln Ser Leu Glu Asp Phe Pro Glu Trp Glu Arg Cys Glu
            690                 695                 700

Lys Pro Leu Thr Arg Leu His Val Thr Tyr Glu Gly Thr Ile Glu Gly
705                 710                 715                 720

Asn Gly Arg Gly Met Leu Gln Val Asp Phe Ala Asn Arg Phe Val Gly
                725                 730                 735

Gly Gly Val Thr Gly Ala Gly Leu Val Gln Glu Glu Ile Arg Phe Leu
                740                 745                 750

Ile Asn Pro Glu Leu Ile Val Ser Arg Leu Phe Thr Glu Val Leu Asp
                755                 760                 765

His Asn Glu Cys Leu Ile Ile Thr Gly Thr Glu Gln Tyr Ser Glu Tyr
            770                 775                 780

Thr Gly Tyr Ala Glu Thr Tyr Arg Trp Ala Arg Ser His Glu Asp Gly
785                 790                 795                 800

Ser Glu Lys Asp Asp Trp Gln Arg Arg Cys Thr Glu Ile Val Ala Ile
                805                 810                 815

Asp Ala Leu His Phe Arg Arg Tyr Leu Asp Gln Phe Val Pro Glu Lys
            820                 825                 830

Val Arg Arg Glu Leu Asn Lys Ala Tyr Cys Gly Phe Leu Arg Pro Gly
            835                 840                 845

Val Pro Ser Glu Asn Leu Ser Ala Val Ala Thr Gly Asn Trp Gly Cys
            850                 855                 860

Gly Ala Phe Gly Gly Asp Ala Arg Leu Lys Ala Leu Ile Gln Ile Leu
865                 870                 875                 880

Ala Ala Ala Ala Ala Glu Arg Asp Val Val Tyr Phe Thr Phe Gly Asp
                885                 890                 895

Ser Glu Leu Met Arg Asp Ile Tyr Ser Met His Thr Phe Leu Thr Glu
            900                 905                 910

Arg Lys Leu Asp Val Gly Lys Val Tyr Lys Leu Leu Leu Arg Tyr Tyr
            915                 920                 925

Asn Glu Glu Cys Arg Asn Cys Ser Thr Pro Gly Pro Asp Ile Lys Leu
            930                 935                 940

Tyr Pro Phe Ile Tyr His Ala Val Glu Ser Ser Ala Glu Thr Thr Asp
945                 950                 955                 960

Met Pro Gly Gln Lys Ala Gly Thr
                965
```

<210> SEQ ID NO 7
<211> LENGTH: 2781
<212> TYPE: DNA
<213> ORGANISM: Drosophila melanogaster
<220> FEATURE:

<400> SEQUENCE: 7

```
tcgaagtgtg tggtatttat aaagtgcgat attcatcaca gctatcgctc atccccaaaa        60

caccggtatg caagaattca ggtcacactt gattttccg atattccaaa aggtttacca       120

atctacggca aatcgccgca gagcaagtgc atccgtgctg accaatcgac tcggcaaggc       180

tttgtgctta aactgcgcca ggatgtcgaa gtcgccggat ggcgggattt ccgaaataga       240

aacggaggag gagccggaaa atctggcgaa ctccctagat gattcgtggc gtggagtttc       300
```

-continued

```
catggaggct atacatcgta atcggcagcc tttcgaattg gagaatttgc caccagtgac    360

tgccggcaat ctccaccggg ttatgtacca gctgccaatt cgtgaaacac cgccacgccc    420

ctacaaatca ccgggaaagt gggactccga gcatgtgcgt ctgccctgtg cgcccgagtc    480

gaaatatccg agggagaatc cggatggcag caccaccatc gattttcgct gggaaatgat    540

cgaacgagcc cttctgcagc ccataaagac gtgtgaggaa ctgcaggcgg cgataatatc    600

atataatacc acctataggg atcagtggca ctttcgtgcc cttcatcaac ttctcgacga    660

ggaactggac gagagcgaaa cacgggtttt cttcgaggat ctattgccgc gcattatccg    720

attggcattg cggctaccgg acttgattca atcgccagtt ccgctgctca agcaccacaa    780

gaacgcctca ttgagcctga gccaacagca gatctcctgc ctgttggcca atgccttctt    840

gtgcacgttt ccccgaagaa acaccctcaa gaggaagtcc gagtacagca cttttccaga    900

catcaacttt aacaggcttt accaatcgac gggaccggca gttctggaga agcttaaatg    960

cattatgcac tattttcgtc gcgtgtgtcc cacagagcgg gatgccagca atgtgcccac    1020

cggtgtggta acctttgttc gtcggagcgg attgccggaa catctgatcg actggagcca    1080

aagtgcggcg ccgttgggtg atgtgccatt gcacgtggat gccgagggaa caatcgagga    1140

tgagggcatt ggactgctgc aagtagactt tgccaacaaa tatttgggtg gcggtgtctt    1200

gggacatggc tgcgttcagg aggagatacg ctttgttatc tgtccggagc tattggtggg    1260

taaactcttt acggagtgtc tgcgaccatt cgaggccctg gtgatgttgg cgcccgaaag    1320

gtatagtaac tatacgggat atgccggaag cttcgagtgg tccggcaact ttgaggattc    1380

aacgccaaga gatagctcag gtcgtcgaca aacggccatt gtggcaatcg atgccctaca    1440

ttttgcccag tcacatcatc aatatcgcga ggatctcatg gaaagggagc tgaacaaggc    1500

gtacattgga tttgttcact ggatggtgac gccgccaccg ggtgtggcaa ctggtaactg    1560

gggttgcggc gcattcggcg gtgactccta tctgaaagcc ctgctgcaac ttatggtctg    1620

cgcccagttg ggcagacctt tggcctacta tacctttgga aatgtggagt ttagggatga    1680

ttttcatgaa atgtgctgt tgtttcgaaa tgacgggact acggtgcagc agctttggag    1740

tattttaagg tcgtacagta ggcttattaa ggagaagagc tccaaggagc cgcgtgagaa    1800

taaggcatcc aaaaagaagc tatatgattt tattaaagag gaacttaaga aggtcagaga    1860

tgtgcccgga gagggagcat ccgccgaagc tggaagctct agagtagctg gattaggcga    1920

aggaaaatca gaaacatcag cgaaatcctc gccagaactc aacaagcaac ccgcccgacc    1980

gcaaatcacc ataacgcaac aaagtaccga tctattgccc gcgcaattat cgcaagataa    2040

ctctaattct tcggaagatc aggcccttct tatgctgtcg gacgatgagg aggccaatgc    2100

catgatggag gccgctagtc tggaggctaa aagcagcgta gaaataagca acagcagcac    2160

aacgtccaaa acgagcagta cagccacgaa atcaatgggt tcaggtggcc gccagttgag    2220

tctgctcgag atgctggaca cccattatga aaagggttcg gcctcgaaga ggccacgaaa    2280

atcacccaac tgcagcaagg ctgagggttc agcaaagagt cgtaaggaga tcgatgtgac    2340

cgacaaggac gaaaaggacg atattgttga ctaggtgata ttgcactaca ggattgttac    2400

tgcccccaaa aattgaagag gtataaaatg tattgtagat aactttaagg acatatttag    2460

ggcattttaa agtaggatca ttgtaagtcg aataaagtga aatttttttt ttttttttaat    2520

tatactattc taatctgcaa agacaatttt actgttaaat ttgtataaca ttcgaattaa    2580

ttaatataat ttgttatatc atgcaaatct agctttttatt atgcgaaatt tgtagttaaa    2640
```

-continued

```
gccagtaaag tttctttta tttaaccgaa accttttgtt tattttattt gaccacaaca   2700

agaacatcaa caacaacaac cacgaaaaaa aagcgaatat atatttgttt gttcgtatat   2760

atatatatat ctaagcagat c                                            2781
```

<210> SEQ ID NO 8
<211> LENGTH: 768
<212> TYPE: PRT
<213> ORGANISM: Drosophila melanogaster
<220> FEATURE:

<400> SEQUENCE: 8

```
Met Gln Glu Phe Arg Ser His Leu Ile Phe Pro Ile Phe Gln Lys Val
1               5                   10                  15

Tyr Gln Ser Thr Ala Asn Arg Arg Arg Ala Ser Ala Ser Val Leu Thr
                20                  25                  30

Asn Arg Leu Gly Lys Ala Leu Cys Leu Asn Cys Ala Arg Met Ser Lys
            35                  40                  45

Ser Pro Asp Gly Gly Ile Ser Glu Ile Glu Thr Glu Glu Glu Pro Glu
        50                  55                  60

Asn Leu Ala Asn Ser Leu Asp Asp Ser Trp Arg Gly Val Ser Met Glu
65                  70                  75                  80

Ala Ile His Arg Asn Arg Gln Pro Phe Glu Leu Glu Asn Leu Pro Pro
                85                  90                  95

Val Thr Ala Gly Asn Leu His Arg Val Met Tyr Gln Leu Pro Ile Arg
            100                 105                 110

Glu Thr Pro Pro Arg Pro Tyr Lys Ser Pro Gly Lys Trp Asp Ser Glu
        115                 120                 125

His Val Arg Leu Pro Cys Ala Pro Glu Ser Lys Tyr Pro Arg Glu Asn
        130                 135                 140

Pro Asp Gly Ser Thr Thr Ile Asp Phe Arg Trp Glu Met Ile Glu Arg
145                 150                 155                 160

Ala Leu Leu Gln Pro Ile Lys Thr Cys Glu Glu Leu Gln Ala Ala Ile
                165                 170                 175

Ile Ser Tyr Asn Thr Thr Tyr Arg Asp Gln Trp His Phe Arg Ala Leu
            180                 185                 190

His Gln Leu Leu Asp Glu Glu Leu Asp Glu Ser Glu Thr Arg Val Phe
        195                 200                 205

Phe Glu Asp Leu Leu Pro Arg Ile Ile Arg Leu Ala Leu Arg Leu Pro
        210                 215                 220

Asp Leu Ile Gln Ser Pro Val Pro Leu Leu Lys His His Lys Asn Ala
225                 230                 235                 240

Ser Leu Ser Leu Ser Gln Gln Gln Ile Ser Cys Leu Leu Ala Asn Ala
                245                 250                 255

Phe Leu Cys Thr Phe Pro Arg Arg Asn Thr Leu Lys Arg Lys Ser Glu
            260                 265                 270

Tyr Ser Thr Phe Pro Asp Ile Asn Phe Asn Arg Leu Tyr Gln Ser Thr
            275                 280                 285

Gly Pro Ala Val Leu Glu Lys Leu Lys Cys Ile Met His Tyr Phe Arg
        290                 295                 300

Arg Val Cys Pro Thr Glu Arg Asp Ala Ser Asn Val Pro Thr Gly Val
305                 310                 315                 320

Val Thr Phe Val Arg Arg Ser Gly Leu Pro Glu His Leu Ile Asp Trp
                325                 330                 335

Ser Gln Ser Ala Ala Pro Leu Gly Asp Val Pro Leu His Val Asp Ala
```

-continued

```
         340              345              350
Glu Gly Thr Ile Glu Asp Glu Gly Ile Gly Leu Leu Gln Val Asp Phe
         355              360              365

Ala Asn Lys Tyr Leu Gly Gly Gly Val Leu Gly His Gly Cys Val Gln
         370              375              380

Glu Glu Ile Arg Phe Val Ile Cys Pro Glu Leu Leu Val Gly Lys Leu
385              390              395              400

Phe Thr Glu Cys Leu Arg Pro Phe Glu Ala Leu Val Met Leu Gly Ala
             405              410              415

Glu Arg Tyr Ser Asn Tyr Thr Gly Tyr Ala Gly Ser Phe Glu Trp Ser
             420              425              430

Gly Asn Phe Glu Asp Ser Thr Pro Arg Asp Ser Ser Gly Arg Arg Gln
         435              440              445

Thr Ala Ile Val Ala Ile Asp Ala Leu His Phe Ala Gln Ser His His
         450              455              460

Gln Tyr Arg Glu Asp Leu Met Glu Arg Glu Leu Asn Lys Ala Tyr Ile
465              470              475              480

Gly Phe Val His Trp Met Val Thr Pro Pro Pro Gly Val Ala Thr Gly
             485              490              495

Asn Trp Gly Cys Gly Ala Phe Gly Gly Asp Ser Tyr Leu Lys Ala Leu
             500              505              510

Leu Gln Leu Met Val Cys Ala Gln Leu Gly Arg Pro Leu Ala Tyr Tyr
             515              520              525

Thr Phe Gly Asn Val Glu Phe Arg Asp Asp Phe His Glu Met Trp Leu
         530              535              540

Leu Phe Arg Asn Asp Gly Thr Thr Val Gln Gln Leu Trp Ser Ile Leu
545              550              555              560

Arg Ser Tyr Ser Arg Leu Ile Lys Glu Lys Ser Ser Lys Glu Pro Arg
             565              570              575

Glu Asn Lys Ala Ser Lys Lys Lys Leu Tyr Asp Phe Ile Lys Glu Glu
             580              585              590

Leu Lys Lys Val Arg Asp Val Pro Gly Glu Gly Ala Ser Ala Glu Ala
         595              600              605

Gly Ser Ser Arg Val Ala Gly Leu Gly Glu Gly Lys Ser Glu Thr Ser
         610              615              620

Ala Lys Ser Ser Pro Glu Leu Asn Lys Gln Pro Ala Arg Pro Gln Ile
625              630              635              640

Thr Ile Thr Gln Gln Ser Thr Asp Leu Leu Pro Ala Gln Leu Ser Gln
             645              650              655

Asp Asn Ser Asn Ser Ser Glu Asp Gln Ala Leu Leu Met Leu Ser Asp
             660              665              670

Asp Glu Glu Ala Asn Ala Met Met Glu Ala Ala Ser Leu Glu Ala Lys
         675              680              685

Ser Ser Val Glu Ile Ser Asn Ser Ser Thr Thr Ser Lys Thr Ser Ser
         690              695              700

Thr Ala Thr Lys Ser Met Gly Ser Gly Gly Arg Gln Leu Ser Leu Leu
705              710              715              720

Glu Met Leu Asp Thr His Tyr Glu Lys Gly Ser Ala Ser Lys Arg Pro
             725              730              735

Arg Lys Ser Pro Asn Cys Ser Lys Ala Glu Gly Ser Ala Lys Ser Arg
             740              745              750

Lys Glu Ile Asp Val Thr Asp Lys Asp Glu Lys Asp Asp Ile Val Asp
             755              760              765
```

-continued

```
<210> SEQ ID NO 9
<211> LENGTH: 2181
<212> TYPE: DNA
<213> ORGANISM: Caenorhabditis elegans
<220> FEATURE:

<400> SEQUENCE: 9

atgagcaaga agtttatcga actgggtgat cctgtcactc aagacgagaa agactacgaa      60

gactatgtcg gagttggttt cgcgcatcaa gtcccgacaa tgaaaaggcg gaagttgaca     120

gaacatggaa atactacaga atcaaaagaa gatcctgaag agccaaaaag ccgtgacgta     180

tttgtctcct cgcagtcaag tgatgagagt caagaagatt cggctgaaaa tccggagatc     240

gctaaagaag tgtcagaaaa ttgtgaaaat ctgacagaaa ctctcaaaat ttctaatatt     300

gagagtttgg acaatgttac tgaaagatct gaacacactc ttgataatca caaaagtact     360

gaaccaatgg aagaagatgt aaacaacaag tccaatattg acgttgcgat taattctgac     420

gaggatgatg aacttgttct ggaagagaat aataaagaaa tgagggatgg agaacaagta     480

caacagttgt cacaggattt attcgctgat gatcaagagc taattgaata tccaggaatt     540

atgaaagaca ctacaactca actggatata acagattctg aagtggagac tgctcaaaaa     600

atggaaatga ttgaagaaac tgaagcagat tcgacatttg taggcgagga ttcaaaagct     660

acgaaaactg tgaggacatc cagttcaagt ttcctgtcaa ctgtttcaac atgcgaagcc     720

cctgcaaaag gacgagcaag aatgtatcaa aaagagttgg aaaagcatgt gattgcattt     780

actgagggaa atctcacact acaaccagat ttgaacaaag ttgatcccga cagaaactat     840

cgatattgta caattccgaa ctttccagct tcccaaggaa aacttcgaga agataatcga     900

tatggcccaa aaatcgtttt gcctcaaaga tggcgagaat ttgattcgag gggccgtaga     960

agagactcat atttctattt caaacgtaag ctcgatggat atttgaaatg ctacaaaaca    1020

actggatatt ttatgtttgt tggacttttg cacaacatgt gggaatttga cccagacatc    1080

acatataaac tgccagcact ggaaatgtat tacaaagaga tgtcggaact tgttggtaga    1140

gaagaggttt tggaaaaatt tgcacgagtt gcccgcatcg caaaaactgc tgaagatatt    1200

ctgccagagc gaatttatcg tcttgttggt gacgtcgaat cagctacctt gagccacaag    1260

caatgtgctg cacttgttgc gagaatgttt tttgcccgac cggacagtcc tttcagtttc    1320

tgccgaattc tctcgtctga taaatctatt tgtgtggaga aacttaaatt cctgttcact    1380

tatttcgaca aaatgtcaat ggatccaccg gatggtgccg tcagttttag acttacaaaa    1440

atggataaag atacgttcaa cgaagagtgg aaagataaaa aattacgttc tcttcctgaa    1500

gttgaattct ttgatgaaat gcttattgaa gacacagctc tctgtacaca agttgatttt    1560

gcgaacgaac atcttggtgg cggagtttta aatcatgggt ctgttcagga ggagatccgt    1620

ttcttgatgt gtccagaaat gatggttgga atgttgttgt gcgagaaaat gaaacaactg    1680

gaagcgattt caattgttgg agcttacgtt ttcagttctt atactggtta tggtcatact    1740

ctaaatgggg cagaacttca accaaatcat tctcgtcaga atacaaacga atttcgagat    1800

cgttttggac gtcttcgggt agaaactatt gcaatcgatg caattctgtt caaaggatca    1860

aaattagatt gtcagacgga gcagttaaac aaagcaaata tcattaggga aatgaagaaa    1920

gcatctatcg gattcatgag ccagggaccg aaattcacaa atattccaat tgttactgga    1980

tggtgggggat gtggagcatt taatggggac aagccactga gttcataat ccaagtaatt    2040

gctgccggag tcgctgatcg tccacttcat ttctgttcat ttggagaacc cgagcttgcc    2100
```

-continued

```
gcaaagtgca agaaaattat agaacgaatg aaacagaagg acgtaacact tggtaagtca      2160

tgtttttcaa tcttcagttg a                                                2181
```

```
<210> SEQ ID NO 10
<211> LENGTH: 726
<212> TYPE: PRT
<213> ORGANISM: Caenorhabditis elegans
<220> FEATURE:

<400> SEQUENCE: 10

Met Ser Lys Lys Phe Ile Glu Leu Gly Asp Pro Val Thr Gln Asp Glu
1               5                   10                  15

Lys Asp Tyr Glu Asp Tyr Val Gly Val Gly Phe Ala His Gln Val Pro
            20                  25                  30

Thr Met Lys Arg Arg Lys Leu Thr Glu His Gly Asn Thr Thr Glu Ser
        35                  40                  45

Lys Glu Asp Pro Glu Glu Pro Lys Ser Arg Asp Val Phe Val Ser Ser
        50                  55                  60

Gln Ser Ser Asp Glu Ser Gln Glu Asp Ser Ala Glu Asn Pro Glu Ile
65                  70                  75                  80

Ala Lys Glu Val Ser Glu Asn Cys Glu Asn Leu Thr Glu Thr Leu Lys
            85                  90                  95

Ile Ser Asn Ile Glu Ser Leu Asp Asn Val Thr Glu Arg Ser Glu His
            100                 105                 110

Thr Leu Asp Asn His Lys Ser Thr Glu Pro Met Glu Glu Asp Val Asn
        115                 120                 125

Asn Lys Ser Asn Ile Asp Val Ala Ile Asn Ser Asp Glu Asp Asp Glu
        130                 135                 140

Leu Val Leu Glu Glu Asn Asn Lys Glu Met Arg Asp Gly Glu Gln Val
145                 150                 155                 160

Gln Gln Leu Ser Gln Asp Leu Phe Ala Asp Asp Gln Glu Leu Ile Glu
            165                 170                 175

Tyr Pro Gly Ile Met Lys Asp Thr Thr Thr Gln Leu Asp Ile Thr Asp
            180                 185                 190

Ser Glu Val Glu Thr Ala Gln Lys Met Glu Met Ile Glu Glu Thr Glu
        195                 200                 205

Ala Asp Ser Thr Phe Val Gly Glu Asp Ser Lys Ala Thr Lys Thr Val
        210                 215                 220

Arg Thr Ser Ser Ser Ser Phe Leu Ser Thr Val Ser Thr Cys Glu Ala
225                 230                 235                 240

Pro Ala Lys Gly Arg Ala Arg Met Tyr Gln Lys Glu Leu Glu Lys His
            245                 250                 255

Val Ile Ala Phe Thr Glu Gly Asn Leu Thr Leu Gln Pro Asp Leu Asn
            260                 265                 270

Lys Val Asp Pro Asp Arg Asn Tyr Arg Tyr Cys Thr Ile Pro Asn Phe
        275                 280                 285

Pro Ala Ser Gln Gly Lys Leu Arg Glu Asp Asn Arg Tyr Gly Pro Lys
        290                 295                 300

Ile Val Leu Pro Gln Arg Trp Arg Glu Phe Asp Ser Arg Gly Arg Arg
305                 310                 315                 320

Arg Asp Ser Tyr Phe Tyr Phe Lys Arg Lys Leu Asp Gly Tyr Leu Lys
            325                 330                 335

Cys Tyr Lys Thr Thr Gly Tyr Phe Met Phe Val Gly Leu Leu His Asn
            340                 345                 350
```

-continued

```
Met Trp Glu Phe Asp Pro Asp Ile Thr Tyr Lys Leu Pro Ala Leu Glu
        355                 360                 365

Met Tyr Tyr Lys Glu Met Ser Glu Leu Val Gly Arg Glu Glu Val Leu
        370                 375                 380

Glu Lys Phe Ala Arg Val Ala Arg Ile Ala Lys Thr Ala Glu Asp Ile
385                 390                 395                 400

Leu Pro Glu Arg Ile Tyr Arg Leu Val Gly Asp Val Glu Ser Ala Thr
                405                 410                 415

Leu Ser His Lys Gln Cys Ala Ala Leu Val Ala Arg Met Phe Phe Ala
                420                 425                 430

Arg Pro Asp Ser Pro Phe Ser Phe Cys Arg Ile Leu Ser Ser Asp Lys
        435                 440                 445

Ser Ile Cys Val Glu Lys Leu Lys Phe Leu Phe Thr Tyr Phe Asp Lys
        450                 455                 460

Met Ser Met Asp Pro Pro Asp Gly Ala Val Ser Phe Arg Leu Thr Lys
465                 470                 475                 480

Met Asp Lys Asp Thr Phe Asn Glu Glu Trp Lys Asp Lys Lys Leu Arg
                485                 490                 495

Ser Leu Pro Glu Val Glu Phe Phe Asp Glu Met Leu Ile Glu Asp Thr
                500                 505                 510

Ala Leu Cys Thr Gln Val Asp Phe Ala Asn Glu His Leu Gly Gly Gly
                515                 520                 525

Val Leu Asn His Gly Ser Val Gln Glu Glu Ile Arg Phe Leu Met Cys
        530                 535                 540

Pro Glu Met Met Val Gly Met Leu Leu Cys Glu Lys Met Lys Gln Leu
545                 550                 555                 560

Glu Ala Ile Ser Ile Val Gly Ala Tyr Val Phe Ser Ser Tyr Thr Gly
                565                 570                 575

Tyr Gly His Thr Leu Lys Trp Ala Glu Leu Gln Pro Asn His Ser Arg
                580                 585                 590

Gln Asn Thr Asn Glu Phe Arg Asp Arg Phe Gly Arg Leu Arg Val Glu
        595                 600                 605

Thr Ile Ala Ile Asp Ala Ile Leu Phe Lys Gly Ser Lys Leu Asp Cys
        610                 615                 620

Gln Thr Glu Gln Leu Asn Lys Ala Asn Ile Ile Arg Glu Met Lys Lys
625                 630                 635                 640

Ala Ser Ile Gly Phe Met Ser Gln Gly Pro Lys Phe Thr Asn Ile Pro
                645                 650                 655

Ile Val Thr Gly Trp Trp Gly Cys Gly Ala Phe Asn Gly Asp Lys Pro
                660                 665                 670

Leu Lys Phe Ile Ile Gln Val Ile Ala Ala Gly Val Ala Asp Arg Pro
        675                 680                 685

Leu His Phe Cys Ser Phe Gly Glu Pro Glu Leu Ala Ala Lys Cys Lys
        690                 695                 700

Lys Ile Ile Glu Arg Met Lys Gln Lys Asp Val Thr Leu Gly Lys Ser
705                 710                 715                 720

Cys Phe Ser Ile Phe Ser
                725
```

<210> SEQ ID NO 11
<211> LENGTH: 31
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<220> FEATURE:

-continued

<400> SEQUENCE: 11

Leu Phe Thr Glu Val Leu Asp His Asn Glu Cys Leu Ile Ile Thr Gly
1   5   10   15

Thr Glu Gln Tyr Ser Glu Tyr Thr Gly Tyr Ala Glu Thr Tyr Arg
            20   25   30

<210> SEQ ID NO 12
<211> LENGTH: 29
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 12

Ala Tyr Cys Gly Phe Leu Arg Pro Gly Val Ser Ser Glu Asn Leu Ser
1   5   10   15

Ala Val Ala Thr Gly Asn Xaa Gly Cys Gly Ala Phe Gly
            20   25

<210> SEQ ID NO 13
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 13

Phe Leu Ile Asn Pro Glu Leu Ile Val Ser Arg
1   5   10

<210> SEQ ID NO 14
<211> LENGTH: 16
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 14

Ile Ala Leu Xaa Leu Pro Asn Ile Xaa Thr Gln Pro Ile Pro Leu Leu
1   5   10   15

<210> SEQ ID NO 15
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 15

gaycayaayg artgyyt   17

<210> SEQ ID NO 16
<211> LENGTH: 17
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 16

ckrtangtyt cngcrta   17

<210> SEQ ID NO 17
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 17

-continued

```
atcatcacag gtactgagca gtac                                            24


<210> SEQ ID NO 18
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 18

gcctgtgtat tcactgtact gctc                                            24


<210> SEQ ID NO 19
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 19

Glu Asp Lys Arg Lys Glu Gln Cys Glu Met Lys His Gln Arg Thr Glu
1               5                   10                  15

Arg Lys Ile Pro Lys Tyr Ile Pro Pro His
            20                  25


<210> SEQ ID NO 20
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:

<400> SEQUENCE: 20

Glu Asp Arg Arg Lys Glu Gln Trp Glu Thr Lys His Gln Arg Thr Glu
1               5                   10                  15

Arg Lys Ile Pro Lys Tyr Val Pro Pro His
            20                  25


<210> SEQ ID NO 21
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Mus Musculus
<220> FEATURE:

<400> SEQUENCE: 21

Glu Asp Arg Arg Lys Glu Gln Cys Glu Val Arg His Gln Arg Thr Glu
1               5                   10                  15

Arg Lys Ile Pro Lys Tyr Ile Pro Pro Asn
            20                  25


<210> SEQ ID NO 22
<211> LENGTH: 32
<212> TYPE: PRT
<213> ORGANISM: Caenorhabotitis elegans
<220> FEATURE:

<400> SEQUENCE: 22

His Gln Val Pro Thr Met Lys Arg Arg Lys Leu Thr Glu His Gly Asn
1               5                   10                  15

Thr Thr Glu Ser Leu Leu Leu Lys Glu Asp Pro Pro Glu Pro Lys Ser
            20                  25                  30


<210> SEQ ID NO 23
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Homo sapiens
<220> FEATURE:
```

-continued

<400> SEQUENCE: 23

Glu Gly Lys Arg Lys Gly Asp Glu Val Asp Gly Val Asp Glu Val Ala
1   5   10   15

Lys Lys Lys Ser Lys Lys Glu Lys Asp Lys
            20   25

<210> SEQ ID NO 24
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Mus musculus
<220> FEATURE:

<400> SEQUENCE: 24

Glu Gly Lys Arg Lys Gly Asp Glu Val Asp Gly Thr Asp Glu Val Ala
1   5   10   15

Lys Lys Lys Ser Arg Lys Glu Thr Asp Lys
            20   25

<210> SEQ ID NO 25
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 25

Glu Gly Lys Arg Lys Gly Asp Glu Val Asp Gly Ile Asp Glu Val Thr
1   5   10   15

Lys Lys Lys Ser Lys Lys Glu Lys Asp Lys
            20   25

<210> SEQ ID NO 26
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Galus galus
<220> FEATURE:

<400> SEQUENCE: 26

Glu Gly Lys Arg Lys Gly Glu Glu Val Asp Gly Asn Val Val Ala Lys
1   5   10   15

Lys Lys Ser Arg Lys Glu Lys Glu Lys
            20   25

<210> SEQ ID NO 27
<211> LENGTH: 26
<212> TYPE: PRT
<213> ORGANISM: Xenopus laevis
<220> FEATURE:

<400> SEQUENCE: 27

Glu Gly Lys Arg Lys Ala Asp Glu Val Asp Gly His Ser Ala Ala Thr
1   5   10   15

Lys Lys Lys Ile Lys Lys Glu Lys Glu Lys
            20   25

<210> SEQ ID NO 28
<211> LENGTH: 25
<212> TYPE: PRT
<213> ORGANISM: Drosophila melanoguster
<220> FEATURE:

<400> SEQUENCE: 28

Glu Glu Leu Pro Asp Thr Lys Arg Ala Lys Met Glu Leu Ser Asp Thr

-continued

```
1              5               10              15

Asn Glu Glu Gly Glu Lys Lys Gln Arg
             20              25


<210> SEQ ID NO 29
<211> LENGTH: 31
<212> TYPE: PRT
<213> ORGANISM: Sarcophaga peregrina
<220> FEATURE:

<400> SEQUENCE: 29

Glu Gly Val Ser Ser Ala Lys Lys Ala Lys Ile Glu Lys Ile Asp Glu
1              5               10              15

Glu Asp Ala Ala Ser Ile Lys Glu Leu Thr Glu Lys Ile Lys Lys
             20              25              30


<210> SEQ ID NO 30
<211> LENGTH: 28
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 30

gctgcgggtc tcgacgatga gtgcgggc                                          28


<210> SEQ ID NO 31
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 31

gcgtctagaa ttcacttggc tcctcaggc                                         29


<210> SEQ ID NO 32
<211> LENGTH: 38
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 32

ccggaattcg ggttttttgt taatgaaaat ttattaac                               38


<210> SEQ ID NO 33
<211> LENGTH: 29
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 33

tcagagcaga tgaactcgag cagtccagg                                         29


<210> SEQ ID NO 34
<211> LENGTH: 61
<212> TYPE: DNA
<213> ORGANISM: Bos taurus
<220> FEATURE:

<400> SEQUENCE: 34

ccaatttgaa ggaggaattc ccgccgccac catgaatgat gtgaatgcca aacgacctgg      60

a                                                                       61


<210> SEQ ID NO 35
```

```
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial sequence
<220> FEATURE: Kozak consensus sequence
<223> OTHER INFORMATION: Synthesized by oligonucleotide synthesizer

<400> SEQUENCE: 35

gaattcccgc cgccaccatg aa                                            22


<210> SEQ ID NO 36
<211> LENGTH: 674
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:

<400> SEQUENCE: 36

agaagaaaat ggccaaggca tgctacaggt ggattttgca aatcgttttg ttggaggtgg    60

tgtaaccagt gcaggacttg tgcaagaaga aatccgcttt ttaatcaatc ctgagttgat   120

tatttcacgg ctcttcactg aggtgctgga tcacaatgaa tgtctaatta tcacaggtac   180

tgagcagtac agtgaataca caggctatgc tgagacatat cgttggtccc ggagccacga   240

agatgggagt gaaagggacg actgcgagcg gcgctgcact gagatcgttg ccatcgatgc   300

tcttcacttc agacgctacc tcgatcagtt tgtgcctgag aaaatgagac gcgagctgaa   360

caaggcttac tgtggatttc tccgtcctgg agtttcttca gagaatcttt ctgcagtggc   420

cacaggaaac tggggctgtg gtgcctttgg gggtgatgcc aggttaaaag ccttaataca   480

gatattggca gctgctgcag ctgagcgaga tgtggtttat ttcacctttg gggactcaga   540

attgatgaga gacatttaca gcatgcacat tttccttact gaaaggaaac tcactgttgg   600

agatgtgtat aagctgttgc tacgatacta caatgaagaa tgcagaaact gttccacccc   660

tggaccagac atca                                                    674


<210> SEQ ID NO 37
<211> LENGTH: 200
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<220> FEATURE:

<400> SEQUENCE: 37

aaaaatagtt gtcaagactc agaagcagat gaggagacaa gtccaggttt tgatgaacaa    60

gaagatggta gttcctccca aacagcaaat aaaccttcaa ggttccaagc aagagacgct   120

gacattgaat ttaggaaacg gtactctact aagggcggtg aagttagatt acatttccaa   180

tttgaaggag gagagagtcg                                              200


<210> SEQ ID NO 38
<211> LENGTH: 29793
<212> TYPE: DNA
<213> ORGANISM: Caenorhabaditis elegans
<220> FEATURE:

<400> SEQUENCE: 38

gatctcgaag taaaaactca cgcagaaaga gctcctcctc ctttagcatg agaatccaac    60

tttgtaatga taacactggc aacatcaaca gtttgagaga aagcacgtgc ttgggcttca   120

caagcttgtc caatagaagc atccatcaca aaaacaacat tatctggtgt aactgcgttg   180

gaaacttgga gcatttcttc gaaaagtgaa gcttcttgct tgtgacgacc tgatgtatca   240

acaatgatga tttcgaaccc ttcttgctgc aaaacaaata ttattaaacc atttttctgt   300
```

-continued

```
gataaattac cgtgaatttt tctactcctt cggcggcaat ttttacgggg tcaatttcag      360

agtatgatcc atagaaggga atacgagctt ttgtggcatt ttgctttaat tgatcaaaag      420

ctccagcacg gaatgtatcg gcacagatca gacatgtttt ccatcctttt ctttggtagt      480

aatacgccat ctgaacttga aaagtgttga aaagttgttg gaagtttact aattaaaaaa      540

tataatgttt gatggtgtgt gagctttcta ttgtaattca tggaacgaac cttggtacaa      600

gtcgtagttt taccggaacc ttgaagacca acaaacatga aaacgttgcg acgtcctttt      660

gttggtgtga aaggagttac accaggatcc acaagcttca gcagttcatt gaatactgtc      720

ttctgaatgt accgacgttt gtttgctcct ccgacgatct cttcgaaatt aatcgctttt      780

ctgaaaatat ttattaaatt taaatcttaa atagcgtaaa aatttacttc acgttgtcct      840

taagttgctt tacaagacga atatgaacat cagattcaat aagagctgta cagacttctt      900

tcagcatcaa atccagctcc ccctcattga taacggtgct ctgaccgagc tttccgatcg      960

catttcggat tttccgcccc aaatcggcca aaaccatttt gaactgaaat ttgaaatgct     1020

ttaatttgtt taagcataga attaaacgcg tttaaatcg agagcaccat aaaaacagtt     1080

tggagaaaaa tcgataattc ttgtaggaga ttcagtccct gtggttttct tcggcttcct     1140

aatcattttt tgacgacata gtggtatttc acaataggtt ttttcaagac acaacagatt     1200

tttcacaaag agtagagaag aaatggaaaa ctgtagattt cttctcgaag agccgagaaa     1260

ggcaaggtat tggaagttta aaaaggtaat gtttctttat tctttttttca aaacaataat     1320

aaatggaaaa tatatattta tagataacaa tttcagacag ttaaaatcac gtgaaaaatt     1380

caaatttcaa cacaaaaatt gacgagtgga accccgttgt tgcgccttga agagtaacgc     1440

ttgcgcgttt gacgatttta ttgacgcgtt tctggtgcat gcgggaaatt ttttattttc     1500

aactttttc ctgtttgttt atcctttttt aattgaattc tcatgatttg aaagctttga     1560

aaaatattat tttgctcaaa aacatgcgtt ttgtaaaaca ttgattagat tcaaggcaat     1620

taatggattt ttgcacgttc caaaaaaaag gaaattcatt ttttgaaaat tttgataatt     1680

taataatgaa aaatgttcca tagatttatt caatgccatc cttctctata atctcgaact     1740

tccgcatcct tcaactgtgg tagaggtatt tgcaatacca tatagtcgta ataataaact     1800

ttagtgaaca aatccaagac atcagctctt gagtaaatga atgatttata aaaactgctg     1860

attttctcgt aggaagaaag agaatcagct aataatccgt cgttgtctat tctgtcaggc     1920

cgcttaaatg ttaaaaaata aaaacgtttt aagctaattt tgtatgtcta gaaactctaa     1980

ctcacaagca tttctgcata cgccggatta gttggttttg caaaaagcga gtaatctaca     2040

aaagtgaatt tttgattcat ctcttccatt tcacaaaacc aattttgtgg tacgtatttc     2100

atatgatctt catccacttt tttagttttt gaatgtattt gtgtgagttg tgtccagatt     2160

tgaataagat aacatctcag atccaacttg caattgaagc aagaacgatc ttctctgaaa     2220

ttttatatga ccttaaactt tatacttttg tagtttcgtc gatatctgat cgttcagttg     2280

tataggtatg tacatctcta ggtttatgtg ctacacgaaa atataatttg ttttacctaa     2340

cacacgcatc cataaaatga tctacaaatc gttcaattgg atcctgtctt ggaaataata     2400

atttccaatt cgtaaagttt gcattcaact cattttctcg tttcaaatcg tcgatatccg     2460

caaaatatgt tagtgaatca ctatcacaca ctctgaaaag cacaatattc atatttcgta     2520

gttaataatg aacctcacga ttcatcatta aatttctctt ggagcccgca taatacttgc     2580

tgcccaatta aagtatcagt ttcacagatt gcagttctat catttccgat agcctcaaat     2640

aagatttaat cttaagcgag tgttctgatc aatttaaata tttgatactc accgcaagtt     2700
```

-continued

```
tcttcgaaac ttgttcgaaa gctggaattt tagaatatcc ttcaaaactt ttttcctcgc    2760

cctcatcaag ccataataag ttttgatcag caatatattc gaataaatta gtctctgata    2820

aatctcgtat cacaatcttt ttttctactc taaagaatac aattttgata agaatgataa    2880

taattataat tataatagtt cgtcgctgag ttgatgaaga ccacataatt agtttaatgg    2940

caagctatgc aacttgttga atactaatag gacttagcaa atcttatctt gaaccttttt    3000

cattcgaaag aaaaatgaga tcgaatctcg ttcaaactgt ggagtagtca gttaagaaac    3060

ttgtttctag tttgtgagga gacactggag aacgtgaaag tattacccat acgcaatatt    3120

tttgcggcga aaaatacggt acccggtctc gacacgacag tttttaaaac ttgtaaatag    3180

gtatgtaaaa gaaacttta attttaaacg tgttgtttcg gaattttcat cgttttgtca    3240

tagttattct acaaataatt atttatgaaa aaaaaactaa aatataacta taataacacc    3300

tgaatattaa caaatcgatc gaaaaaaaac tatgaaaaaa atggatgaaa attccgcagc    3360

aacgagagtt tgaaatttca gtattcttta aaggcttacc gatttcaata aatagtgaca    3420

ctgaaaattg tagttttaaa actagttggt tagtatcatc aaatattcaa tccttcaaaa    3480

attcctcaat attaacgtat tttctctaat tgtcttcatt atctaaaaaa aagttgcaat    3540

atatttttcc aggcagaaat agactttcac aaaacacatc gacacttcga atgagcaaga    3600

agtttatcga actgggtgat cctgtcactc aagacgttag ttatagtttt tattacttga    3660

acattatcat cttttttacag gagaaagact acgaagacta tgtcggagtt ggtttcgcgc    3720

atcaagtccc gacaatgaaa aggcggaagt tgacagaaca tggaaatact acagaatcaa    3780

aagaagatcc tgaagagcca aaaagccgtg acgtatttgt ctcctcgcag tcaagtgatg    3840

agagtcaaga agattcggct gaaaatccgg agatcgctaa agaagtgtca gaaaattgtg    3900

aaaatctgac agaaactctc aaaatttcta atattgagag tttggacaat gttactgaaa    3960

gatctgaaca cactcttgat aatcacaaaa gtactgaacc aatggaagaa gatgtaaaca    4020

acaagtccaa tattgacgtt gcgattaatt ctgacgagga tgatgaactt gttctggaag    4080

agaataataa agaaatgagg gatggagaac aagtacaaca ggtcaggaaa ttttacaagt    4140

gaatgaaata agttaatcac caaaatgaat aaggacattt cccatcagaa aggtcttctg    4200

aattttaggt gtaatgttaa tttttttgctg tagtttttcc cattgtttga aatttttgcc    4260

aaaattagtt attgcatacc cttcatgttt ttgaagattg tttaggaatg agaaaacatt    4320

ttggacgctt ttattattag gacaccaaac actttttgtt gaaaaaacag ctcgtttaaa    4380

aaaagctttt tccaaaaaat ctgacgcaag gcttgtgaat tttcgttttc ccctgatttt    4440

taaaatttct cctaaagttt tttgctaata tttttcgcta tcgcgtaatt tactagtgaa    4500

tcaacaaaaa attttttttt tttcatagat tttttataag tttttgaaaa catagattta    4560

aaacttaaac ttaaattttg acaaggcgag aggaaaaaat taaaaattgc tgaacattca    4620

gatgccggtt accttatttt tggttcaaaa atcccaatat tacgcgtctg ggttatagtc    4680

atttgccttt attaaattaa tggtgttcct tggaaaagta agttctgttt tgttttcagc    4740

ttatcacttc atcaaacgga aggaaaggtt gattaaggaa agtaaacata ttttatgttg    4800

ttcttgtcac ttcctccatt tcgcaataat ataactcgag aaatatagaa ttttgttcga    4860

agttttcttt ttccttcaac attttaaata ttgttagtat tacccagaaa aatagaaaaa    4920

atcgaagaaa tttgcaaaaa agcagacgta gaggctacgt acttcttaag cacgcccctt    4980

ttctttttaaa tttgttcggt cgtaccgaga tccggtacct tattttacaa cgttttctgt    5040
```

-continued

```
tccaaaaata ataatgtact gcagttgtca caggatttat tcgctgatga tcaagagcta    5100

attgaatatc caggaattat gaaagacact acaactcaac tggatataac agattctgaa    5160

gtggagactg ctcaaaaaat ggaaatgatt gaagaaactg aagcagattc gacatttgta    5220

ggcgaggatt caaaagtgag acaaaatcat tctgacaagg attcctgcga gcactcagtc    5280

aagagcgagt cacggcaact cggtccaaaa ccatttctaa ttagtaaact ctcaaaaacc    5340

acaactaaat agcttaaaac ctttgtaaat tagcttattt ttgctaatta gcaatgattt    5400

taagctaatt agttgtggtt tttgagagtt tactaattag aaatggtttt ggaccgagtt    5460

gccgtgactc gctcttgact gagcacaagc aaacttttgt ggatgttgag aatcagcggc    5520

aaagtggcac tactagtgac gaagttgacg cagattctca gattaatttg gtaagacaaa    5580

gaaaatataa attttattac ccagatgcat attttcatga ttctgatgca aaaaatacgg    5640

tacccgatct ggatactaca attttttgtaa aatgcgaaaa ggtttgcacc tttaaaaaga    5700

actgcaattt caaacacttg ttgctgtgga ttgtttatcg gttttttaata ttttttggtg    5760

agagtaaatg agaaaagcga gttcccgcat tatctgtgtg cgatttggaa tacagtactt    5820

ttcaaagacg cacaccattt tgcatataac aaacatttgt cgtgtcgaaa ccgggtaccg    5880

tgattttgca ttaaaagttg caaaatttca catagttttt ataatttagg ctacgaaaac    5940

tgtgaggaca tccagttcaa gtttcctgtc aactgtttca acatgcgaag cccctgcaaa    6000

aggacgagca agaatgtatc aaaaagagtt ggaaaagcat gtgattgcat ttactgaggg    6060

aaatctcaca ctacaaccag atttgaacaa agttgatccc gacagaaact atcgatattg    6120

tacaattccg aacttttccag cttcccaagg aagtacgttg ttcaataaaa catactaggt    6180

atataattaa ttatttcaga acttcgagaa gataatcgat atggcccaaa aatcgttttg    6240

cctcaaagat ggcgagaatt tgattcggta catttctatt gaattaatta tatactactt    6300

actagaaaca ccatggagaa agaatgcaaa aaattgaatt ttaaaaacta atttttttaat    6360

tttggctaaa ttttcagttt gaatttaatc caaaatgaaa actgcgacca atcaatgact    6420

tttcaaaatc acttttcaac caatcaaacg gagtgtgctg ggctcgaaga cgctgattgg    6480

ttcggaaatg ggcgtggttt ctcattttgg agggaattca aaaaaaggca tttggtcaca    6540

gttgaaaatc atgttttcaa aagatgcatt ttttattcct tctcgatttt ttttgatttt    6600

cttttgtggt atttctgaat ttaaaggtgg tgtagtcgaa ttttttttatt gctttattag    6660

actcaaaatt ttctgaaaac gccaaatttc ataatgaaac ttcttgaaaa ctcttcagca    6720

aaaagttatg acggctcaaa aaatggccta aaattagtta agattggaga tttgaccgac    6780

ttgtcaatgt cgcagcggct ggaaacaatt ttttttgaaa tcaccgtcaa atttttaagta    6840

tacaacttga ttattttgcg ttttaaactt tatttaggta tttaaaagtc gatggacggc    6900

gagttttggc tcaaaaaaat taaaaatctc gccgtccatc gatttttaaa taccttaatc    6960

aagaataaaa caaaaggtag gcaacttgta tattcaaaat ttgacggtga ttgcaacttt    7020

taactaattt caggccattt tttgagccgt cataactttt ttctaaaaag ttttcaagaa    7080

gtttcattat gaaattcggt gttttcagac aattttgagt ctaataagga aataaaaaaa    7140

attcgagtac accaccttta agaaaatttt ggatttccgc tacgctaatc caccttttaat    7200

caaaaatatt tgaagttatt caaagttaaa gaattatatt ttcagagggg ccgtagaaga    7260

gactcatatt tctatttcaa acgtaagctc gatggatatt tgaaatgcta caaaacaact    7320

ggatatttta tgtttgttgt aagttttttga aatacaattc gtttgaagat ttactctatt    7380

ttcagggact tttgcacaac atgtgggaat ttgacccaga catcacatat aaactgccag    7440
```

-continued

```
cactggaaat gtattacaaa gagatgtcgg aacttgttgg tagagaagag gttttggaaa   7500

aatttgcacg agttgcccgc atcgcaaaaa ctgctgaaga tattctgcca gaggtatgat   7560

ttatgagata tacagcattt cctctaatag tattgcatat aaacatttca ctttgaggtt   7620

atatcttggt ttattttaaa aatatcaata aatacaaaac aatagaaaaa tgataaaaaa   7680

acattttgtc agttgataat ttgggtatag tattcattca taatttgatt tttttagcga   7740

atttatcgtc ttgttggtga cgtcgaatca gctaccttga gccacaagca atgtgctgca   7800

cttgttgcga gaatgttttt tgcccgaccg gacagtcctt tcagtttctg ccggtgagta   7860

atacaagaat gctcatattt ttagaatcaa tatttgcaag gaactttaat cttacgtacg   7920

tcttaagatg agcattttcg cacatatctt acgcgcacga gtctcgacac gcgaacatcg   7980

agcttctgta actcgtatca atttacaagc cgttattaca tcagttttta atgaattta   8040

agaaatcgt gcaaaagtag tgtcgagagc cattcgcgta agatatggtg agatttatca   8100

tttttagacg tctagtggat atctaacaaa actttataca tttttatttc agaattctct   8160

cgtctgataa atctatttgt gtggagaaac ttaaattcct gttcacttat ttcgacaaaa   8220

tgtcaatgga tccaccggat ggtgccgtca gttttagact tacaaaaatg gataaagata   8280

cgttcaacga agagtggaaa gataaaaaat tacgttctct tcctgaagtt gaattctttg   8340

atgaaatgct tattgaagac acagctctct gtacacaagt tgattttgcg aacgaacatc   8400

ttggtggcgg agtttttaaat catgggtctg ttcaggtagt tatttaaagg aatataagaa   8460

tttgaagttt tattttttttt atgcaggagg agatccgttt cttgatgtgt ccagaaatga   8520

tggttggaat gttgttgtgc gagaaaatga aacaactgga agcgatttca attgttggag   8580

cttacgtttt cagttcttat actggttatg gtaagtctag actttcaaaa aaaactgttc   8640

caatatgtca atatatttca ggtcatactc taaaatgggc agaacttcaa ccaaatcatt   8700

ctcgtcagaa tacaaacgaa tttcgagatc gttttggacg tcttcgggta gaaactattg   8760

caatcgatgc aattctgttc aaaggatcaa aattagattg tcagacggag cagttaaaca   8820

aagcaaatat cattagggaa atgaagaaag catctatcgg attcatgagc cagggaccga   8880

aattcacaaa tattccaatt gttactggat ggtggggatg tggagcattt aatggggaca   8940

agccactgaa gtgtatgtta tttcattcgt taaatattga agatggagga gagtgaatgg   9000

ggatttttgct tcttttgcaa aatggcctcc ctatgtacct gaaaaaaaaa tgaaaaaatc   9060

gagaaatatt gaaaaccaaa caacgaattt ttcacaattt tgcctaaatt tttgaatttt   9120

cgccaaaatc ggaatcagcg attcgctcca cccatttttc cgccaatcat ttataatgtg   9180

cggagctcaa aaacactgat tggctagaaa gtgggcgtag cttcttattt cggaggaaat   9240

tcaaataggg aagttaatct aaattaaaac aatctcgtta aaaaatgttt cttttttcaa   9300

tcttccctat ttgtttaaat ttttcttttt aaagatcgtc taaaagctac cagtatctga   9360

ttcaattatc ggttttttttc agtcataatc caagtaattg ctgccggagt cgctgatcgt   9420

ccacttcatt tctgttcatt tggagaaccc gagcttgccg caaagtgcaa gaaaattata   9480

gaacgaatga aacagaagga cgtaacactt ggtaagtcat gtttttcaat cttcagttga   9540

tttgaaaaag ttgtatcgag ttggaaacag cttttaatct aaattctgct aacttacagg   9600

catgctattc agtatgataa acaacaccgg cttgccacat aagcactttg aattctacgt   9660

cttcgataga atttctactt atctcagtag ttcggaagat gttgagtctt cgaaatcatc   9720

accttcagta tcccgagcat aattcgaatc gcccacacgg ccataaagac cggttccttt   9780
```

-continued

```
cgattaaatt ctgttaaata tgcatgctcc gtctttaaaa aatcagtccc cgtattttaa     9840

acgttttgat tttaatgttc atattattat ccgaaattag tatactcgcc gtcatgaaag     9900

cccgagatat ctagttcgca agtcagaaat ttttcggagc atcgtcgtga tatatgaata     9960

aatacattcc tgtttttcac aagtgtagtg tgaaaccaat ccatgcagac gtttatttct    10020

gaattaattt tgaaacagat ttcagagaca gtgaggttga cattagatat gggcaagtaa    10080

caataacagc agggcagtta ttatgattat ggatgctgat ataggaaagt cagaacagta    10140

taatcgacga gaataaaaag agatgagaag ataggcgaga ataaagaacg ttaacgaaaa    10200

tcactgaaga gctacatttc caacagaata agaaatgtag ttggaaatcc ctaatcaaac    10260

agaaaagcga gaaatcatga ctttcgagat aaagagattt atctgcaaac aattcttgaa    10320

cataaaatta aagcaccaca gactgtccaa attataaaat cagtttctcg ctacagtctg    10380

ggggtactct agttccattc aaaaacttct tgcaaacaaa gagaaataaa cagacttgta    10440

cgggacacat ataaaatcta agcatgcttt gaaaagcgga gaacatacga tctattcggg    10500

gatatacata tatatatata tatttcatct catctagagg atcaccatcg ttactcatca    10560

aattggttgg tgtggtggaa gttatgaaaa gagcaatttt aaccgaaaat caccaaaaca    10620

gaaaccaaat taatgtataa tcgacgagaa tcatgatgag atgatgattt gcttctagca    10680

gaagtttaga agcacatgct atcattcatg ctcacgatga cgataggttc gttatgcatt    10740

cttgaagcca atgacacttc cattgctcct tctcttgcgc tcacacaatt tccattctcg    10800

tcgtaaatcg ttcgactttc gaatatccac atcttaccgg gcggcacttt tggcctggtt    10860

tggcagatct gaaataaaat cttttcataa tttaaagtct gatatcccga gaaacaatag    10920

ctgaattgaa acagaagaat aaatctcacc tgaatatcca cgtttgcaag tgaagtttct    10980

ttcacaaacg gctgtgtttc ctcatagaga tcatctgaac cgtaggagaa tggacggagc    11040

aagtcgttca gcttcctcat gtgctgttca tttgccggtc tcacgtgctt ctttacggga    11100

gcagtggcgg cagcatacgc tgatttagat gctcgcatag tgtcattcct acgactttga    11160

ggcttccttt cattgttgta atgcggttgc atttggaacg gtgcgttttg aaatcctcgc    11220

atgacttgag acgattgatg atgcgatggt ggaggaatgt ctgcaagatt atagttatgt    11280

attaaaaatc aaaaatttgt gtggttccca ttttaaaata aaaaaaaaat atttttacgc    11340

actttgctga ggcaaccgat aactatttcc tcgctggcga ctacttctct tattgtgagc    11400

attatagctc atgttctcat gattgagttg acctgaacga tcaaggttaa aactaggcct    11460

aaaactagtc aaaattactg agtttctcct tccacgtcgt ctgtcgagca ggctccgagt    11520

acatttttac tggaaaacta taataaatta caaaaatcac gccgaaaatg gggaaaagaa    11580

ttgaaaaatt gaaggaacac agaacatttt ttcaatgcgt ctctcacgtt cgagactact    11640

gtattcgtgg tgagacccaa ctccctcata aaagcatgcg cctttagttt tttaatttaa    11700

ttcatgttgc caatattggc caattaattt caagagactc tgattgaaag tgttataatt    11760

aaactacata tatttaagct ttcagcattt ttttcaatgc acttgagacg caaattgaat    11820

aatcaggcac gtaatgtgtt ttcgaggacg actataaatt gtacctttgc tatccagtgg    11880

gttctttaat tttcccattc caatcgattt tttctcccac tctggcagtt tctttgtcat    11940

cactggacga gggcattgga atgggagatg attcatgtga caatccacac atcctgcaat    12000

aatgacatta ttttttaaaa atgttaagat gatatgctta ccaggagtaa atatcatatc    12060

ctttttcttta ttagttggct tagccttgcg gccacgttta ccatttgaca ttatagttac    12120

ctgaaaattc aaaaaaattag atattcaaaa aggtataaat ataatataaa tgcgatttgg    12180
```

```
taaatacgga tgtaatgggc aacccattct atacaggaaa accaaaaaat tcccgcaaaa   12240

ttattttttt ccgaataaaa tgatctactt tgttttatgg tgccgctcta tgtgttatga   12300

cccttcgatt agtagataga aaagaaaaag gaatgtacga gaatatcgtt tattatttat   12360

tatttgaaaa atcccagaga cataaaaaat cacacagaaa agggaaacag tatttctgac   12420

aatgttcaaa agtttggttt caatcagcac taataatgtg aaaggtaacc gtatcaatag   12480

tgatattttc ttattaaaaa actgttcgag actacaagaa ggcctgaaaa agcccgcaac   12540

gacgactaaa ttcgaaattt cgaattaggt tttaaagatc agaagatcgg cagaaaagta   12600

tctgataaaa atataagaaa tcggaatagg aatgcgatga ggaggtagaa atatggtgaa   12660

gagatacaga agaatgaggt aagatcggat gaacttgaag cactttttga gattttttgat   12720

ggtgaagttg gtggatgtag acgtttcatg gaacatctga aaattaagat ttttctaaaa   12780

cacattttct atagaatata atagaatgcc aaatagagaa actagactta cttgaatttc   12840

tttcgatttc tgtctttcaa ccttctaact gaaatcaact ttcgacgtgt tctcggtgtt   12900

tcaacaacac catcaacaga acactcagca ccaaattcag catcggaatc atcagaagaa   12960

gactcatcgg aatccaaata gaaattggat ttagtattca tcaattcaaa agaatccaat   13020

gatactgtcg attcagcaag ttggactgaa cttgatggtt gactacgaac ccattgaggg   13080

cgtcgaggca gaagtcgaga gtatgaggat gcaacgtgga ttgatgatga cgtcaacaat   13140

ctttggtgtt gagatgaaga agtggctgat gcagatgttg acagacggaa tggagatgag   13200

tgaagagcaa gaagacatct gaaaatttga aacgttgttt atgtggacag tactgtaaag   13260

atcttacctt ggatcataac tacttgccct ctgtttttctc ttctcttgac ttctacttaa   13320

aagcatttcc gtctcgattc tccggttact tgaaaatcca actccagaat tttcagcaca   13380

aagctgctct cccgaaccgt agactgttgc accacgttga ggggttgaca aggatctgaa   13440

atcagatgtt taaagcatgg caagtagagc aacaatgtta accaaaattt ctgaaacttt   13500

ttcgaatata gtcaaaaatt gacaataact cagtttcacc tatcatagtt ttggaagtca   13560

accaaaaatt tttgaaattt cataaaaatt ccaaactttc taaaaatttg gaagattgat   13620

atgattgata tgaaagtatt tatatatttt ttaacctggc agacgatact tcaccattaa   13680

agacacacat gtggagaaga attattttac ttttagtaat ccaacgtttg cacttacctt   13740

ggagcatgca agctttttagt cattaaagct ggaattctag atggagttct tcttggtgtc   13800

gacattgttg aaataaacat tcgtggttca ttgattgatg atgacgtcat agaaccacgc   13860

ccagatgaca atggattacg gtagtcatca gaatcagtag attcattcaa ttttctagtc   13920

atttcttctg ttttctggaa aattaaattt taattaaaga tctaacaaaa atctggcact   13980

tacattaata agataatcaa catattctaa ctcattcatc gtttcattat tttctaattc   14040

tggcttcttc tcatcgaacc gttcggtggc attgtgtcgt tgcgggcttg accgtttttt   14100

gaatttctga aatgtttttc atgcaatttt tgttcttatt tgtgtgtcat atacagtgaa   14160

aatcaaaaac tagtacaaac taattccgtt tagtaaataa aaaatcgatg taaaatctca   14220

gcaaagccaa gatcttggcg ggtccttata tccaagtttt gttgccattt tatttcagat   14280

attcttttcg aaagtcagaa aatttgaatt tagaatcgaa tggacccatt tcttgtttttt   14340

ttttgttgca ttttttaact gtactttttt cgtcagcata tattttcact attaaaacag   14400

aatattcatg acaataattc cacaaaaaaa cgtactttaa tatcatagtc gattggttca   14460

gaattggaac gagaaccttc gacgcgtcga ttgtcagatt ctcgattgat ggacgacgtg   14520
```

-continued

```
ctgactgaaa atttctggat tgaaaaaata ttcaaatgaa aaaataaatg agaaactcaa   14580

agtctaaaaa atgaatgttg ttaataacga atatttctga tgagaagagg atagagaaaa   14640

aaaacgagtc taataaaatg catgtgatat cctgcataaa aatcccttct tttttcacta   14700

atccttcgct caattcattc aaatagaact ttgatttcta ttagagttga ggttgtttga   14760

acaattttaa taaattaaca ataagccata aaacctcgaa acgtaccatc atcattgagt   14820

ttgaaaaagt ggacggatcc gagtcagtca cctctggaac aaatcgttcc agagcactga   14880

aaacgacaac gttctcccca cagaatcgga ttgtctcctc gggaattgtc gcctcgacaa   14940

acgatcctga acctgaaaat tttcgatttt tgtaagctca atggatttta aactgaaat   15000

gtagtcaaga agtcaagaaa aactgatgga gttctaaatt cggtgttagg ttttgaaaag   15060

atcgtcaaac aaacaaatgc ataaaactag gtagggaaca aatagtgaaa tagaaaaatg   15120

aaaggcgaca actgccggga gcaagagtac acacaaagaa aaaaagttgc ggaagagcac   15180

agagagcgtc agtccatcag aactgcatag ataaatagat aaagagaaac atgaaacata   15240

aggccacccg ggagagacga caggccagtt ttccggtgaa gatgagagtg cgagaattag   15300

ataagaaaac ggaaattgtg atgaaacttt ttcaatccaa acttctagaa ttataagaga   15360

cacctaaagt aattagataa gtgtttttaag tgatatttta gattcactgt atcatgttta   15420

aaaaagatat ttcaaaaata tatacctgat ataggaggcc tcctctgagc accgaattgt   15480

tctcgagctg tttccacgag catccgctca cacattgaca taggccgtcg acagccagga   15540

gttgccacct gaataaataa ttattcaatt taaacctaat ttagtaatgg taactttgta   15600

aatgatggtg gatagctcat ataaaatttg aattggttct aaagttatac aaattttaat   15660

ttcggtcaaa cttatgaact gtacttttga gttatactat tacaataata ttacccaaat   15720

tattgtattc agattttgt aatcagtact aacagatttt aggcaacgtc ctgccagaaa   15780

catgggaata tatttgagca gttttttagta agttgccaca gcttgtataa gggaattgta   15840

tcaaaatgta cttaatactt tctaagcact gacatagtga actacaaaag tcggtattat   15900

acaatgccac tacaaataaa aatattcaga attcgactga aaaatgagaa aaggaacaac   15960

tgaattggac acacgatgtc gtgattttca agaacacaaa aaaaagaaaa agaaatcgaa   16020

aatgttgttt gcctcttttt cttttttctat atgagctaga atctcgaatg catgcctaat   16080

ggagccactc gctctcgttt ctctaagtct cttctcacca gtctttttgtc caaaaattgc   16140

gatgtcgcag gcgtcccgtt tccgccgctc acggagacac cactatcggc accagatgat   16200

cgtgtaaaga caccgtcttc gttgacttca attgctgaaa taagaggaat tagttttgaa   16260

ttggaaatct gattaaataa aagtcccctca ttcaatctaa ttaattttta aacacaaaac   16320

ttactattgt ttaatggtgt tgacgaatta gaagaagttg attgaaatgc gttaacattc   16380

cattcaaagc tatcttcatt ccattctgct cgttcttta tcctttcact cacgtctcga   16440

gggatgaagt tttcaacaat aagaagcctg aaaacttata ttattctatt aaaaaaaatg   16500

aacatcaaat cctaacgaaa gaaaattctt ctgggggggaa aaggagagaa ttgtgagaat   16560

aaagaacctg cgctgtcggt atcaaattac actatttgaa ttcaaattag aatacgaaag   16620

aaagtgaaag aaatgaaaat gagtgagaat ctattaaatt gtaattgaga tatcactgaa   16680

cttacttcaa cttcaattcc ttgctcactt ccgcaattgt ctgatccaga tcttgtcgtt   16740

cgtcggaata tgctccagac acatcacgaa tctcattgcg agcctgaaac attcacaaac   16800

cttatcttga cacctggtac atctgaagtc aaacctgtct caactttatc aacatcttct   16860

ttaacttttt tgtctttgcc tccacctctg tccttaaatc cgaaaatgtt tgtttcaaat   16920
```

-continued

```
ccacagtatc ctcttcctgc cgttccaatg cttcaaccat ttctctttcc cttcgttttt   16980

gttcggcaag ttctcttctc ttcttttcca gttgtgcatg ttgttctttt gtccttgatt   17040

ctaaccttcc atcttcttca gatcctacga taagtcgact ttgaatgttt gctattcttt   17100

cagcaacccg tgcttgttct atccgttcct tttctaacag atcatgcttc tcttgaattt   17160

ctcttattaa tcgatccttt tcatgtttta tcagtgaatc atctttttga attgcttcaa   17220

tatcatcttc aagttttgct cgttcagcat cataaaaact ttgagttgct ccatccctcg   17280

atcttgtctt tctctgcttc agttgctcac ggagcatttc aatttcttct tggaattctc   17340

gcagtaaagc atccttagga tcttcattaa tttccggttg attcttgatg tttttagctc   17400

gatttgcata tcgtaatgta ccaagtgtct cctcaaaatt gtaacttgca ggtccaatac   17460

aagcaaccat aactgtcttt gaatttccac cgagagaatc ttgaagaagt cgagtcagtt   17520

ttgaatctcg ataaggaata tgggcagatt tcgcatccac caatgcactg attacatttc   17580

caagagccga taatgaaaga ttgattttcg tagcttcttt aaatctttcg ccagttgctc   17640

ctgttttcga ttgccgttct gaaccagcta aatctacaag atttagtcga ccaactgtaa   17700

tatgactttc tccgtcttca ccaattcggg aacattcaac agtaatgata aagatagcgt   17760

gggaacgaga cgaatgctca ttcatgttgg ttcgcctgaa aattttagta aaatcaaatc   17820

caacggcgac cacagaaata acttacccta cagaccgatg cccatttcct cgaatcatca   17880

cttcgtgtat ttcacctact gtccttgtta attttgactg aaactttgaa atttatagtc   17940

gtcttctatt tcagaaaact atcacttacc gttaaatctt tcacataaac tcctccatct   18000

ggacgttctt taatttctaa tttcttattc gattcggctt ctaataaatc tcgaagttcc   18060

tcctaaagat ttcatttttg taaatcacac atcctaacgc cttacctgat aaatttccaa   18120

atagctagct ctaactaaat actcttgatt atgtgatgct gccatgtgct caaaaatatg   18180

gtcaatacac ttatagatga cacctcgttg ttctggatcc gatgattttc cttccattgt   18240

gtgagtcttt ccagttccag tttgaccata tgcaaaaatc gtggcattat atccgtttag   18300

aaccgaatca actagatctc gaaaggtttc ttcatataga tccgattgtg tggaactata   18360

aaatatatat ttttaaaaaa gagaactcat aaaatcataa acataaaatt gtggagaaat   18420

aattttgaaa aatactaata tttctatagc aggtgaaaaa aaagtgatgt actcctagaa   18480

ataaataatc ttacttttca tcataaattg catcgaatgt aaaatccttc gatggctcat   18540

cttgctcttt tggattttc agctcaattt gcccacgttg tggtcgcata tgtactattc   18600

tgaaaatgat cgaaatttca aaatataaat atttcaaact ttacttactt tgaataatta   18660

tttgcaattt cttgtgaaga taacggtcga catctcacaa ttacctgtaa acataaataa   18720

atacatttat ttgaatttgg aaatgtataa aactggatta tgaaattttt aagctggtgg   18780

tttttgtatg agaagtaacg aaaaaaagta caatttactt agagtcttgt gattttctt   18840

tcaaatgcaa aactcaactg aatcataaat agtgatgctt cgaaaagttt ttagaggaaa   18900

attgtatttt tagtaaaaac taatatacgt tttggactta aaaaaaaatt atgttaaaac   18960

ttgaaaaatt acgtttatta gtgcttatat taaaatacgg tttcaaatta atttaaaatt   19020

aaaataactc accttttggt caaaatcaga cattttagaa actagcatgt actttattac   19080

gttgaatata acttatgttg gaaaatggaa aatttgaaga caggtgaatt ttagtttttt   19140

ttcttttttcg tacttctaaa aaatacttca tttattttac attttgagaa ctaattttttg   19200

aacatgtttc gaacaaaaaa aaagattttg aaaaccccaa aaaaacttac tttgacagtc   19260
```

-continued

```
tcctgtttttg aagattttttt cattatttcc accatttttt gtcactaaat atttggctat  19320

caatgtaggt gtcaaggaaa attttggtgc attcctgatt tagtgagagt ggtctggaac  19380

ttaagaagat tagtttaatg tggaaaaata atcatattgt atcgagaaac ggaattttga  19440

agcaataacc gctagagaaa gtgactaaaa accagaaatt gtagtcgtgg aatttcaata  19500

ttttttggttt tatgtcacat ctggacaatc ggaaaaatat gcatacattt gaaattttta  19560

gaaatatttt gaattaactt taaaggaaaa aaatgcatta aaaagattga aaacatcatt  19620

gacgttgaaa aatggagaaa atttctaatt tctcatcaaa atattaaaat attaaagttc  19680

ttcaataata tgaaaatgtg aataaaatgt ctaaataagc aaaaaaaaca gatcctattc  19740

attataaaat gttcacacaa gtgttacatt tcgtacaaag aagtactaaa acggatggac  19800

taaagtaata ttgtcactcc cgaaaagacg aggaagaagt aatcggaaga agatgtcgga  19860

agatgagtga tagtaaaaat acgaagagac gcagatagag agtttgagag aaggagactt  19920

ctggaggaat aaaaggtggt ttcaagatgg gggacagaga gggagagggt taaaagagca  19980

caaaatgtgc ataatatcga tcctgcgcag ttgagagacg cagacaatgt gaagaatgga  20040

gcatatgttt ctagtgaaca ctcagaagta gttgttcatg tgtccgaaac tttggaaaca  20100

tatacatttt aaacttgacg ttttttgaatt ataaagggat ggaggtgctt caaaaagtaa  20160

tcatagacat gtgtagattt taaattaaaa cacaactaga cataggatga atcagaagct  20220

taccataaca ttgttgattt atttaaaaat gagaaaaagt aaaattccgg atagtcttct  20280

ttgaaaaaat tcacagagaa gttataatgt ttgatgatat tcactgattt gtaatacatt  20340

attagtagca tggcttctat gtatatagac tatttttata tcacatacat gaaaaagggt  20400

taaggcatgc gccagggcct gaaaacgcat ctacctacca ggggagctct agctcttagt  20460

tattaattca agagactttt gaaacttgat ttttttgagat tttattcaat gattggttta  20520

aaaaaaaaga ttatttgcaa aaaattacaaa ttttaatgtc tatactctga catcggttta  20580

gaacaatttt agacaggctg caatgaaagc aatgaaataa aatttccttg aaattataat  20640

agagaatcag taaaatgttg cagattattt gaaaatgcat gcaagaattc gcagaaaatt  20700

cagtgaagca gaaaagtgcg acaggagacc gaagtctaaa aaagtgaatt atgaataaaa  20760

acaaatcatg tgactggata taattgaagg tcttgattcg gaaaagataa ttggagctct  20820

ttgcttaggc caggctctag atatttttatt gaagctttttc agaaatgttc aaaattatca  20880

ggaacagttc tctttgcact ttctctatgg ctcaactacc agggctttttc cttttttcttc  20940

aaaaagtaga attttaaatt ataatttttaa aatttaaata ccaagcaaaa aatcatatac  21000

tcatcatatc atgtgatcat atcatataat catatagggc tcgttctttt tttttttcaaa  21060

aaattaaaaa tttactagaa ccaagcatat gacaataaaa tattttgaat tcactttaat  21120

gggaaaaaaa caagaaaatt tcattaacat tattgaaaac atcgttggca ataggaatgt  21180

agaaaatcaa atcaaaatca agtgagatta ggaaagaatc gaaattaggt agaattggaa  21240

aatctcgatt ttttaagttg gattcttaca cgattttttc gggatatttt tcatttttat  21300

tttgtagtat ttcagcctag acggctgaga attcttttca aaccttccaa tttcaaagag  21360

attcttccat aatttaatat aatttttcatt cgatattagc atccattata tacgtatgat  21420

tccccttttta aaatcgattc tccttttcaa ctgactcatc acttaagaat tgttgagtca  21480

tcaactgata gtgagcagac accaacaacc atctctttag tttccgttcc gtttattttta  21540

ttttggaatc taacatattc aagaaaatta acttgaaatt agaataaatg tttcttgcta  21600

gattttttttg tcataagtat ttcttatttg gattataatt ttcatctcga aatcgtagag  21660
```

-continued

```
agtttttcac tatttttttt tgagttctaa acacttcctt cctcatcgat gatgaagttt    21720

ttgacaaatc aactagtttt ttactcatat ctcacatcaa tctatgattt tattcaaaaa    21780

cagttaaatt tttttaacga aattaaaatg gtcatcggac cgagcaaaag ctttcagaat    21840

caactgcttc tttaaattct ttaaaattca atcaactttt cgtgtccaaa gtcacaaact    21900

acacctttca aaaaatattt ctacattatt tgcccacatc ttggcacagt tttcttgcca    21960

ttcttcaata ttttcttctc tgcgtttccc acactcttat tttctgactg ttgacttttc    22020

cattgtatag actcaatttt actttcgttt tttcaatttt tttttctgcg aagttcggtg    22080

ttaaacctcc attttgcaat attaaaaatt tcaatattgc ccgtttttggc ttgaatctat    22140

taaaattatg ctgttttttt ttcagaaagc accaaaacat gccagatgat attccaaaat    22200

tgccacgaca cagaggaaag aaaaatcagc cgaaaggttt gaaaaattta gaaaaatctg    22260

aagttacttt tttaattctt tagacacacc ttggaaacaa caaaaactgc ctgctttacg    22320

gcctcattat aacataactt cagcaattcc agttactctg ataacaggag tagccacgtt    22380

ggcaatggga attgctcttt atttcggaca taatggatgt gagttttttag agtttattat    22440

cccaaaaaca aaaatatcaa ttactctttc ctggtaataa gtaagaaaaa gctaaagaaa    22500

acaaatttct tgtcaaaatt ttacattgta aaccgatagc aacaaaaaac aagtgtcata    22560

aaaactgtaa gaaaatcgat aattttgcta caatttcaca aagctaaaaa atattttta    22620

ttttaccgtg ttagtaccgg aatgttctgc acttgagcct tactattagt tacacaaaat    22680

ggatcaattt tgagcaattt gttgtgaatc tgacaataat tagtcctatt gatatagctt    22740

taggccactc attcgtgttc gtaattttcg ttttccttga acttgtaaag gtacagtttt    22800

tgaaaacagg gatgtagtcc aagtagtcaa atattgattc ttgtagcatt agaacaagag    22860

attgtgtaca cggattgtgc tctttcaaat ggaacacaag cttcacgaat tatgagaact    22920

gaaatgggaa atcaaacatt taaatgtgca tatacaatta ctttgaatga cgattatact    22980

gtaagttgag ttttaatttt taaatcatca aagaaaacat atgtatattt ttgcgaagga    23040

aattttggat ctggtcttag gatgaaacga cattgtaaca ttttgattaa agagcccta    23100

gttggaagtg agtgtatctg gtaaaaacac aattcgaaaa tatttaacca aatatgtata    23160

aagcctaggt tgaacctgct ctgcagttcc taattttttca cattatttt cttcaaaata    23220

ttactatgat atttcaaagc ccggggtacc atcttaaaat catcatttgc aagtatcaca    23280

attaatgttc aacattacag ggcgaagtga agttttatta cggtctttcc aagttctatc    23340

aaaacaatcg attatacttc aactcacgaa acgatcaaca gctacgtgga aaagttactg    23400

aaactgacgg atgtgatcca ttagaatatg tggatgttaa tggaactaaa gttcccattg    23460

cgccgtgtgg gaaagtggct gattcaatgt ttaacggtgc atttcaattg attgcttaat    23520

ttcagtattg caacattttt cattttttat aatacatcta acttcaaaat ttgttttttt    23580

ttcagatacc ttcgaattat tttatatcaa tgataaagcc tcaaacgcgg taacacgggt    23640

tccatggaca actcgtggag tactcggtgc aactgaaatg aaaagaaaat tcagaaatcc    23700

gattcgagcg gaaaaccaga cattatgtga tgtgtttgcg gttgaaatga ataagaaaa    23760

aaaataaatt aaactccatc ttttagggaa caatgcctcc gccatcatgg agatatccga    23820

tctgtcaatt gggactaaac agtattgatc cagatgttgg cattggtttc gagaacattg    23880

atttttatggt ttggatgaag gttgcagctc ttccaaaatt cagaaaactg tatagaatac    23940

tgaatcgaca agttgatatg ttcagtaatg gattacctaa aggacaatat cagttgacca    24000
```

-continued

```
ttaattacag tatgtttatg ttaatgttga atttatgtat ttatgcaaaa aatttactgc   24060

aaaagttcac aataattcca cccaaacctg cttaaatatg gagatgcaag ttttttgttt   24120

cagataaaca gtggctccaa aaaaccaatc tttgttataa aacctcacaa aaatttctcg   24180

atatttcttt attatggttc aaacttttga gaaaaaaggg aaatttagaa aattctttca   24240

agcgaaattg tcaaaatttt tcaaaaccaa atttgatttt ccagatttat tttttgtcga   24300

cttgacaata gtaaagaaaa aacaagttga atttttctat atgaattctt atagctgaac   24360

attttttgatc aatttgaaaa taatcaatag acaattttttc tccatactac tgattttcag   24420

actatccagt ggatatgtat tcgggcgaca agtacttcgt tatagccaat gaaaactggg   24480

ttggacccag gaatctgttt ctaccagtaa tctatttggt tgttggaaca ttcttacttc   24540

tcgttactat tctcttcata ttgatttggt taaaacagag actgtcgagg gttcatccaa   24600

catgaattgg aaaaactaat tgaaaataga cggatgaact tcaaatttgt ttacaagagt   24660

tgaagtctca aaataagctg gtagcatgta ttgtacggga acagatttgt atactttgct   24720

ttgtaaataa aataaaatgt tattatatta gtctgtaatt ttatgtatag ttcaatttaa   24780

ttgaaataca taatacccccc ttcagtttat caattaaagc tccaactatc attcgctggt   24840

tgagattaat tgtcgagtga gggcatctga aatgtaaatt taaaattaca aaataaataa   24900

ttgtaagtgc tatcagatat aacaaatgat catttaatta aggaggaaaa acaaacatt   24960

aatttaaaaa atttatcaaa aaacaaaaaa aaacggtcaa atattttttc aaacaaacaa   25020

agtaaagcta atttctatta aagttgatct aaatactggt tgtgtaggca tactatagtt   25080

gatttcaacg ggaagaaggc caaatcagca agtgtacatt gtgttctgaa aaattgaaat   25140

tcaacagttg aatataagta gaaactctac ctattgctaa catttattgc aattcttctg   25200

tgttttgaac aatatcgaga tcgctccatc catcggataa ttccgtatga tttgatgaca   25260

tctcatctac agcttccaat tctccaatta tctgatcctt cagtttcagc ttaatatcaa   25320

acgattttttg aatttcctgg atatttgctt cataaactct cgagatttca gatttaactt   25380

gttgaatctc tttaaattgc tctgaaatct tcttctcaag aactctttttc tgataatata   25440

gctcagtgat ttctcgagtt ctttctttca taatcatttc agtattcatt tgttcttctt   25500

taacattttc ttcaagtttt tcaatctttc gtacataatc acagaaatga tcaaccacct   25560

gcaaccattg cgggtcattt cgcatagttt tgagtcctcc gggttgttca agaattgcga   25620

caagactttc tgtctgttca agttcagtt tttctaatgt ttgctcaagt gggaattctc   25680

tgacctcctg gtttgcctct tcggaaggat cagaaatttt ttcagaatgg aacgtcaaaa   25740

tttcttgttc caaatgggga tatgttctac tagtccttg actagaagtc tcactagaga   25800

tttaagtgt cagttctcga acattacgct ccaattcgg agaatttcca gattcagtgc   25860

tcacatgact ctttaatttg acaatctcat cattcttatc aaagatttga ttttccagtg   25920

cagagacctt cacttgacaa tcttttgtct tccatgacaa ttcatctgcc aacatcttga   25980

tcatgttctc attcgaatca atcgttttt tcatatcttt tatcatgtct tcatcagttt   26040

tgattgtaac attttgcttt gaaatttcac gtttcacaga attcaaagca attttcaaag   26100

aattgttgaa attttcgagc atcaaacttt caacaccttc ggatttatca ttcttggcaa   26160

cattccgatc attatttagt tcagttgata tagaattggt atcatcaact gagaatactg   26220

ttaaattctg gtgttgaagt tccaaaaatt tctccatgac ttttttcaata ctatccttct   26280

gataaacatt gaaggattct tgaagcattt taatctcttc attctttttc ttgagttcgg   26340

aaaacagaat attctttctt ttttggaatt ccactgtcac taagagataa tcatctttgt   26400
```

-continued

```
tttccaaaga tgtaaccagc tgcgatggat tcaaactttc caagtttttc gtaagatagt   26460

caacttcgtc ttcaagtttt tgaatgatct gtttgttgtc ttccatcttt tttgttataa   26520

gtataggatc cttgaaataa agagaaaacg tgactatgat cttgtcaata gtttccagca   26580

agtggaaaat gtcataataa tctccatcat ttaatacttt taatttgtcc aaaagttgat   26640

ccatcaactt ctcttgtttc ggtgtttcat caccaattaa tattccaccg taaccgttaa   26700

ccggatatgg cgacaaatca taaaattgtt tttgaagatc ctcatattta gttttgagaa   26760

ttgagaaatc ttcatttctc attatcaaca acttcttcaa tcttctagct tctgtctctg   26820

cttttatttg gaaaatttcg aattgcattt cagctagtat tatctcatct tcttgttcat   26880

cgattaattt ctcaacttct tcttttaatt ttttgatatt ttgatctttt tctgccatag   26940

cattttgaaa atcttctagt gttgcaaact gatattcagt ggatgtactc gtggattctt   27000

gagtcgaaat ttcagtgttc ttgtttattc gttttacttc ggagcttctg actattttct   27060

ctggagtcca aaacttgtct acttccaaaa aatgtgtttt tttgcttctg aaaaacatat   27120

attaagtaac atctttaaga tattcaggtg cacttacatt tttgaaatat ttggtgacaa   27180

actttgaatt atcaatctga attcttctgc ggttccagtg aagcaagcat aattctgaaa   27240

ataaaaatta cagcttttga aaccaatgaa acgaaacaac tattgtattt aaaaaatgct   27300

cacttcaact ccattctctt ccaccgctgc ttcttttttc acacttttcc agtttatcaa   27360

ttaaaaattc aagtttctgt tgttcaggtg aaggctgaga tgctgtgaac gacatagttc   27420

tgaaaatagt taatttaaat gtagcagaaa aatcttttct agaaagtaaa aaaaatcagt   27480

aaaaacaagt actaagagaa attgaataaa ccaatcacaa taatgacttc ttaacaagct   27540

gaaaaataat gcaatagcaa agaaaaacga gtagtttcgg taactccata gtacattatt   27600

tcgttattgg gatcatcata tcatttattg atgaggatat tatgagttaa ttctaataac   27660

ccgagagtaa aggcaaaaaa tagcatggag tgaaaaaacg gatcaagcaa agaaatcgtg   27720

ttaacttta taacatctag ttgacactgt cagaccaaaa acttaataaa attttcactt   27780

gtacataaca gctagctgaa actgtaattt aattttatat tccctcggtc aattctagct   27840

aaattagcga ttctgagcta agccttcatt tcaaaattaa caaaaaaaat gcaatgaaat   27900

tttcacttgt acataacagc tagctgaaac tgtaatttaa ttttatattc tctcggtcaa   27960

ttctagctaa attagcgatt ctgagctaag acttcatttc aaaaataaca aaaaaaatga   28020

attgaaattt tcacttgtac ataacagcta gctgaaactg caatttaatt ttatattcct   28080

tcagtcaatt tcagctaaat tagcaatttt gagctaagtg ttgttgtttc ttaaaacaat   28140

gcaaattttg atggttttc gtgttcagtg aacaaacaaa caaacaaaaa aattctggta   28200

aataaccaca agctgaaact gtgagataat tttttagtga ccattgagtg actgctcata   28260

gacagtggct tggaattaag actagaatga ttatctctca tgataacata ttatacagag   28320

aagttgggaa gaatgtaggt cattgtaaag cgacagacag gtcgcattga tcaaagagaa   28380

tataagtcga actctttcgt ttggtaactt gagggccaat gttatttgct attagggaaa   28440

attaacattt aaggagcaaa ggattgcaaa caaaatgcga taagatatat gattatagta   28500

ttttatcttt tgtaagtgtt gccataattt cagtaacgaa aaaaataaca aggcaattt    28560

agatgttagg aaaatcgaat ttgtctgact agccaacgaa tgttctcaat tgaagttatt   28620

gttcttttt aagatgtttt catacaaatt agtcagtttt cgaagcttca gccacactta   28680

tccgaattga gcaatttcaa aactatttt tgtaaaataa aatacatctc cgaaaattta    28740
```

-continued

```
catcgagttc ccaacaatac tgtatggata gaaaatacct accaatactg cacatgaaac   28800

gctctgaaaa taatcggaaa ggaaatgaga accttttaaa tataaaatga gcacaataag   28860

taatactaac tttattgaga aagaacataa ttgttatgag aatagttttt aaatgaggtg   28920

agaaacagaa tatccctgag aataagtgaa gatacttgaa aatttgtgaa atagtaataa   28980

gtaaaatgtt ttcacattag tataaacaat gacagagtca cgcaaaagta cgggaaacat   29040

atgaagttta taatacagtg cagtacagaa aaggtacaaa gtttacaaga atacaattgt   29100

tttttaaaaa taattttttg ttgaaggctt aaggtaatac gattaaagag ctactttctt   29160

ccaatacgaa gttgaattta aaatttaaaa ggaaaaaagg aaaaaaatta aaaagcatat   29220

gaaaaatcgg ggcgcatttt tagtgcaaaa aattagatgg catttatttt atcccatcca   29280

tctgaatctt cactgtgtgt ggatttattg tcgtcatctt gatcgatcat tgtatcatca   29340

gcttctcctt cttgattgat aagaagacct tgcagttttt ccgaaagttc cgaaatcttc   29400

aaatccttct ctctcaatgc atcatgcatc ttctgaattt cagcggatcg ttcgctattt   29460

tgaataagtt ccatcagaca ctcaattttg ctatcttttt ccatgatttc tcttttatga   29520

tttgcaatct gttcttcttt tgattcacat tctctctttg aattggctga aataaaagaa   29580

aatgcttaca gatgtgtgta aaacccctag aaaactttca caagcttacc tgtcaatact   29640

tcaaattgcc ccaataagtt gtgcttccac tcttcagttc gaagtttaag atcttcaact   29700

gatgtattaa gcgtggcttt ttcctgctga gtgtttgcaa gttgcatctc taacgccatg   29760

acggtcgagt tatgttgatc caaaatatga ctg                                29793
```

We Claim:

1. A method of screening candidate molecules for ability to modulate activity of an enzyme which catalyzes release of ADP-ribose from an ADP-ribose polymer, comprising the steps of:
   providing a purified enzyme encoded by a nucleotide sequence that is at least 80% identical to the nucleotide sequence as set forth in SEQ ID NO: 1, wherein the enzyme has a molecular weight greater than 100 kilodaltons as determined by SDS-PAGE;
   assaying the enzyme in the presence of a candidate molecule to be screened; and
   comparing the activity of the enzyme in the presence of the molecule to the activity of the enzyme in the absence of the molecule, wherein a difference therebetween indicates that said molecule modulates activity of said enzyme.

2. The method of claim 1, wherein said enzyme has the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6.

3. The method of claim 1, wherein said enzyme is encoded by the nucleotide sequence of SEQ ID NO: 1, 3, or 5.

4. A method of screening candidate molecules for ability to modulate activity of an enzyme which catalyzes release of ADP-ribose from an ADP-ribose polymer, comprising:

providing a purified enzyme which comprises the amino acid sequences set forth in SEQ ID NOS: 11, 12, 13, and 14 and has a molecular weight greater than 100 kilodaltons as determined by SDS-PAGE,
assaying the enzyme in the presence of a candidate molecule to be screened, and
comparing the activity of the enzyme in the presence of the molecule to the activity of the enzyme in the absence of the molecule, wherein a difference therebetween indicates that said molecule modulates activity of said enzyme.

5. The method of claim 4, wherein said enzyme is encoded by a nucleic acid molecule, the complementary sequence of which hybridizes, under stringent conditions, to the nucleotide sequence of SEQ ID NO: 1.

6. The method of claim 4, wherein said enzyme is encoded by a nucleic acid molecule having the nucleotide sequence set forth in SEQ ID NO: 1, 3, or 5.

7. The method of claim 4, wherein said enzyme has the amino acid sequence set forth in SEQ ID NO: 2, 4, or 6.

8. The method of claim 4, wherein said enzyme comprises amino acids 647-977 of SEQ ID NO: 4.

* * * * *